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Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilise the exquisite 
selectivity of antibodies for membrane receptors to selectively deliver cytotoxic warheads to 
specific cell types, such as cancer cells. Much effort has been invested in recent years to 
deliver ADCs with improved pharmacokinetics, toxicology and overall pharmacological profiles 
over early generation ADCs. In particular, advances in linkage strategies through antibody 
engineering or enzymatic modification have yielded homogeneous ADC products with defined 
modification sites and stable linkages. Despite significant advances in this regard, these 
strategies are typically laborious and low-yielding, and the immunogenicity of these unnatural 
modifications is still unclear.  
The primary aim of this work was to obtain a linker technology that yields homogeneous, stable 
and functional ADCs from native antibodies. To this end, cysteine bridging strategies, whereby 
a bis-reactive scaffold covalently cross-links the two cysteines of a reduced disulfide, were 
identified as a reported method to produce homogeneous and functional ADCs. However, a 
limited number of these reagents have been described in the literature and it was postulated 
that an expansion of the toolbox of these reagents would be beneficial to the ADC research 
community.  
This report details the development of a novel set of divinylpyrimidine (DVP) cysteine bridging 
linkers. Early investigations into divinylpyridine reagents were initially conducted, but 
disappointingly, were deemed to have insufficient reactivity to enable efficient antibody 
disulfide rebridging. Alteration of the divinyl-heteroaryl scaffold by switching to a pyrimidine 
core was then explored. In the first instance, monovinylpyrimidine small molecule models 
demonstrated the improved reactivity of the scaffold, while maintaining the stability and 
chemoselectivity that was observed with the vinylpyridine reagents. DVP linkers including a 
dual-functional DVP were then readily prepared and were shown to efficiently rebridge the 
reduced disulfides of native antibodies, antibody fragments and other disulfide-containing 
proteins. Functionalisation of the protein substrates with biologically-relevant moieties (e.g. 
cytotoxins, fluorophores) could be achieved either before rebridging with a pre-functionalised 
linker or after rebridging through bioorthogonal chemistry. In addition, the receptor affinity and 
cellular selectivity of the antibodies were unaffected by rebridging and the antibody conjugates 
displayed exceptional stability in human plasma over two weeks. Critically, ADCs synthesised 
through DVP conjugation demonstrated highly potent and selective cytotoxicity in a series of 
in vitro cellular assays. 
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Chapter 1 – 
Introduction 
1.1 Cancer Therapy 
Cancer constitutes a serious risk to human health. The Cancer Research UK (CRUK) predicts 
that >50% of people currently under the age of 65 will be diagnosed with cancer in their life.1 
It can be characterised by a rapid and uncontrollable division of aberrant cells with mutations 
in their genetic material. The DNA mutations that result in oncogenesis can have multiple 
origins. Inherited faulty genes, environmental causes (e.g. diet, smoking, infection), random 
mutations or a combination of these can drive the activation of oncogenes or the inhibition of 
tumour suppressor genes.2 Although more than 200 types of cancer have been identified, 
many forms of this disease are now curable but this is dependent on the aggressiveness of 
the cancer and the stage at which it is diagnosed, amongst other factors.3 
Chemotherapy has been widely implemented since the 1940s as an effective method for the 
eradication of malignant cancer cells.4,5 Most chemotherapeutics traditionally employ a small 
molecule to perturb a distinct mechanism that is crucial for cell survival or division, driving the 
cell toward apoptosis. For example, DNA cross-linkers such as the platinum-based alkylating 
agents (e.g. cisplatin, carboplatin, oxaliplatin) prevent DNA replication or DNA repair, and 
consequently block cell division (Figure 1.1).6,7 Tubulin inhibitors such as paclitaxel or the 
Vinca alkaloids (e.g. vinblastine) prevent tubulin polymerisation or stabilise microtubules, thus 
inhibiting mitosis through metaphase arrest and induce apoptosis (Figure 1.1).8,9 Although 
these mechanisms of action affect rapidly dividing cells such as cancer cells more than slowly 




Figure 1.1: DNA cross-linkers such as cisplatin, carboplatin and oxaliplatin, and tubulin inhibitors such 
as paclitaxel and vinblastine are widely used chemotherapies. 
Some small molecule therapies target cancer-specific mechanisms, thereby giving better 
selectivity profiles over standard chemotherapeutic regimens. For example, many breast 
cancers are driven by overexpression of the estrogen receptor (ER) transcription factor, which 
is activated by estrogen hormones.11 ER inhibitors such as tamoxifen or fulvestrant can inhibit 
the growth of and eliminate such cancers (Figure 1.2).12,13 However, many of these drugs still 
result in the death of healthy cells. Whilst small molecule drugs have undoubtedly had a hugely 
beneficial effect on cancer survival rates, the harmful side effects associated with these 
treatment strategies often cause a poor quality of life for the patient. Drug concentrations 
required to achieve in vivo efficacy cause severe side effects while lower concentrations that 
reduce the side effects limit the drugs effect. 
 
Figure 1.2: Estrogen receptor inhibitors tamoxifen and fulvestrant. 
Many chemotherapeutic agents are administered as part of a combination therapy program, 
which can involve co-administration of multiple agents with distinct mechanisms of action or 




















































Radiation therapy requires the use of radioactive particles to induce cancer cell apoptosis by 
damaging its DNA.14 Although radiation therapy can be physically directed toward the 
malignant tissue, harmful side effects are typically associated with this approach and it can 
only be used to treat solid tumours. 
Interest in biopharmaceuticals like small interfering RNA (siRNA) or antisense 
oligonucleotides (ASOs) as drug molecules has seen renewed growth in recent years.15–17 
Furthermore, complex biologics, including chimeric antigen receptor T cells (CAR-T) or 
genome editors such as clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas systems have witnessed a surge in the research landscape; these strategies have the 
potential to revolutionise the treatment of serious human disease through curative intervention 
with a single treatment.18–20 However, many of these modalities are in early stages of 
development and have issues with cost, delivery or safety that must be overcome before 
widespread use for cancer treatment as well as other diseases can be implemented. 
Monoclonal antibody (mAb) therapies have proven to be the most developable biotherapeutic 
format. There are currently more than 80 mAbs approved for a range of diseases with 
approximately half of these used to treat an array of oncology indications.21 The mechanism 
of action of mAb drugs can vary depending on the antibody, its cognate antigen and the cell 
type that it targets.  
1.2 Antibody-Drug Conjugates  
The concept of targeted drug delivery dates back to 1913 when Paul Ehrlich proposed the 
hypothesis of specifically delivering a ‘toxophore’ to a tumour using a ‘heptophore’.22 By 
targeting a cytotoxic drug to a specific cell type, debilitating side-effects can be lowered, thus 
allowing the use of more potent toxins. The culmination of these events is that targeted 
therapeutics can decrease the minimum effective concentration (MEC) required to eradicate 
the cancer while concurrently increasing the maximum tolerated dose (MTD) of the drug, 
resulting in an overall increase in therapeutic index (TI) (Figure 1.3).  
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Figure 1.3: Targeted therapeutics have a larger TI than small molecule drugs. 
The emergence of antibody-drug conjugates (ADCs) over the past 40 years lends promise to 
the realisation of Ehrlich’s proposed ‘magic bullet’ therapy. An ADC is a ternary molecule 
comprised of a cytotoxic molecule that is covalently attached to a mAb via a chemical linker 
(Figure 1.4). Each of the three components has their own role within the ADC. However, each 
of the components also influences the function of the other and the construct design must be 
balanced to accommodate all three moieties. 
 
Figure 1.4: General structure of an ADC. 
ADCs utilise the unique cell targeting ability of an antibody for its cognate antigen to 
discriminate between healthy and cancer tissue and selectively deliver a highly potent 
cytotoxin to the cancer cells. However, it is possible to use ADCs to target any cell type that 
expresses an appropriate antigen.23 ADC binding of the cell surface antigen typically causes 
internalisation of the entire complex. Subsequent sub-cellular trafficking and processing in 
either the endosomes or lysosomes releases the cytotoxin which is then able to carry out its 






















Figure 1.5: Internalisation, trafficking and processing of an ADC to release the active cytotoxin. 
The first ADC was reported in 1958 by Mathé et al. who described the attachment of 
methotrexate to a leukemia cell-targeting antibody (Figure 1.6).27,28 However, it wasn’t until 
2000 that the first ADC made it to market when gemtuzumab ozogamicin (Mylotargâ) gained 
Food and Drug Administration (FDA) approval for the treatment of acute myeloid leukemia 
(AML). A post-approval study demonstrated that Mylotargâ did not offer any patient benefit 
than standard chemotherapy and was voluntarily removed from the market by Pfizer in 2010.29 
Mylotargâ was re-introduced to the market in 2017 for patients CD33-positive AML, 
dependent on adverse risk factors.30,31 
 


















































The disappointment of Mylotarg’s initial removal from the market in 2010 was quickly 
overcome with the approval of brentuximab vedotin (Adcetrisâ) in 2011 for the treatment of 
relapsed or refractory Hodgkin’s Lymphoma (HL) and anaplastic large cell lymphoma 
(ALCL).32–35 In 2013, trastuzumab emtansine (T-DM1, Kadcylaâ) was approved for the 
treatment of HER2-positive metastatic breast cancer.36,37 Apart from the re-introduction of 
Mylotargâ, 2017 also witnessed the approval of inotuzumab ozogamicin (Besponsaâ) to treat 
relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) via targeting of 
CD22.38,39 There are currently over 80 other ADCs in the clinic, nine of which are in advanced 
trials. Sacituzumab govitecan has completed Phase III trials and is expected to be granted 
approval by the FDA and European Medicines Agency (EMA) in 2019 for the treatment of 
triple negative breast cancer.21 In addition, polatuzumab vedotin is an anti-CD79b ADC that is 
under investigation for diffuse large B cell lymphoma (DLBCL) – a type of non-Hodgkin’s 
lymphoma (NHL). Roche has submitted a request for accelerated approval of polatuzumab 
vedotin based on promising Phase II clinical data.21,40,41 
1.3 Monoclonal Antibodies (mAbs) 
Antibodies are Y-shaped glycoproteins comprised of four polypeptide chains – two identical 
light chains (LCs) and two identical heavy chains (HCs) (Figure 1.7). Together, these 
polypeptides form two Fab (fragment, antigen binding) arms and an Fc (fragment, 
crystallisable) stem. The Fc contains four constant domains – two on each HC (CH2 and CH3). 
Each Fab is comprised of two variable domains – one on the LC (VL) and one on the HC (VH) 
– and two constant domains – one on the LC (CL) and one on the HC (CH1). The constant 
regions of an antibody are highly conserved for a particular antibody subtype while the variable 
domains can have large degrees of sequence and structural variance. The CH2 domains also 
contain a conserved glycosylation pattern at Asn297.42,43 The most abundant antibody format 
in humans is immunoglobulin G (IgG). 
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Figure 1.7: General structure of an IgG1 antibody. 
B lymphocytes comprise one half of the adaptive immune response. Upon detection of a 
foreign species through interaction of B cell receptors with surface receptors on the foreign 
pathogen, the B cell produces antibodies as part of the host defence against the infection. An 
antibody has two main functions. The first is to recognise and bind specific cell surface 
receptors called antigen. Antibodies recognise and bind to their target antigens via interactions 
at the hypervariable loops at the amino termini of the variable domains, called 
complementarity determining regions (CDRs).44 Upon antigen recognition, the antibody then 
carries out its second function of recruiting effector immune cells to engulf and destroy the 
bound cell. The Fc region of the antibody is responsible for this identification and can cause 
pathogen removal through interaction with complement proteins or via antibody dependent 
cellular cytotoxicity (ADCC) by virtue of interaction of the Fc with Fc receptors (e.g. FcgR) on 
immune cells.45,46 
In 1997, rituximab became the first stand-alone anti-tumour antibody to obtain FDA approval 
for the treatment of relapsed or refractory CD20+ B cell non-Hodgkin’s lymphoma.47 Despite 
the large number of mAb based therapies that have reached the market, many of them are 
insufficiently efficacious to eradicate the cancer on their own and require combination therapy 
strategies to cure the disease.21 In contrast, highly toxic ADCs offer the opportunity to achieve 
the same selective cell killing offered with mAb therapies but with a decrease in the dose 
required to obtain that cancer eradication. 
An ADC can only be used to selectively deliver cytotoxins to cancer cells if those cells express 
an antigen at higher levels than healthy cells. A range of targetable antigen have been 
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(mAb) can then be matured to specifically bind that surface antigen. Advances in hybridoma 
and protein engineering mean that the production of therapeutic mAbs is now a relatively 
straightforward procedure.49,50  
1.4 Cytotoxic Drugs 
The cytotoxic drug (often referred to as the warhead or payload) is responsible for killing the 
target cancer cells. Early ADC research utilised existing chemotherapies such as 
methotrexate or doxorubicin (Figure 1.8).27,51 However, early clinical investigations revealed 
much lower activity than predicted from preclinical evaluation. For example, the Lewis-Y 
targeted ADC BR96-doxorubicin demonstrated almost no clinical activity against metastatic 
breast cancer, having demonstrated selective toxicity preclinically.52 
 
Figure 1.8: Early ADC research used existing chemotherapy agents such as methotrexate or 
doxorubicin as their payload. R indicates that modifications are on both cysteine residues. Cytotoxin 
highlighted in blue and linker in black. 
There are a number of reasons that may explain the markedly lower clinical effect of these 
ADCs compared to the effect seen on preclinical evaluation. Due to the complex and variable 
route that an ADC molecule must undergo before an active drug molecule can be released 
inside a cancer cell, only a small amount of the administered dose will generate an active 
warhead in a cancer cell.53 This means that payloads with exceptionally high toxicity (sub-


































may go some way to explaining their failure.54 In addition, a number of other criteria must be 
met for a cytotoxic drug to be used as an ADC warhead. Cytotoxic drugs tend to be lipophilic 
molecules and as such can have great influence on the pharmacokinetics of the ADC. 
Increased lipophilicity must be limited as this can cause antibody aggregation and increased 
clearance.55 Furthermore, the drug must have some degree of aqueous solubility to enable 
conjugation to the antibody and it must be suitable for chemical modification with a linker. 
After the failings of initial ADC trials using classic chemotherapy payloads, second generation 
ADCs explored more potent warheads. Investigations in this area focused on natural products 
and their derivatives that had been discovered and found to be too potent for use in 
chemotherapy. Combined, the calicheamicins, auristatins and maytansinoids account for all 
of the approved ADC payloads and the majority of those under clinical investigation. 
Calicheamicin is a potent anti-cancer natural product that causes site-specific double strand 
DNA breaks, initiating apoptosis (Figure 1.9a).56 N-acetyl-g-calicheamicin can be 
functionalised with a linker and is used as the cytotoxic payload in gemtuzumab ozogamicin 
and inotuzumab ozogamicin. 
Dolastatin 10 is a highly potent cancer drug that causes cell death by binding to tubulin, thus 
preventing microtubule formation and subsequent mitosis. Monomethylauristatin E (MMAE) 
and monomethylauristatin F (MMAF) are synthetic derivatives of dolastatin 10 that have found 
widespread use in ADC research (Figure 1.9b).57,58 Indeed, approved brentuximab vedotin 
contains an MMAE warhead, with many more ADCs in clinical development using either an 
MMAE or MMAF payload.33 
Maytansinoids such as emtansine (DM1) and ravtansine (DM4) are another group of 
antimitotic agents based on the natural product maytansine, and are frequently used in ADC 
development (Figure 1.9c).59 Indeed, trastuzumab emtansine has a DM1 payload.37 
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Figure 1.9: Widely used ADC payloads a) N-acetyl-g-calicheamicin, b) auristatin payloads MMAE and 
MMAF, and c) maytansinoid payloads DM1 and DM4. 
In recent years, the number of different ADC payloads under investigation has increased 
significantly. For instance, DNA alkylating agents such as the pyrrolobenzodiazepine (PBD) 
dimers and duocarmycins; antimitotic drugs including the tubulysins; and DNA topoisomerase 
I inhibitors such as the camptothecin analogues have all been studied as ADC payloads, with 
numerous examples of these payloads reaching the clinic (Figure 1.10).60–67 All of these 

























































































Figure 1.10: Natural product analogues currently under investigation as ADC payloads. 
The choice of payload is dependent on the antibody, molecular characteristics of the cancer 
type and the desired release mechanism from the antibody.  
1.5 Linkers 
The ADC linker is responsible for connecting the cytotoxic warhead to the mAb. Linker 
reagents are hetero-bifunctional molecules with orthogonal functional groups to allow 
chemoselective reaction with the antibody and the payload. ADC linkers should adhere to a 
stringent set of prerequisites to ensure a safe and efficacious ADC is administered. First, the 
conjugate must remain intact while circulating the bloodstream as decomposition of the 
conjugate could cause systemic toxicity. The linker should then permit release of the cytotoxin 
from the antibody upon internalisation into target cells. It is crucial that the linker enables 
traceless release of an unmodified warhead or that the payload that is cleaved from the 
antibody is not inhibited by the attached linker.68 Moreover, the conjugation chemistry should 
enable efficient and reproducible ADC synthesis. Aside from these absolute requirements, the 



















































1.5.1 Release Mechanism 
ADC linkers can be classified in numerous ways. Oftentimes, they are categorised based on 
the method by which the payload is released from the antibody. In this sense, ADC linkers can 
be regarded as cleavable or non-cleavable. 
1.5.1.1 Cleavable Linkers 
Cleavable linkers utilise the distinct chemical or enzymatic intracellular conditions of the cell 
to release the payload from the antibody. Upon internalisation, the ADC-antigen complex is 
encapsulated in an endosome via receptor-mediated endocytosis. From here, the complex is 
trafficked to a lysosome, where proteins, including antibodies are digested into their 
constituent amino acids. Initial ADC linkers aimed to exploit the different intra- and 
extracellular chemical environments to release the drug molecule. Endosomes (pH 5.0 – 6.5) 
and lysosomes (pH 4.5 – 5.0) are more acidic than the bloodstream (pH 7.4).69 This acidic 
environment can be exploited through the use of acid-labile groups to cause linker decay and 
subsequent drug release. Approved ADCs Mylotargâ and Besponsaâ both utilise linkers that 
contain an acid-sensitive acyl-hydrazone, which upon exposure to endosomes or lysosomes 
triggers the release of calicheamicin from the antibody (Figure 1.11).70 
Cytoplasmic concentrations of free thiols such as glutathione (GSH) are also much higher (1–
10 mmol/L) than the extracellular environment (~5 µmol/L).71,72 As such, disulfide linkers 
enable free thiol-mediated cleavage of the ADC to release the cytotoxic warhead (Figure 
1.11). Maytansinoid payloads are commonly connected to the antibody via a disulfide 
linkage.73 However, steric bulk around the disulfide is often required to ensure ADC stability 
in circulation. In spite of this, chemically-cleavable linkers containing disulfides or hydrazones 
tend to suffer from poor in vivo stability, lowering the MTD of these ADCs.74,75 
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Figure 1.11: Chemically-cleavable disulfide and hydrazone ADC linkers. Disulfides can be cleaved in 
highly reducing conditions of the cytoplasm. Hydrazones can decay in the acidic endosomes or 
lysosomes to release the cytotoxic drugs. 
Enzyme-cleavable linkers offer a more stable alternative than their chemically-sensitive 
counterparts. The cathepsins are a family of peptidases that recognise and cleave short 
peptide sequences in a sequence-specific manner. Cathepsin B is a member of this family 
that is overexpressed in many cancer types.76,77 This enzyme catalyses the cleavage of the 
C-terminus amide of a number of short peptidic sequences. The valine-citrulline and valine-
alanine dipeptides have been extensively used with auristatin and PBD payloads, respectively 
(Figure 1.12a). ADC payloads tend to be large, sterically-demanding molecules; a self-
immolative p-aminobenzoylcarbonyl (PABC) spacer is typically used on the C-terminus of the 
linker to give the enzyme room to cleave the desired bond and to enable traceless release of 
the payload (Figure 1.12b).78 Indeed, the approved ADC brentuximab vedotin contains a val-
cit-PABC cleavable linker.33 A number of other cathepsin B-sensitive motifs with enhanced 
enzyme selectivity or better physiochemical properties have also been developed, such as a 
simple lysine amino acid or a cyclobutane-containing linker (Figure 1.12a).66,79,80 
b-glucuronidase has been shown to be overexpressed and present in high quantities in the 
lysosomes of cancer cells.81 b-glucuronic acid-containing linkers have been developed and 
used in ADC research over the last decade to exploit this. In addition, the high polarity of a b-
glucuronide moiety potentially masks the hydrophobicity of cytotoxic warheads, thus 
preventing antibody aggregation.82 A PABC-type self-immolative spacer is also routinely used 
for these linkers. b-glucuronic acid linkers have been used to synthesise ADCs with various 
payloads including MMAE, MMAF, duocarmycin analogues and camptothecin analogues 
(Figure 1.12a).83–86 
The development of pyrophosphate diester linkers has recently been described by 
researchers at Merck. Phosphodiesterases are known to be present at high levels in 











characteristics make such molecules attractive candidates as cleavable ADC linkers. ADCs 
containing glucocorticoid payloads have been described with phosphate diester linkers (Figure 
1.12a). These ADCs were shown to be stable and efficacious in a series of in vitro 
investigations.88–90 
 
Figure 1.12: a) Enzyme-cleavable linkers used in ADC research include moieties that are sensitive to 
cathepsin B, b-glucuronidase and phosphatases. The cleaved bonds are indicated with a red line. b) A 
self-immolative PABC spacer is often incorporated in cathepsin B and b-glucuronidase linkers.  
1.5.1.2 Non-Cleavable Linkers 
An alternative strategy is to utilise the lysosomal degradation of the antibody into its constituent 
amino acids to release the warhead. Such linkers do not contain a specific release trigger and 
so the cytotoxic molecule is released with the linker and the amino acid on the antibody to 
which it was conjugated (Figure 1.13).91 The success of so-called non-cleavable linkers is 
dependent on the mechanism of action of the warhead and the position on the warhead where 
the linker is attached. Ado-trastuzumab emtansine contains the non-cleavable linker 4-
(maleimidylmethyl)cyclohexane-1-carboxylate (MCC). Conjugation of this linker to 
trastuzumab occurs via lysine modification and so the released maytansine contains a Lys-
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Figure 1.13: Non-cleavable ADC linkers such as the MCC linker shown here release the payload with 
the linker and conjugating amino acid attached. 
The cleaved payload in non-cleavable linkers is zwitterionic. Therefore, it has poor membrane 
permeability and will not be able to diffuse out of the cell where it was released.92 This can be 
seen as both beneficial or detrimental, depending on the cancer type that is being treated. In 
one sense, this can be advantageous as a highly potent cytotoxin cannot enter peripheral 
healthy tissue, causing harmful side-effects. However, the molecular characteristics of 
tumours can be highly heterogeneous; in certain cancers, large areas of the tumour may not 
express the target antigen of the ADC. The administered ADC will have little effect on these 
cells if a non-cleavable linker is employed. In contrast, the use of cleavable linkers will release 
an uncharged, unmodified payload that can permeate into neighbouring tumour cells, also 
killing these cells in a phenomenon known as the ‘bystander effect’.93,94 
1.5.2 Antibody Modification 
The second main requirement for any linker molecule is to conjugate the drug to the antibody. 
The type of chemistry used to link the payload and subsequently the linker-drug to the antibody 
can greatly affect the performance of the ADC. Connecting the drug to the linker can typically 
be achieved with simple, robust chemistry. However, due to the large size (~150 kDa) and 
abundance of various functionalities on an antibody, reaction between the linker and the 
antibody can pose a formidable challenge. Reactions used in protein modification must meet 
a strict set of requirements to ensure efficient and robust conjugation; the reaction must work 
in aqueous conditions at low micromolar concentration, be selective for its target amino acid, 
and proceed with rapid reaction rates under mild conditions.95,96 A large toolbox of protein 
modification reactions has been developed, enabling modification of many natural and 
genetically incorporated unnatural amino acids (UAAs).97–100 The following sections will 
primarily focus on protein modification techniques that have been used for the modification of 

















1.5.2.1 Drug-Antibody Ratio and Modification Site 
An important consideration in ADC development is the number of drug molecules that are 
attached to each antibody molecule. A surface-expressed antigen can only internalise one 
ADC molecule and, depending on the target antigen, this internalisation can be limited. In 
order to maximise the cytotoxic potential of the internalised ADC, loading the antibody with 
many drug molecules to give a higher drug-antibody ratio (DAR) is desirable. However, this 
must be balanced with the physicochemical and toxicology properties of the antibody to 
ensure that the drug loading does not cause increased aggregation and clearance, or a poor 
safety profile. The site of attachment on the antibody can also affect its function by inhibiting 
antigen recognition and binding. The conjugation technique used to attach the payload can be 
used to modulate the DAR and location of conjugation. For example, synthetic procedures 
used to synthesise gemtuzumab ozogamicin generate a batch of ADC in which 50% of the 
antibody does not have any calicheamicin attached (i.e. DAR = 0).101 Unconjugated antibodies 
will still bind the target antigen, inhibiting binding of ADC molecules and decreasing its 
potential efficacy. In contrast, overloaded antibodies with high DAR tend to have increased 
hydrophobicity and aggregation, resulting in higher clearance rates. ADCs with DARs ranging 
from two to eight have been widely investigated as drug loading to this degree offers a balance 
between reaching sufficient intracellular concentration of the payload without causing 
significant toxicity or pharmacokinetic (PK) issues. Even small alterations to the average DAR 
of the same ADC can result in dramatically different PK and toxicity profiles. A study has 
shown that in vivo, an anti-CD30 antibody conjugated with auristatin payloads with an average 
DAR of four demonstrated almost identical cytotoxicity as the same ADC with an average DAR 
of eight. The highly loaded DAR eight ADC was cleared from the body at a greater rate, 
suggesting that similarities in cytotoxicity were related to its poor PK profile.102 
The site of payload conjugation on the antibody can also be critical to its resultant 
pharmacology. Attachment of the drug in the Fab region can affect antigen recognition by the 
antibody, with the potential to lower antibody-antigen binding and consequently the efficacy of 
the ADC. Additionally, the attachment position can also affect the stability of the linkage 
between the antibody and the linker.103,104 Unstable conjugation resulting in premature 
cytotoxin release lowers the TI of the ADC by increasing off-target effects and decreasing 
efficacy.105 
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1.5.2.2 Heterogeneous Antibody Modification  
Natural amino acids contain side chains with a range of functional groups. From a protein 
modification viewpoint, nucleophilic side chains such as the amino group of lysine residues or 
the thiol of cysteine represent the most attractive targets for conjugation sites via reaction with 
complementary electrophilic groups on a linker.  
A) Lysine Modification 
Early strategies for the covalent attachment of cytotoxic warheads onto mAbs targeted 
solvent-exposed lysine residues. Lysine amines can be readily functionalised via reaction with 
modified N-hydroxysuccinimide (NHS) esters (Figure 1.14). Indeed, Mylotargâ, Kadcylaâ and 
Besponsaâ are all synthesised via reaction of exposed lysines with NHS ester derivatives of 
their respective payloads. However, a standard IgG antibody has approximately 80 lysine 
residues, half of which are chemically modifiable. Therefore, synthesising an ADC with an 
exact DAR and control of the conjugation location is virtually impossible. ADCs synthesised 
via this stochastic lysine modification result in a mixture of ADC structures with varying DAR 
and with numerous regioisomers of ADCs with the same DAR. For example, Wang and co-
workers demonstrated that modification of an IgG antibody with an NHS ester payload 
generated ADCs with DARs ranging from 0 to 6. In addition, the synthesised batch of ADC 
contained over 4.5 million different chemical species.106 Each ADC will have its own unique 
pharmacokinetic, stability, toxicity and efficacy profile making it difficult to predict what the 
properties of the ADC mixture will be after administration.43 
A number of other methods have also been described for the modification of IgG lysines 
including acyl fluorides, b-lactams, isothiocyanates and sulfonyl acrylates (Figure 1.14).107,108 
Although there are many surface lysine residues available for conjugation in a standard mAb, 
the microenvironment around these lysines is typically quite different and can alter the pKa 
values of lysine amines. Amines with decreased pKa will be less likely to be protonated at 
physiological pH and therefore have higher nucleophilicity than protonated lysines.109 A 
number of studies using b-lactams and sulfonyl acrylate reagents have exploited this 
phenomenon to modify specific lysine residues in an antibody.110–112 However, precise control 
with these methods and the generality of the approach is not yet clear. 
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Figure 1.14: Methods used for the modification of antibody lysines.  
B) Cysteine Modification 
Cysteine modification has emerged as a popular modification site for synthesising ADCs. The 
unique reactivity of the cysteine side chain sulfhydryl enables selective modification with a 
catalogue of available reagents.113,114 All IgG cysteines are present as disulfides, which must 
first be reduced to reveal the reactive thiol. Both intra- and interchain disulfides are found in 
IgG molecules. Favourably, reduction of accessible interchain disulfides is more facile than 
the buried intrachain disulfides. IgG1 antibodies, which are most commonly used in ADC 
research contain four interchain disulfides that upon reduction yields eight free thiols available 
for reaction. Cysteine modification offers more control than lysine modification in terms of 
conjugation site as the interchain disulfides are all located either in or near the hinge region of 
the antibody, far from the CDR antigen-binding domains. Although cysteine conjugation also 
offers marginally better control of DAR than lysine modification with only eight available 
conjugation sites, heterogeneous mixtures of ADC are typically produced by modification of 




























































controlled by a combination of partial reduction-reoxidation strategies and linker stoichiometry. 
This process is difficult to control and can lead to alterations in the antibody structure, 
potentially diminishing its biological function. Moreover, conjugation to these residues breaks 
the only covalent bonds that connect the heavy and light chains and may affect the stability 
and biological profile of the antibody.115 
Maleimide reagents are routinely used for cysteine modification (Figure 1.15). Maleimides are 
easily functionalisable and react rapidly and efficiently with cysteine thiols under mild 
conditions. In the field of ADC research, maleimide linkers have been incorporated into a host 
of various linker-drug types, including chemically-cleavable, enzyme-cleavable and non-
cleavable linker-drugs. Notably, Adcetrisâ is synthesised via maleimide-mediated payload 
attachment to interchain cysteine residues. Many other ADCs containing interchain cysteine-
maleimide modifications are currently in clinical or preclinical development.54 However, the 
generated thiosuccinimide linkage is inherently unstable and can undergo a retro-Michael 
addition to reform the unconjugated maleimide drug-linker and free thiol (Figure 1.15). In the 
absence of alternative thiols, the released drug-linker can simply react with the mAb again to 
reform the ADC. Unfortunately, thiol-containing molecules such as human serum albumin 
(HSA) are present in circulation, resulting in undesired maleimide exchange reactions. The 
payload is now no longer targeted to the desired cell type leading to undesired systemic 
toxicity and a decrease in efficacy.116–118 
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Figure 1.15: Maleimide linkers can be used to modify antibody cysteines. However, the thiosuccinimide 
product is unstable and can result in the release of the payload from the antibody and trapping of the 
reformed maleimide by serum thiols such as HSA. R indicates the same chemical modifications are 
present on both cysteine residues. 
The stability of maleimide bioconjugates can be greatly increased by post-conjugation 
hydrolysis of the succinimide ring (Figure 1.16a).119 A number of modified maleimide linkers 
and novel methods120 have been developed that promote this hydrolysis (Figure 1.16b). The 
hydrolysis of N-alkyl maleimides takes days to proceed under physiological conditions. 
However, the rate of hydrolysis can be increased significantly via alteration of the N-
substituent. Incorporation of a polyethylene glycol (PEG) group, a suitably placed primary 
amine, or a 1,3-dioxane (or dioxolane) between the maleimide and the payload results in rapid 



























Figure 1.16: a) Hydrolysis of a maleimide-derived thiosuccinmide generates a mixture of stable 
isomers. b) A range of modified maleimide linkers that have been developed to promote thiosuccinimide 
hydrolysis post-conjugation. 
Other methods that have been reported for the single modification of interchain cysteines 
include the use of a-halocarbonyl linkers or a palladium-mediated cysteine arylation (Figure 
1.17).117,127 
 
Figure 1.17: Interchain cysteine modification with a-halocarbonyl reagents and Pd-mediated arylation. 
R indicates the same chemical modifications are made on both cysteine residues. 
1.5.2.3 Site-Selective Antibody Modification 
Early generation ADCs relied on modification of native lysine and cysteine residues, which 
generated heterogeneous ADCs with variable pharmacokinetics, stability, toxicity and 
efficacy. More recent research into linker technologies has focused on strategies that enable 
the production of homogeneous ADCs with predictable and robust pharmacology. A variety of 

















































of additional natural or unnatural amino acids, enzymatic modification of amino acid side-
chains or antibody glycans, or disulfide rebridging linkers. 
A) Enzymatic Antibody Modification 
Enzymes are renowned for their high levels of substrate and reaction specificity. Exploitation 
of these attributes for the generation of homogeneous ADCs via site-selective antibody 
modification is an attractive concept, which has been investigated in recent years.128 
Microbial transglutaminase (MTGase) catalyses the formation of an amide bond between a 
glutamine side chain and an amino-alkyl substrate. It has high specificity for a sequence-
specific glutamine residue but broad amino-alkyl substrate compatibility. The conserved Q295 
in the CH2 domain has been found to be an excellent substrate for MTGase if the conserved 
glycosylation at N297 is first removed by treatment with peptide:N-glycosidase F (PNGase F). 
PNGase F is an efficient and robust enzyme that completely deglycosylates mAbs. 
Homogeneous auristatin ADCs with DARs of two or four have been produced via MTGase-
mediated modification of Q295 (Figure 1.18).129,130 
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Bacterial sortase is a transpeptidase that cleaves between threonine and glycine in the LPXTG 
sequence (X = any amino acid). The enzyme then enables the addition of a glycine-
functionalised linker to the C-terminus of the threonine residue. Antibodies containing the 
LPXTG sequence at the C-termini of the HCs and LCs have been produced and used to 
synthesise homogeneous ADCs via sortase catalysis (Figure 1.19a).131,132 
Similarly, formylglycine-generating enzyme (FGE) utilises a consensus sequence to modify 
the antibody structure. FGE catalyses the oxidation of cysteine in a CXPXR sequence (X = 
any amino acid) to a formylglycine amino acid. The CXPXR sequence must be genetically 
incorporated into the antibody sequence, most commonly at the C-termini of the HCs and LCs.  
This UAA can react to form oxime or hydrazine linkages via bioorthogonal chemistry. 
Furthermore, a hydrazine-iso-Pictet-Spengler (HIPS) reaction has been used to synthesise 
homogeneous ADCs via reaction of a hydrazine-functionalised indole with the generated 
formylglycine amino acid (Figure 1.19b).133,134 
 
Figure 1.19: a) Sortase-mediated antibody modification and b) FGE conversion of cysteine to 
formylglycine followed by HIPS conjugation. R indicates that modifications are present on both HCs. 
While the enzymes mentioned above catalyse modification of the amino acid residues of the 
antibody, it is also possible to use enzymes to modify the glycan moiety. As was discussed in 
Section 1.3, IgG antibodies contain conserved glycosylation at N297. However, this 





















































heptasaccharide comprised of N-acetlyglucosamine (GlcNAc) and mannose can be modified 
with additional fucoses, galactoses and sialic acids.135,136 
The most common method of modifying the antibody glycan is via the introduction of non-
natural monosaccharides containing bioorthogonal reactive groups (Figure 1.20). For 
example, a mutant galactosyltransferase (b1,4Gal-T1-Y289L) has been developed that 
enables the incorporation of ketone-modified galactose (2-keto-Gal) or azide-containing N-
azidoacetylgalactosamine (GalNAz).137 The removal of any terminal galactose or mannose 
sugars from the glycan using b1,4-galactosidase is required before attachment of the modified 
monosaccharides. Homogeneous ADCs with DARs of two or four have been synthesised via 
glycan modification.138,139 
 
Figure 1.20: Mutant glycosyltransferases can be used to install non-natural monosaccharides 
containing bioorthogonal functional groups such as azides or ketones onto antibody glycans, enabling 
the synthesis of homogeneous ADCs. UDP = uridine diphosphate. 
B) Genetic Engineering 
The most widely employed method of achieving site-selective modification is through the 
alteration of the antibody gene sequence to enable the incorporation of additional reactive 
natural amino acids (e.g. cysteine) or UAAs with reactive bioorthogonal side chains.  
i) Unnatural Amino Acid Incorporation 
The incorporation of UAAs into a protein was pioneered by Schultz and co-workers in the 
1980s.140 In this method, a degenerate amber stop codon (TAG) representing the desired UAA 
is incorporated into the gene encoding the protein of interest. An orthogonal amino acyl-tRNA 


































protein sequence during ribosomal translation.141 A range of UAAs with bioorthogonal side 
chains have been incorporated into antibodies using this technology to enable site-selective 
modification. Homogeneous ADCs have been generated by modification of genetically 
incorporated p-azidomethyl-phenylalanine, p-acetylphenylalanine, selenocysteine or azide 
and cyclopropene lysine derivatives, using established bioorthogonal reactions. (Figure 
1.21).142–146 
 
Figure 1.21: A range of UAAs including azide and ketone-modified phenylalanines, azide and 
cyclopropene-modified lysines and selenocysteine have been incorporated into antibodies, enabling 
the synthesis of homogeneous ADCs. SPAAC = strain-promoted azide-alkyne cycloaddition, iEDDA = 
inverse electron demand Diels-Alder. 
ii) THIOMAB 
One of the earliest investigated methods for site-selective conjugation was the mutation of 
selected cysteines from interchain disulfides to serine residues in the anti-CD30 antibody 
cAC10. This generated an antibody with two or four exposed cysteine thiols for conjugation. 
A highly homogeneous ADC could be produced compared to conjugation using the partially 
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other locations on the light or heavy chains. In these so-called THIOMAB antibodies, carefully 
selected serine, threonine or more commonly alanine residues are mutated to cysteine 
residues via site-directed mutagenesis.148–150 While THIOMAB ADCs have generally shown 
better efficacy and toxicology profiles than their corresponding heterogeneous ADC 
counterparts, it has become clear that the site of mutation is crucial to the stability, safety and 
efficacy of the ADC.42 Moreover, many THIOMAB ADCs are produced with maleimide linkers, 
which have safety concerns of their own (vide supra). A small number of THIOMAB ADCs 
have been reported that use alternate cysteine modification reagents such as 
bromomaleimides, carbonylacrylates, quaternised vinylpyridines and disulfide reagents 
(Figure 1.22).151–154 
 
Figure 1.22: Overview of the linkers used to synthesise THIOMAB ADCs. Maleimide, bromomaleimide, 
quaternised vinylpyridines, carbonylacrylates and disulfides have been reported. 
Complementary to the THIOMAB antibodies, researchers at MIT have reported two methods 
for sequence-specific cysteine modification. Both methods involve fusion of a short cysteine-
containing peptide to the C-terminus of the HCs. In one approach, a perfluoroaryl reagent 




































(Figure 1.23a).155 In the second method, an aza-dibenzocyclooctyne (DBCO) reagent reacts 
selectively with the cysteine in a seven-residue LCYPWVY tag (Figure 1.23b).156 In both 
cases, homogeneous ADCs were synthesised and no reactivity was observed with reduced 
interchain disulfides of a trastuzumab antibody.  
 
Figure 1.23: Sequence-specific cysteine modification via a) perfluoroaryl-mediated modification of a 
so-called p-clamp tetrapeptide sequence and b) DBCO-mediated modification via a LCYPWVY 
heptapeptide sequence. R indicates the same peptide tags and chemical modifications are present on 
both HCs. 
Numerous strategies have been discussed so far that have enabled the production of 
homogeneous ADCs via site-selective antibody modification. While the ADCs synthesised via 
these methods typically had improved efficacy, pharmacokinetics and safety data compared 
to heterogeneous ADCs, all of these methods have drawbacks. Genetic engineering to install 
UAAs, synthesise THIOMABS or install affinity tags requires extensive optimisation for every 
mAb and the immunogenic or antibody mechanistic effects of installing UAAs or modifying the 
antibody sequence is still unclear. Additionally, the effects of glycan alteration on mAb biology 









































C) Disulfide Rebridging 
Disulfide rebridging linkers have emerged as an attractive reagent choice to achieve site-
selective, homogeneous ADC production from non-engineered antibodies without the need 
for enzymatic amino acid or glycan modification. In this technique, interchain disulfides are 
reduced to reveal eight free thiols (for an IgG1). A bis-reactive linker subsequently rebridges 
the cysteine residues by cross-linking of the thiols. In this way, a covalent bond is reformed 
between the polypeptide chains, the DAR of the ADC can be controlled (DAR of four) and the 
site of modification is consistent, away from any antibody-antigen recognition sites.157 A limited 
number of rebridging reagents have been described for the synthesis of ADCs.  
The groups of Caddick, Baker and Chudasama have conducted seminal work in this area 
through the development of next-generation maleimide (NGM) and pyridazinedione linkers, 
which have been shown to produce homogeneous and stable ADCs with precise control of 
the DAR (Figure 1.24). The NGM platform encompasses both dibromomaleimides and 
dithiophenolmaleimides. Initial work with NGM linkers demonstrated their ability to selectively 
rebridge reduced mAb disulfides.158–160 However, NGM bioconjugates may also suffer from 
the same instability issues observed with classic maleimide linkers. To circumvent this, 
optimisation of this platform to afford rapid post-conjugation hydrolysis of the maleimide ring 
has recently been demonstrated for NGM reagents.161 ADCs generated from NGM linkers 
have shown high levels of serum stability post-hydrolysis and good efficacy in vivo.162 
Similarly, a number of studies have shown the utility of pyridazinedione linkers to generate 
homogeneous (DAR two or four) and stable ADCs with excellent in vivo activity.163–169 Of note, 
these reagents enable the attachment of multiple different payloads onto the antibody via 
compatible bioorthogonal chemistry. 
While the NGM and pyridazinedione reagents have witnessed the most significant 
developments in the field, a number of other linkers in this class have been recently reported 
for the synthesis of ADCs. Bissulfone reagents have been used to synthesise ADCs with DARs 
ranging from one to four (Figure 1.24). ADCs synthesised via this method were shown to be 
stable and highly potent through in vivo investigations.170–172 In a different approach, the C-
Lockä platform developed by Concortis Biosystems involves the use of dibromomethyl 
heteroaryls, particularly dibromomethyl quinoxalines to synthesise ADCs via disulfide 
rebridging (Figure 1.24).173 A C-Lockä ADC is currently undergoing Phase I clinical 
evaluation.157 Similarly, arylene-dipropiolonitrile (ADPN) reagents have also been reported for 
 29 
the synthesis of a trastuzumab ADC, which was shown to be highly potent in vitro (Figure 
1.24).174 Finally, a Novartis patent illustrates the use of dichloroacetone reagents for two-step 
synthesis of ADCs via initial installation of a ketone functionality on the mAb, followed by oxime 
formation upon treatment with a cytotoxin-functionalised amino-oxy linker (Figure 1.24).175 
 
Figure 1.24: Disulfide bridging linkers used for the synthesis of homogeneous ADCs include 
bissulfones, dibromomaleimides, pyridazinediones, dibromomethyl-quinoxalines (C-Lockä), arylene 





















































Chapter 2 – 
Project Overview and Aims 
The primary aim of this project is to develop a novel methodology for the synthesis of stable 
and homogeneous ADCs using native antibodies. The technique should be suitable to any 
antibody without extensive case-by-case optimisation requirements. At the time that this work 
commenced, the only disulfide rebridging strategies that had been reported were the NGM, 
pyridazinedione and bissulfone strategies. With such a small toolbox of rebridging linkers 
available, the effects of using a different linker for rebridging were unknown. Expansion of this 
toolbox with a new methodology may unlock further information about the widespread 
applicability of disulfide rebridging for the synthesis of ADCs. Early ADC linkers suffered from 
the heterogeneity and poor stability of the synthesised bioconjugates. It was thought that a 
rebridging strategy would potentially alleviate issues of heterogeneity. For that reason, the 
primary objective of this work was to develop a rebridging linker that generated an 
exceptionally stable linkage between the antibody and the payload.  
The linkers developed in this work will be required to satisfy a number of criteria: 
• Synthesis of the desired rebridging reagent should use simple chemistry and require 
minimal reaction steps (<5). 
• The reagents should be stable and soluble in aqueous media. 
• The rebridging reaction should be fast, efficient and proceed with high conversion. 
• Rebridging should not affect the structure or biological activity of the mAb. 
• The bioconjugates should be stable in human plasma for at least one week. 
• Functionalisation of the linker with a variety of payloads should be synthetically facile 
and involve robust, efficient chemistry. 
• The linker should not affect the activity of the attached payload. 
The work described in this thesis can be divided into three distinct sections.  
In Chapter 3, investigations centred around divinylpyridine linkers as a novel method of 
functional disulfide rebridging. A series of reactivity and stability analyses were initially carried 
out on a small molecule system. Upon completion, cysteine rebridging was then optimised on 
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a model protein, which was cloned and expressed to contain spatially adjacent cysteine 
residues. Finally, evaluation of the divinylpyridine linkers as antibody rebridging reagents was 
conducted. This scaffold was found to have insufficient chemical reactivity to enable efficient 
antibody modification and ADC synthesis. 
In Chapter 4, the divinyl-heteroaryl motif was investigated further. Improvement in scaffold 
reactivity was achieved through use of a divinylpyrimidine core. Small molecule studies 
demonstrated the improved reactivity of the scaffold, and that doing so did not compromise 
conjugate stability. Subsequently, modification of an IgG mAb, a Fab and a non-antibody 
protein then highlighted the ability of the divinylpyrimidine linkers to efficiently modify a range 
of protein substrates with various functional payloads (multiple cytotoxins and a fluorescent 
tag). Finally, biological evaluation of the modified antibodies demonstrated their exquisite 
stability, binding affinity and cell-selective cytotoxicity. 
In Chapter 5, synthesis of and payload attachment to a dual-functional divinylpyrimidine linker 
is described. Preliminary conjugation studies were then conducted on this linker, which 
enables the attachment of two different payloads via orthogonal chemical reactions.  
  
 32 
Chapter 3 – 
Divinylpyridine Cysteine Rebridging Linkers 
3.1 Introduction 
Vinylpyridine reagents have been used for many decades for the modification of cysteines in 
proteins. Most commonly, they have been documented as a method for quantifying the 
number of thiols present in biological fluids or on proteins (Scheme 3.1a).176–181 Vinylpyridines 
have also been described as robust and stable thiol protecting groups, with removal only 
possible after quaternisation of the pyridine nitrogen.182,183 Iksuda Therapeutics (formerly 
Glythera) have utilised the exceptionally high stability of vinylpyridine-derived bioconjugates 
to synthesise ADCs via interchain or THIOMAB cysteine modification (Scheme 3.1b). ADCs 
synthesised via this so-called PermaLinkä technology have been shown to have much higher 
stability and better in vivo efficacy and safety than maleimide-derived ADCs.184,185 
 
Scheme 3.1: a) Vinylpyridines have been used for the cysteine-selective modification of proteins, 
generating highly stable bioconjugates and b) cytotoxin-functionalised vinylpyridines (PermaLinkä) 
have been developed by Iksuda Therapeutics to synthesise stable, safe and efficacious ADCs. 
Building upon previous reports of successful monovinylpyridine reagents for protein 
modification, it was envisaged that incorporation of a second reactive vinyl group within such 
scaffolds could generate novel divinylpyridine linkers (Figure 3.1). The primary aim of the work 
described in this chapter was to investigate the use of divinylpyridine linkers for the synthesis 
of stable, homogeneous and functional ADCs. As was set out in Chapter 2, these linkers 

















rebridging, generation of a stable bioconjugate, easy functionalisation and having little effect 
on the attached payload. 
 
Figure 3.1: The initial focus of this work will be to investigate the properties of divinylpyridine linkers for 
the functional rebridging of mAbs. 
Upon starting investigations, we first identified a potential obstacle presented by the different 
reactivity of the three accessible vinylpyridine regioisomers. Due to their previous use in 
protein modification, and their demonstrated applicability as reactive cysteine handles, efforts 
focused on the 2- and 4-vinylpyridines. Moreover, the applicability of these moieties has been 
demonstrated through their incorporation within PermaLinkä. Since both 2,4- and 2,6-
divinylpyridine isomers could potentially be used as rebridging reagents, focus was placed on 
investigating the reactivity differences between the 2- and 4-vinylpyridine species (Figure 3.2). 
It was also necessary to determine a suitable reactive handle to enable successful payload 
attachment (vide infra).  
 
Figure 3.2: Potential use of 2,4-divinylpyridine or 2,6-divinylpyridine linkers for disulfide rebridging. 
3.2 Reactivity of 2-vinylpyridine and 4-vinylpyridine 
In order to determine the difference in reactivity between the 2- and 4-vinylpyridine scaffolds, 
two model substrates were chosen to mimic the final linker and reaction conditions. Since 
reactivity studies will be carried out in aqueous conditions, inclusion of an amino moiety on 
the pyridine was deemed necessary, with the potential deactivation of the system toward 














coupling from 2- and 4-bromopyridines affected the corresponding vinylpyridine products 1 
and 2 in good yields (Scheme 3.2).186,187 
 
Scheme 3.2: Suzuki cross-coupling a) from 2-amino-4-bromopyridine to 2-amino-4-vinylpyridine 1 and 
b) from 4-amino-2-bromopyridine to 4-amino-2-vinylpyridine 2. 
With vinylpyridines 1 and 2 in hand, determination of the reactivity of these linkers toward 
conjugate addition with cysteine was subsequently conducted. In these studies, N-Boc-Cys-
OMe was utilised as a model surrogate for an antibody cysteine and therefore used as the 
limiting reagent, whilst the stoichiometry of the vinylpyridine substrates was varied to 
determine the effects of relative linker concentration on reactivity. Accordingly, 1 and 2 were 
reacted with N-Boc-Cys-OMe in a mixture of sodium phosphate buffer (NaPi, pH 8) and 
acetonitrile at 37 °C (Table 3.1). Aliquots were removed from the reactions at 15-minute 
intervals and analysed by TLC for consumption of N-Boc-Cys-OMe. For both vinylpyridine 
isomers, N-Boc-Cys-OMe remained after four hours when using one or two molar equivalents 
of 1 and 2 (Table 3.1, entries 1, 2, 6 and 7). Small differences in reactivity were seen between 
the linkers at five and ten molar equivalents of linker (Table 3.1, entries 3, 4, 8 and 9). 
Interestingly, when the substrate was exposed to 20 molar equivalents of 1 or 2, in both cases, 
full consumption of N-Boc-Cys-OMe and conversion to conjugates 3 and 4, respectively, was 
observed after only 30 minutes by TLC analysis (Table 3.1, entries 5 and 10). This result 
suggested only marginal reactivity differences between the 2- and 4-vinylpyridine isomers and 
























Table 3.1: Evaluation of the reactivity of N-Boc-Cys-OMe with a) vinylpyridine 1 to form conjugate 3 
and b) vinylpyridine 2 to form conjugate 4. 
 
Entry Reaction Eq. Cys Eq. 1 or 2 Consumption of Cys (min) 
1 A 1 1 >240 
2 A 1 2 >240 
3 A 1 5 180 
4 A 1 10 60 
5 A 1 20 30 
6 B 1 1 >240 
7 B 1 2 >240 
8 B 1 5 240 
9 B 1 10 90 
10 B 1 20 30 
 
3.2 Divinylpyridine Synthesis and Functionalisation 
It was envisaged that a divinylpyridine featuring a carboxylic acid or alkyne handle could be 
convenient points for payload attachment. Thus, having ascertained that 2-vinylpyridines 
exhibit similar reactivity to 4-vinylpyridines, and due to the increased synthetic tractability, the 
2,6-divinylpyridine scaffold was initially explored (Figure 3.3). It was hypothesised that 
introduction of a modifiable chemical handle at the 4-position of such a species would be 
beneficial for two reasons; 1) this scaffold would generate the least steric hindrance to 
incoming thiols, and 2) the symmetric nature of the scaffold would prevent the formation of 
N NH2 BocHN CO2Me
HS
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regioisomeric products. In line with this and previous reactivity studies, a carboxylic acid-
functionalised pyridine served as an attractive candidate for several reasons; 1) it would 
activate the ring further to conjugate addition chemistry, 2) it would have increased aqueous 
solubility through the potential presence of a carboxylate anion, and 3) it would enable facile 
modification of the linker through amide formation.    
 
Figure 3.3: Proposed divinylpyridine linker 5. 
To this end, reaction of commercially available 2,6-dibromopyridine-4-carboxylic acid under 
Suzuki cross-coupling conditions produced 2,6-divinylpyridine-carboxylic acid 5 in good yield 
(Scheme 3.3). To ensure that further functionalisation would be possible, carboxylic acid 5 
was then reacted with 4-amino-1-butyne hydrochloride under N-[(Dimethylamino)-1H-1,2,3-
triazolo-[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-
oxide (HATU)-mediated amide coupling conditions to yield alkyne 6 in moderate yield 
(Scheme 3.3). In addition to demonstrating the functionalisation capability of the carboxylic 
acid, another linker was generated that would be amenable to copper-catalysed azide-alkyne 
cycloaddition (CuAAC) to later modify the linker with desired payloads. Indeed, the CuAAC 
has been widely used as a bioorthogonal method of functionalising proteins and a wide range 
of azide-functionalised payloads are commercially available or can be routinely 
synthesised.188,189 
 
Scheme 3.3: Synthesis of divinylpyridine linker 5 through Suzuki cross-coupling and subsequent 
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3.3 Divinylpyridine Stability 
With a viable route to access functionalisable divinylpyridine linkers in hand, the next 
challenge involved investigating the stability of divinylpyridine-derived conjugates. The high 
stability of bioconjugates derived from vinylpyridine reagents is well known,176,184 but whilst it 
could be inferred that divinylpyridine conjugates should also display a high degree of stability, 
this has not been previously reported. Consequently, to evaluate the stability of the conjugates 
produced by cysteine alkylation with divinylpyridine reagents, a small molecule stability assay 
was envisaged. First, divinylpyridine 5 was reacted with N-Boc-Cys-OMe in a mixture of NaPi 
and acetonitrile, generating 7 in good yield (Scheme 3.4). 
 
Scheme 3.4: Synthesis of conjugate 7 through reaction of divinylpyridine 5 and N-Boc-Cys-OMe. 
To test the stability of the linkage formed from divinylpyridine conjugation to two cysteine 
residues, 7 was incubated with an excess of reduced L-glutathione (GSH) in a mixture of 
deuterated aqueous buffer (NaPi, 50 mM, pH 7.4) – representative of physiological pH – and 
deuterated methanol (Figure 3.4a). The use of deuterated solvents was chosen to allow 
reaction monitoring by 1H NMR. After 200 hours incubation under these conditions, no 
evidence of the GSH addition product or of released vinylpyridine could be observed (Figure 
3.4b). These results suggest that conjugates produced through divinylpyridine conjugation 
would be stable under physiological conditions containing an excess of other free thiols, and 
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Figure 3.4: a) Incubation of conjugate 7 with GSH under physiological relevant model conditions and 
b) 1H NMR analysis over 200 hours. 
3.4 PfRadA-dCys Modification 
Having evaluated the reactivity, stability and synthetic tractability of functionalisable 
divinylpyridine reagents, investigations commenced into the feasibility of protein modification 
with the divinylpyridine linkers. It was postulated that a model protein containing a single 
cysteine bridging site (i.e. two cysteine residues) would serve as an excellent initial substrate, 
enabling facile optimisation and analysis of the reaction without incurring the complications of 
working immediately on a full antibody with multiple polypeptide chains and multiple target 
disulfides for rebridging. 
3.4.1 PfRadA-dCys Cloning and Expression 
This work was conducted under the supervision of Dr. Marko Hyvönen, Department of 
Biochemistry. PfRadA is a DNA recombinase enzyme from Pyrococcus furiosus.190 Its C-
terminal ATPase domain (residues 108 – 349) has previously been expressed in bacterial cell 
cultures and has proven a viable substrate for mutagenesis.191,192 Importantly in the context of 
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contain any cysteine residues. Therefore, it was proposed that a construct could be generated 
via mutation of two neighbouring surface residues to cysteines to facilitate divinylpyridine 
cross-linking. To select suitable amino acids for mutation, the crystal structure of the ATPase 
domain of PfRadA was examined using PyMol. Two residues (N188 and E344) were identified 
as good sites for mutation due to their close proximity in the tertiary structure and the exposure 
of their side chains to solvent (Figure 3.5).  
 
Figure 3.5: a) Crystal structure of ATPase domain of PfRadA showing mutation sites of N188 and E344 
and b) close-up view of mutation sites. 
To begin production of the designed protein, it was hoped that the desired mutations could be 
inserted into the PfRadA gene sequence through molecular cloning using the well-described 
technique of site-directed mutagenesis via overlap extension polymerase chain reaction 
(PCR) (Figure 3.6). Briefly, incorporation of the desired mutation into forward and reverse 
primers enables the mutant gene to be synthesised in two halves via PCR. In turn, purification 
of each gene fragment and further PCR with the 5’ and 3’ primers of the gene facilitates 








Figure 3.6: Overview of site-directed mutagenesis via overlap extension PCR. Upon identification of 
the point mutation, complementary forward and reverse primers (oligonucleotides) are designed that 
contain the desired mutated codon. The gene is then synthesised in two fragments with termination 
occurring at the forward and reverse primer sequences. The gene segments are purified and are 
recombined for further PCR cycles. After melting, the complementary forward and reverse primers 
anneal and the full gene can be synthesised using forward (5’) and reverse (3’) primers for the native 
gene. Note that half of the original fragment gene DNA does not elongate as the 5’ and 3’ primers are 
in the opposite direction. 
Thus, forward and reverse primers containing the desired codon mutations were designed 
and purchased (Sigma) (Table 3.2). Importantly, due to the close proximity of the E344C 
mutation to the 3’-end of the gene, this mutation was inserted in the reverse primer for the full 



































5’ or 3’ primer
Oligonucleotide containing mutation
Primers containing desired mutation are designed
Gene synthesised in two halves
Complementary mutation oligonucleotide sequences
anneal to synthesise full gene
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Table 3.2: Forward and reverse primers were designed for site-directed mutagenesis. Mutated 
codons are underlined. 





PfRadA101 5’ GAAATTGCCCAGTGTAGAGGGTTG 3’ 





This method of two-step overlap extension PCR proved successful, enabling the desired gene 
sequence to be synthesised with ease. Agarose-gel analysis of the resulting two segments of 
the construct containing the desired mutations revealed DNA of appropriate base pair (bp) 
lengths (~500 and ~300 bp) (Figure 3.7a). In the second step, the complementary forward and 
reverse primers annealed and subsequent cycles of PCR amplified the complete PfRadA-
dCys gene (~700 bp) (Figure 3.7b). 
 
Figure 3.7: Agarose gel analysis of the synthesis of the mutant PfRadA-dCys gene via overlap 
extension PCR. a) in the first step, the mutant gene is synthesised in two segments and b) the two 
segments are combined in the second step to synthesise the full gene.  
In order to achieve PfRadA-dCys expression in Escherichia coli, the mutated gene was 
inserted within a pBAT4 vector.193 This plasmid contains a T7lac promoter with expression 
conducted by T7 RNA polymerase and which is induced by isopropyl-β-thiogalactopyranoside 
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and XhoI (restriction site: 5’ CTCGAG 3’) restriction sites, enabling precise insertion of the 
gene. Furthermore, protein expression using this vector generates an untagged protein. 
Upon restriction digestion of the synthetic gene and pBAT4 vector with NcoI HF and XhoI 
(Figure 3.8a), the gene was ligated into the plasmid and transformed into DH5α strain 
Escherichia coli., a high-quality strain commonly used in DNA cloning. Transformants were 
then selected, sub-cultured and the DNA extracted from the cells for restriction analysis. 
Isolated DNA was digested with NcoI HF and XhoI restriction enzymes. If the cells have taken 
up the plasmid containing the desired insert, a gene of the appropriate size will be observed 
by agarose gel analysis. A band at approximately 700 bp was observed in all cultures (Figure 
3.8b). The sequence of the genes from appropriate colonies were confirmed by DNA 
sequencing (Department of Biochemistry DNA Sequencing Department – Appendix D). 
 
Figure 3.8: a) PfRadA-dCys gene was digested with NcoI HF and XhoI restriction enzymes and purified 
from agarose gel. b) Restriction analysis of DH5a colonies. 
With a protocol in place to obtain a plasmid containing the desired mutation, a small-scale 
expression test was carried out to find optimal conditions for protein expression in BL21 (DE3) 
strain of E. coli. Analysis of the expression tests via sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) revealed that PfRadA-dCys (~25 kDa) was present in high 
quantities in the soluble cellular fraction and that many of the other proteins could be removed 
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Figure 3.9: SDS-PAGE analysis of PfRadA-dCys expression test. The desired protein was found in the 
soluble fractions and appeared thermostable. The empty vector does not contain the PfRadA-dCys 
gene and so no band appears in the gels at ~25 kDa. 
Having obtained a viable system for protein expression, scale-up commenced to produce 
larger quantities of protein to enable conjugation investigations. In this case, after heat 
treatment, the protein was further purified by ion exchange chromatography (Figure 3.10a) 
and finally using gel filtration (Figure 3.10b). LCMS analysis of the protein also confirmed its 
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Lane 1: Soluble, PfRadA-dCys 
Lane 2: Soluble, Emtpy vector 
Lane 3: Soluble, Heat treated PfRadA-dCys 





Figure 3.10: Protein fractions after a) ion exchange chromatography and b) gel filtration, c) mass 
spectrum of PfRadA-dCys and d) deconvoluted mass spectrum of PfRadA-dCys. Expected mass of 
25,305 Da with N-terminus methionine cleavage. 
3.4.2 PfRadA-dCys Bioconjugation 
With bis-cysteine containing protein, PfRadA-dCys in hand, site-selective cysteine rebridging 
of this protein using the divinylpyridine linkers was then investigated. Reducing agents such 
as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine hydrochloride (TCEP) are widely used 
disulfide reducing agents in chemical biology. PfRadA-dCys was firstly treated with TCEP for 
one hour at 37 °C to reduce any potential intra- or intermolecular disulfide bonds. The reduced 
protein was subsequently treated with linker 5 (10 molar equivalents) in 5% DMSO in a Tris 
buffer (50 mM Tris HCl pH 8, 150 mM NaCl) (Table 3.3, entry 1). Aliquots were removed from 
the reaction after 1-, 2-, 4- and 24-hour incubation and analysed by LCMS. Disappointingly, 
only minimal conversion to the desired bioconjugate 8 was observed, even after 24-hour 
incubation. In subsequent attempts to increase the conversion to the modified protein, 
numerous conditions were screened. First, linker stoichiometry was varied using 10, 20, 50 or 
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treating the protein with 50 and 100 equivalents of 5, significantly higher consumption of the 
unmodified protein was observed. However, undesired bis-alkylated PfRadA-dCys 
bioconjugate 9 was also observed as a major side product at these higher linker 
stoichiometries. To overcome this issue, the reaction concentration was lowered from 3 
mg/mL to 1 and 2 mg/mL. Again, the same relative concentrations of 5 were tested in these 
systems (Table 3.3, entries 5-12). However, no improvement in conversion to the bridged 
derivative 8 was observed by LCMS analysis.  
Table 3.3: Optimisation of the reaction of PfRadA-dCys with 5. Buffer conditions – pH 8 (50 mM Tris 


































pH SM (%)* 8 (%)* 9 (%)* 
1 3 10 5 8 90 10 0 
2 3 20 5 8 60 40 0 
3 3 50 5 8 20 75 5 
4 3 100 5 8 20 70 10 
5 2 10 5 8 70 30 0 
6 2 20 5 8 70 30 0 
7 2 50 5 8 40 60 0 
8 2 100 5 8 40 60 10 
9 1 10 5 8 95 5 0 
10 1 20 5 8 90 10 0 
11 1 50 5 8 45 65 0 
12 1 100 5 8 40 50 10 
13 2 15 (x2) 5 8 95 5 0 
14 2 20 10 8 95 5 0 
15 2 50 10 8 90 10 0 
16 2 10 5 7 95 5 0 
17 2 20 5 7 95 5 0 
18 2 50 5 7 80 20 0 
19 2 100 5 7 75 25 0 
20 5 20 5 8 10 80 10 
21 5 35 5 8 5 85 10 
22 5 50 5 8 5 85 10 
23 7 20 5 8 20 60 20 
24 7 35 5 8 5 85 10 
25 7 50 5 8 5 75 20 
* conversion measured by LCMS after 4 hours reaction time 
In light of these findings, attempts to add the linker batch-wise (Table 3.3, entry 13), use higher 
equivalents of TCEP (Table 3.3, entries 14 and 15) or alteration of the reaction pH (Table 3.3, 
entries 16-19) were trialled. In all cases, minimal effects on conversion were observed and 
large amounts of unreacted PfRadA-dCys remained. Finally, it was thought that increasing the 
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reaction concentration to 5 and 7 mg/mL and using lower linker equivalents may generate 
desirable conversion to 8 (Table 3.3, entries 20-25). Encouragingly, at 5 mg/mL and using 35 
equivalents of 5, good conversion to 8 was observed with only a relatively small amount 
(~10%) of bis-alkylated protein observed. Moreover, these conditions also resulted in the most 
successful conversion to the desired bridged conjugate 8 (85%) leaving only 5% unreacted 
PfRadA-dCys remaining. Examples of the typical deconvoluted LCMS traces are shown in 
Figure 3.11. 
 
Figure 3.11: Examples of the deconvoluted mass spectrums obtained in the optimisation of the reaction 
of PfRadA-dCys and divinylpyridine 5; a) Entry 5 – poor reactivity with unmodified PfRadA-dCys 
(expected mass 25,305 Da) as the major product and some bridged bioconjugate 8 (expected mass 
25,480 Da), b) Entry 4 – mixture of unmodified protein, 8 and bis-alkylated protein 9 (expected mass 
25,655 Da), and c) Entry 21 – major product is desired 8 with small amounts of unreacted protein and 
9 present. 
Given the comprehensive screen of conditions explored, it was concluded that achieving 
complete modification of PfRadA-dCys to bridged bioconjugate 8 would not be possible 
without forming any unbridged, bis-alkylated bioconjugate 9. It was proposed that incomplete 
conversion to the cysteine rebridged protein may have been due to the orientation of the 
engineered cysteine residues. Specifically, the cysteines incorporated into PfRadA-dCys may 













3.5 Antibody Modification 
Given the intrinsic difficulty in engineering a simple, monomeric protein model substrate 
bearing only one disulfide bridge, we decided to move onto a full antibody. Despite the 
aforementioned issues with multiple cysteine bonds and polypeptide chains, we envisioned 
that this would be a more feasible way to test our linker strategy on a relevant substrate. 
Furthermore, it was hypothesised that the right orientation of the disulfide bridges would be 
the most important factor in determining the feasibility of our strategy. 
3.5.1 Trastuzumab and HER2 
The human epidermal growth factor receptor 2 (HER2, ErbB2, neu) is a receptor tyrosine 
kinase that has been found to be overexpressed in 20-30% of invasive breast carcinomas and 
typically correlates with poor prognosis.195–198 It is a transmembrane receptor comprised of an 
extracellular binding domain and an intracellular tyrosine kinase domain. Tyrosine kinase 
activity can be induced by receptor hetero- or homo-dimerisation, or ligand binding. Upon 
induction, a resulting signalling cascade is initiated which promotes cell proliferation through 
the RAS-MAPK pathway and inhibits cell death through AKT-mTOR signalling (Figure 
3.12a).199 
Trastuzumab is a monoclonal antibody against the HER2 receptor. It was developed by 
Genentech/Roche and gained its first FDA approval in 1998 for HER2-positive metastatic 
breast cancer.200 Trastuzumab is a humanised murine IgG1 antibody that is now used in 
multiple cancer types that overexpress HER2.201 It has been proposed that trastuzumab can 
act via several mechanisms of action and that is it is likely that synergistic effects between 
many of these contribute to the tyrosine kinase inhibition, inducing cell death. For example, 
trastuzumab inhibits receptor dimerisation and shedding of the extracellular domain, whilst 
increasing HER2 endocytosis. Ultimately, all of these actions prevent tyrosine kinase activity 
of the HER2 intracellular domain and lead to cell death. Furthermore, trastuzumab has been 
shown to initiate immune activation at the tumour site through Fc-mediated recruitment of 




Figure 3.12: a) Mechanism of HER2 signalling through the tyrosine kinase induction and b) 
mechanisms for trastuzumab activity via c) inhibition of receptor shedding, d) inhibition of receptor 
dimerisation, e) immune recruitment and subsequent antibody-dependent cell-mediated cytotoxicity 
(ADCC) and f) receptor endocytosis. Reproduced with permission from Hudis, copyright Massachusetts 
Medical Society.202 
3.5.2 Trastuzumab Modification 
IgG1 antibodies such as trastuzumab contain four interchain disulfides that can be chemically 
reduced to reveal nucleophilic free thiols. Before commencing a conjugation study, 
identification of suitable conditions to afford complete reduction of the trastuzumab interchain 
disulfides was required. Following a literature procedure developed by Schumacher et al.,159 
treatment of trastuzumab in borate buffered saline (BBS) buffer (25 mM sodium borate pH 8, 
25 mM NaCl, 0.5 mM EDTA pH 8) with 10 molar equivalents of TCEP for one hour at 37 °C 
yielded full reduction of the interchain disulfides, as evidenced by SDS-PAGE (Figure 3.13a 
and b). Quantification of the number of free thiols present was also conducted using an 
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Ellman’s assay which utilises 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB or Ellman’s reagent). 
Using this method, free thiols react with Ellman’s reagent, producing a characteristic UV-vis 
absorbance that is then used to calculate the number of free thiols present in solution. This 
analysis revealed the presence of 8.15 free thiols, confirming that all of the trastuzumab 
interchain disulfide bonds had been reduced (Figure 3.13c and d). 
 
  




e412 = 14,150 M-1 cm-1       Abs412 = 0.15 
e280 = 215,380 M-1 cm-1     Abs280 = 0.28 
Figure 3.13: a) Reduction of trastuzumab with TCEP as evidenced by b) SDS-PAGE. Lanes; M) 
molecular weight marker, 1) unreduced trastuzumab, 2) reduced trastuzumab, and c) Ellman’s assay, 
d) formula used in Ellman’s assay to calculate the number of free thiols present. Buffer conditions – 
BBS; sodium borate pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM). 
With conditions in hand to afford interchain disulfide reduction, modification of trastuzumab 
with divinylpyridine linkers was subsequently investigated. To this end, conjugation with simple 
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SDS-PAGE and LCMS were used to monitor reaction progression, with aliquots removed from 
the reactions after 2-, 4- and 8-hour incubation for analysis. Attempted reaction optimisation 
included varying the stoichiometry of 5 (40, 60 100, 200 and 500 molar equivalents), reaction 
concentration (2.5, 5 and 7.5 mg/mL) and reaction buffer (Tris-buffer saline [TBS] or BBS).  
Table 3.4:  Conditions screened in the reaction of trastuzumab with 5. Buffer conditions – TBS; Tris 
HCl pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM). BBS; sodium borate pH 8 (25 mM), NaCl (25 





5 Eq. Buffer pH Time (h) Conversion 
1 2.5 40 TBS 8 2, 4, 8 Moderate 
2 2.5 60 TBS 8 2, 4, 8 Moderate 
3 2.5 100 TBS 8 2, 4, 8 Moderate 
4 2.5 200 TBS 8 2, 4, 8 Moderate 
5 2.5 500 TBS 8 2, 4, 8 Moderate 
6 5 100 TBS 8 2, 4, 8 Moderate 
7 5 200 TBS 8 2, 4, 8 Moderate 
8 7.5 100 TBS 8 2, 4, 8 Moderate 
9 7.5 200 TBS 8 2, 4, 8 Moderate 
10 2.5 100 BBS 8 2, 4, 8 Moderate 
11 2.5 200 BBS 8 2, 4, 8 Moderate 
12 5 100 BBS 8 2, 4, 8 Moderate 
13 5 200 BBS 8 2, 4, 8 Moderate 
14 7.5 100 BBS 8 2, 4, 8 Moderate 
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In all investigations, analysis by SDS-PAGE suggested conversion from unmodified light and 
heavy chain to the desired rebridged antibody 10 improved over time. Examples of the typical 
gels obtained are shown in Figure 3.14a. However, a number of other species were also 
observed in the reaction mixture, such as the half antibody conjugate formed from correct 
rebridging of the light and heavy chains but intrachain misbridging of the cysteine residues in 
the heavy chain hinge region (Figure 3.14b). The heavy-heavy-light and heavy-heavy partially 
rebridged species were also identified in the gel. Unfortunately, large quantities of unreacted 
light and heavy chain were also observed, ostensibly showing poor reactivity of divinylpyridine 
5 (Figure 3.14). Alteration of the linker concentration, reaction concentration or buffer had little 
effect on the conversion. Unmodified light and heavy chains and the half-antibody conjugate 
could also be identified and characterised by LCMS analysis (Appendix C). Formation of the 
half antibody conjugate as the dominant product of the reaction can be attributed to the close 
proximity of the heavy chain hinge region cysteines. These residues are separated by just two 
proline residues, enabling an intramolecular cysteine cross-linking reaction to occur upon 
conjugation of the first vinyl group of 5 to one cysteine. Indeed, formation of half-antibody 
trastuzumab bioconjugates has been observed with other cysteine rebridging reagents such 
as the isobutylene reagents reported by Sun et al. and the ADPN reagents developed by 





Figure 3.14: Analysis of the reaction between reduced trastuzumab and 5 by a) SDS-PAGE. The gel 
shown here is typical for all of the gels run in this analysis. Numbers above lanes represent entry 
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3.6 Conclusions 
Investigation of a divinylpyridine linker system for bridging of protein cysteine residues was 
described in this chapter. The reactivity of the scaffold was firstly detailed, followed by the 
synthesis of divinylpyridine reagents with reactive handles for further derivatisation with 
biologically-relevant payloads. Divinylpyridine conjugates were shown to be exceptionally 
stable in the presence of other free thiols in a small molecule model assay. Subsequently, 
genetic engineering and expression of a PfRadA-dCys protein containing two non-native 
cysteine residues was carried out followed by optimisation of the conjugation reaction of a 
divinylpyridine linker with PfRadA-dCys. Finally, an extensive screen of conditions was 
attempted to modify a trastuzumab antibody with a divinylpyridine linker. Disappointingly, the 
divinylpyridine linker was insufficiently reactive to enable efficient modification of trastuzumab. 
Although the trastuzumab modification results were disappointing, the work undertaken in this 
chapter did suggest the potential utility of a divinyl-heteroaryl motif for the synthesis of ADCs 
upon improvement to the scaffold reactivity.  
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Chapter 4 – 
Divinylpyrimidine Cysteine Rebridging Linkers 
4.1 Introduction 
Initial investigations with divinylpyridine linkers suggested that the vinyl-heteroaryl scaffold had 
the potential to fulfil the primary objectives of this work to generate highly stable bioconjugates. 
However, the poor reaction profile observed in antibody conjugation experiments 
demonstrated that in order to generate a robust bioconjugation platform, the reaction rate 
needed to be improved. It was also important to ensure that any modifications to the scaffold 
would not compromise the stability of the conjugates. Guided by these observations, it was 
hypothesised that increasing the electron deficiency of the ring would lead to an improved 
conjugate addition rate. This could be achieved by decorating the pyridine ring with electron 
withdrawing groups (e.g. NO2, CF3) or by replacement of the pyridine ring with a more electron 
deficient ring (e.g. a pyrimidine) (Figure 4.1). The pyrimidine core was chosen as a starting 
point for reactivity improvement due to the availability of starting reagents and the anticipated 
synthetic tractability of potential linkers. 
 
Figure 4.1: Potential strategies to increase the reactivity of the vinyl-heteroaryl motif. 
4.2 Reactivity of 4-vinylpyrimidine  
To begin investigations into the vinylpyrimidine scaffold, it was crucial to ascertain the rate of 















from commercially available 2-amino-4-chloropyrimidine via a Suzuki reaction in good yield 
(Scheme 4.1). 
 
Scheme 4.1: Synthesis of vinylpyrimidine 11 via Suzuki cross-coupling. 
Monovinylpyrimidine 11 (50 mM) was subsequently reacted with N-Boc-Cys-OMe (50 mM) in 
a mixture of acetonitrile and NaPi (50mM, pH 8) at 37 °C (Scheme 4.2). Monitoring of the 
reaction by TLC suggested that both starting materials had been consumed after just 15 
minutes. In comparison, analogous vinylpyridines 1 and 2, showed incomplete conversion 
after 240 minutes under the same conditions (Table 3.1, entries 1 and 6).  
 
Scheme 4.2: Reaction of vinylpyrimidine 11 with N-Boc-Cys-OMe to generate 12. 
Commonly used bioorthogonal reactions have second-order rate constants ranging from 10-4 
M-1 s-1 to 103 M-1 s-1.205 Inspired by the encouraging initial result, the rate constant for the 
reaction between cysteine and vinylpyrimidine 11 was measured to compare to other widely 
used bioconjugation methods. 1H NMR was determined to be an appropriate method for 
measuring the rate constant as the characteristic signals from the vinyl protons would be lost 
upon reaction. To this end, vinylpyrimidine 11 (10 mM) was treated with an excess of N-Boc-
Cys-OMe (50 mM, 100 mM or 150 mM) and the reaction monitored by 1H NMR with scans 





























11, 50 mM 50 mM 12
 57 
 
Scheme 4.3: Reaction rate studies between 11 with N-Boc-Cys-OMe. 
Disappearance of the vinyl proton signals could indeed be observed over time and could be 
used to quantify consumption of 11 (Figure 4.2a-d).  
 
Figure 4.2: a) Typical 1H NMR spectra obtained over time of reaction, with disappearing vinyl signals, 
and graphs of consumption of vinylpyrimidine 11 over time with b) 5 c) 10 and d) 15 molar equivalents 
of N-Boc-Cys-OMe. 
Utilising these NMR results from the treatment of vinylpyrimidine 11 with an excess of N-Boc-
Cys-OMe enabled determination of pseudo-first order rate constants for the consumption of 
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Table 4.1: Pseudo-first order reaction rates of 11 with increasing concentration of N-Boc-Cys-OMe. 
Entry [Cys] / mM k1 / s-1 Error / s-1 R2 
1 50 4.396´10-3 6.673´10-5 0.999 
2 100 9.475´10-3 2.239´10-4 0.997 
3 150 1.241´10-2 2.648´10-4 0.999 
 
The pseudo-first order rate constants could then be used to calculate a second order rate 
constant (k2) for the reaction of vinylpyrimidine 11 with N-Boc-Cys-OMe by plotting these 
calculated rate constants against the concentration of cysteine used (Figure 4.3). The second 
order rate constant was determined to be ~10-1 M-1 s-1. 
 
Figure 4.3: Calculation of second order rate constant for the reaction of N-Boc-Cys-OMe with 11 from 
experimental pseudo-first order rate constants. 
Although the rate constant for the reaction of vinylpyrimidine 11 with cysteine was on the lower 
end of the scale of typical bioconjugation rate constants, it is in a similar range to that of the 
ruthenium catalysed cross metathesis reaction or the strain-promoted azide-alkyne 
cycloaddition (SPAAC), both of which have been used extensively in bioorthogonal protein 
modification.206–209 It was also proposed that the relatively low rate constant for this reaction 
compared to other bioconjugation reaction may be beneficial as it could potentially offer a 












 = 0.990 
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4.3 Monovinylpyrimidine Stability 
In light of these promising reactivity results, it was hoped that the increase in reactivity of 
vinylpyrimidine 11 compared to the vinylpyridine reagents would not negatively affect the 
stability profile of this scaffold. To determine the stability of vinylpyrimidine conjugates, 12 was 
prepared from vinylpyrimidine 11 and N-Boc-Cys-OMe under the conditions described in 
Scheme 4.2 (Scheme 4.4). In order to compare the stability of cysteine conjugate 12 to a 
widely used cysteine modifying reagent, maleimide conjugate 13 was prepared in excellent 
yield by reaction of N-benzyl maleimide with N-Boc-Cys-OMe (Scheme 4.4). 
 
Scheme 4.4: Synthesis of vinylpyrimidine derivative 12 and maleimide derivative 13. 
Vinylpyrimidine-derived 12 and maleimide-derived 13 were subsequently incubated in a 
mixture of deuterated methanol and deuterated NaPi (50 mM, pH 7.4) in the presence of an 
excess (3 equivalents) of GSH (Scheme 4.5).  
 
Scheme 4.5: Stability analysis of conjugates 12 and 13 in the presence of GSH. 
The stability was monitored over two weeks by 1H NMR, with spectra obtained at 24-hour 
intervals (Appendix A). Encouragingly, 12 displayed >95% stability over this time course with 
only minimal degradation observed (Figure 4.4). In comparison, under the same conditions 
<50% of the maleimide-derived conjugate 13 remained intact over two weeks. This analysis 
suggested that circumvention of the reactivity issues observed with the vinylpyridine linkers 
by switching to a vinylpyrimidine core had not affected the stability of the cysteine conjugates 












































Figure 4.4: The degradation of 12 and 13 after two weeks incubation with GSH, as determined by 1H 
NMR; see Appendix A. 
4.4 Monovinylpyrimidine Chemoselectivity 
As was discussed in Chapter 3, vinylpyridine reagents selectively react with cysteine residues 
over other amino acids, even at basic pH. However, it was unknown if this was also the case 
for vinylpyrimidine reagents. In particular, it could be envisaged that vinylpyrimidines could 
also react with the nucleophilic amine of solvent-exposed lysine residues. To investigate the 
selectivity of the reagent for cysteine residues over lysine residues, a competition experiment 
was conducted. Vinylpyrimidine 12 was incubated with N-Boc-Cys-OMe and N-Boc-Lys-OMe 
under the previously used conjugation conditions of 30% MeCN in NaPi (50 mM, pH 8) at 37 
°C (Figure 4.5a). Analysis of the reaction after two hours by HPLC suggested that conversion 
to the cysteine adduct was the sole reaction product. Pleasingly, no evidence of the lysine 








Figure 4.5: a) Chemoselectivity competition experiment by reaction of 11 with N-Boc-Cys-OMe and N-
Boc-Lys-OMe. HPLC analysis of b) 11, c) 12 and d) the reaction after 2 hours.  
These promising reactivity, stability and chemoselectivity results inspired confidence that the 
vinylpyrimidine scaffold could be explored further and developed into a divinylpyrimidine motif 
for investigations into cysteine rebridging of antibodies. 
4.5 Divinylpyrimidine Synthesis 
In Section 3.3, the rationale for investigating symmetrical divinylpyridine linkers was explained. 
Similarly, it was decided that a symmetrical divinylpyrimidine (DVP) scaffold would be 
beneficial due to the potential synthetic tractability and the prevention of regioisomeric product 
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Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 21
Injection Date  : 16/03/2018 15:07:52                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-16 15-02-55\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 16/03/2018 15:02:56 by SYSTEM
Additional Info : Peak(s) manually integrated



































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.590 BV    0.1022 1.06420e4  1548.24377  59.1224
   2   3.668 VB    0.0812 7357.94629 1359.31262  40.8776
 
Totals :                  1.79999e4  2907.55640
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-16 15-02-55\STEVEW0249.D
Sample Name: SW465P1
HPLC 16/03/2018 15:42:50 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                           Location : Vial 14
Injection Date  : 13/03/2018 19:20:12                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-13 19-15-10\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 13/03/2018 19:15:11 by SYSTEM
Additional Info : Peak(s) manually integrated
























                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   7.822 BB    0.0797  531.91724  100.64706 100.0000
 
Totals :                   531.91724  100.64706
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-13 19-15-10\STEVEW0244.D
Sample Name: SW528P1
HPLC 16/03/2018 14:41:10 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 23
Injection Date  : 14/03/2018 18:59:06                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-14 18-54-10\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 14/03/2018 18:54:11 by SYSTEM




































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.683 BB    0.1526 1713.60327  153.02345  98.1095
   2   7.923 BB    0.0571   33.02035    8.93385   1.8905
 
Totals :                  1746.62362  161.95730
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-14 18-54-10\STEVEW0248.D
Sample Name: SW529_120min







were chosen as the starting point for investigations. Accordingly, commercially available 
building block 2-amino-4,6-dichloropyrimidine was subjected to Suzuki reaction conditions to 
synthesise divinylpyrimidine 15 in good yield (Scheme 4.6).  
 
Scheme 4.6:  Synthesis of DVP 15 via Suzuki cross-coupling. 
With a viable synthetic route to 15 in hand, synthetic efforts then moved toward modifying the 
amino group with other functionalities that would be amenable to payload attachment. A series 
of alkylation and amidation reactions were attempted in this endeavour (Table 4.2). First, 
amide coupling of 15 with 4-pentynoic acid was attempted under N,N,N’,N’-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) and propylphosphonic anhydride (T3P) conditions 
(Table 4.2, entries 1-4). Disappointingly, no evidence of the desired product was evident in 
the crude reaction mixtures via LCMS or TLC analysis with only unreacted starting material 
observed in all cases. To increase the reactivity of the acylating reagent, 4-pentynoic acid was 
converted into its corresponding acyl chloride and used immediately. Several bases (NEt3, 
NaH, DMAP) were screened in these investigations, yet no desired product was observed 
again after LCMS or TLC analysis of the reaction mixtures (Table 4.2, entries 5-9). Having 
tested a number of conditions in an attempt to acylate 15, it was proposed that its primary 
amine may be more amenable to alkylation. To this end, 15 was initially treated with propargyl 
bromide in the presence of a strong base (NaH) (Table 4.2, entry 10). Under these reaction 
conditions, double alkylation of the amine was observed in the reaction mixture via LCMS and 
1H NMR analysis. Although encouraging, mono-alkylation of the amine was desired and so a 
less reactive alkyl halide was explored. However, treatment of 15 with 6-chloro-1-hexyne and 
NaH yielded no observable product on analysis via LCMS (Table 4.2, entry 11). Gratifyingly, 
replacement of the alkyl chloride with its corresponding alkyl iodide generated the desired 
product 18 in 15% yield (Table 4.2, entry 12). Attempts to improve the conversion by varying 
the concentration of 6-iodo-1-hexyne and NaH garnered an increase in yield to 36% (Table 
4.2, entries 5-9). Indeed, increasing the scale of the reaction under the optimised conditions 
resulted in isolation of the desired alkynyl DVP 18 in 52% yield. However, further attempts to 
alkylate 15 to introduce other functional handles other than an alkyne under the optimised 































1 a (10) HBTU (10) DIPEA (10) DMF 16 rt 16 (0) 
2 a (20) HBTU (20) DIPEA (20) DMF 3 rt 16 (0) 
3 a (10) T3P (10) DIPEA (10) DMF 16 rt 16 (0) 
4 a (10) EDC (10) DMAP (10) DMSO 16 rt 16 (0) 
5 b (10) - NEt3 (2) CH2Cl2 16 rt 16 (0) 
6 b (50) - NEt3 (10) CH2Cl2 16 rt 16 (0) 
7 b (10) - DMAP (10) THF 16 rt 16 (0) 
8 b (50) - NaH (10) DMF 16 rt 16 (0) 
9 b (50) - NaH (10) DMF 16 80 16 (0) 
10 c (6.2) - NaH (6.2) DMF 6 rt 17 (0) 
11 d (2) - NaH (2) DMF 16 rt 18 (0) 
12 e (1.2) - NaH (1.2) DMF 6 rt 18 (15) 
13 e (5) - NaH (5) DMF 6 rt 18 (36)a 
14 e (5) - NaH (10) DMF 16 rt 18 (15) 
15 e (10) - NaH (5) DMF 16 rt 18 (34) 
16 f (5) - NaH (5) DMF 16 rt 19 (0) 
17 f (10) - NaH (10) DMF 16 rt 19 (0) 
18 g (5) - NaH (5) DMF 16 rt 20 (0) 

































In light of the difficulties observed with the attempted derivatisations of 15, it was proposed 
that another synthetic route may provide easier access to a range of functionalised 
divinylpyrimidines. Nucleophilic aromatic substitution (SNAr) is typically considered to be a 
robust and reliable method for the substitution of electrophilic aromatic halides with 
nucleophilic reagents. Research within the Spring group (Dr. Masao Yoshida, unpublished 
work) has demonstrated that SNAr chemistry can be used to substitute a single chlorine in 
hetero-aryl substrates containing multiple chloride groups. Thus, it was suggested that a 
trichloropyrimidine could firstly undergo SNAr with an appropriate nucleophile, followed by 
Suzuki cross-coupling to install the vinyl groups. To achieve this, 2,4,6-trichloropyrimidine was 
first treated with sarcosine ethyl ester hydrochloride in the presence of triethylamine for two 
hours at 0 °C (Figure 4.6). Analysis of the reaction mixture by LCMS and TLC suggested the 
formation of regioisomers from substitution at both the 2- and 4-position on the pyrimidine. 
Both regioisomers were isolated after FCC and subsequent identification by 13C NMR 
spectroscopy revealed that the 4-substituted isomer 22 was formed as the major product 
(50%) while the desired 2-substituted isomer 21 was generated as the minor product in just 
22% isolated yield.  
 
Figure 4.6: Nucleophilic aromatic substitution reaction between 2,4,6-trichloropyrimdine and sarcosine 
ethyl ester produces a mixture of isomers through substitution at the 2- and 4-positions.  
Dichloropyrimidine 21 was subsequently subjected to Suzuki reaction conditions to obtain 
DVP 23 in excellent yield. To complete the synthesis, hydrolysis of the ethyl ester of 23 was 
achieved using lithium hydroxide monohydrate, producing the desired DVP 24 in good yield 
(Scheme 4.7).  
 
Scheme 4.7: Synthesis of 23 via Suzuki cross-coupling and subsequent ester hydrolysis to provide 











































Whilst the yield for the SNAr reaction was disappointing, it was thought that the short synthetic 
route and inexpensive starting materials would enable the use of this synthetic sequence to 
access functionalised DVP reagents. As a result of this work, two short synthetic routes were 
now available to generate divinylpyrimidine scaffolds with suitable reactive handles for 
attachment of biologically-relevant modalities. 
4.6 Divinylpyrimidine Stability 
In Section 4.3, the stability of monovinylpyrimidine-derived conjugate 12 in the presence of 
another free thiol (GSH) was assessed, demonstrating that this conjugate was highly stable 
under the conditions tested. Before proceeding further in DVP development, it was important 
to confirm that the DVP scaffold also demonstrated the same high levels of conjugate stability. 
Accordingly, DVP linkers 15, 18 and 24 were reacted with N-Boc-Cys-OMe in 30% MeCN in 
NaPi (50 mM, pH 8) at 37 °C to yield cysteine conjugates 25, 26 and 27 in moderate to 
excellent yields (Scheme 4.8). 
 
Scheme 4.8: Synthesis of 25, 26 and 27 through reaction of DVP linkers 15, 18 and 24 with N-Boc-
Cys-OMe. 
Cysteine conjugates 25 and 27 were subsequently incubated with an excess of GSH in 40% 
CD3OD in deuterated NaPi (50 mM, pH 7.4) (Scheme 4.9).  
 





15; R = H, R1 = H
18: R = (CH2)4CCH, R1 = H
24; R = CH2CO2H, R1 = CH3
BocHN CO2Me
SH 30% MeCN/NaPi
(pH 8, 50 mM)











25; R = H, R1 = H, 55%
26: R = (CH2)4CCH, R1 = H, 91%











25; R = H, R1 = H
27; R = CH2CO2H, R1 = CH3
40% CD3OD/NaPi 
(D2O, pH 7.4, 50 mM)
GSH (3 eq.)
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The stability of the conjugates was monitored by 1H NMR over two weeks, with spectra 
obtained every 24 hours (Appendix A). Pleasingly, both 25 and 27 displayed >95% stability 
under the conditions investigated (Figure 4.7). Attempts to monitor the stability of cysteine 
conjugate 26 under the same conditions were unsuccessful due to its poor aqueous solubility. 
 
Figure 4.7: Graph representing the degradation of 25 and 27 after two weeks incubation with GSH and 
comparison with 12 and 13 as detailed in Section 4.3. 
4.7 Divinylpyrimidine Chemoselectivity 
In Section 4.4, the chemoselectivity of monovinylpyrimidine 11 for cysteine residues was 
determined via a competition experiment. Studies to ensure that the DVP linkers maintained 
that chemoselectivity for cysteine over lysine residues were then undertaken. In this assay, 
DVP reagents 15, 18 and 24 were treated with N-Boc-Cys-OMe and N-Boc-Lys-OMe in 30% 
MeCN in NaPi (50 mM, pH 8) at 37 °C. As each linker had two reactive vinyl groups, the 
excess of DVP in the reaction would potentially result in the formation of a mixture of mono- 
and bis-conjugated products. The reactions were monitored over four hours by HPLC and 
LCMS. In all cases, the mono-conjugated cysteine products (28, 29 and 30) were observed 
as the major product, with some evidence of the bis-conjugated cysteine products (Scheme 
4.10 and Appendix B). No evidence of the lysine-modified reagents was observed, confirming 







Scheme 4.10: Chemoselectivity competition experiment of 15, 18, and 19 with N-Boc-Cys-OMe and 
N-Boc-Lys-OMe. Only the cysteine conjugates were observed on analysis by HPLC and MS. 
4.8 Protein Chemistry 
Having investigated the potential of a DVP linker platform on a series of small molecule model 
systems, efforts now shifted toward the use of the synthesised DVPs for the modification of 
protein susbtrates. Initial protein investigations on the divinylpyridine reagents focused on the 
modification of PfRadA-dCys as a model protein with genetically incorporated cysteine 
residues (Section 3.4). This was chosen on the basis of using a simpler protein for initial 
reactivity investigations. However, it was thought that a more reflective model protein might 
be found in the use of an antibody fragment, such as an antibody Fab. Antibody fragments 
have experienced widespread interest in recent years as potential therapeutic agents and as 
potential delivery vehicles for cytotoxic warheads.210–212 Antibody fragments such as a Fab, a 
single chain variable region fragment (scFv), or diabodies are attractive molecules for targeted 
therapy development as they typically maintain the receptor affinity and selectivity that is seen 
with full antibodies, but their smaller size can allow better tissue penetration, faster clearance, 
and eliminates Fc-mediated antibody biology, which can result in non-cell-specific antibody 
internalisation.213–215 A Fab fragment is comprised of two polypeptide chains that are 
covalently linked by a single disulfide. One of the polypeptide chains is the light chain of an 
antibody (VL and CL domains) and the other is comprised of the VH and CH1 domains of the 
antibody heavy chain (Figure 4.8). Indeed, there are currently three antibody Fabs that have 
gained FDA approval for different diseases.216 It was envisaged that the small size (~50 kDa) 
and single native disulfide of an antibody Fab would make it an ideal candidate for initial 
studies on the DVP linkers. In addition, modification of Fab molecules may also generate 
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25; R = H, R1 = H,
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28; R = H, R1 = H,
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30; R = CH2CO2H, R1 = CH3
30% MeCN/NaPi 
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Figure 4.8: Comparison of the structures of an IgG antibody and an antibody Fab. 
4.9 Trastuzumab Fab Synthesis 
The simplest method for generating antibody Fabs is through enzymatic digestion of an IgG 
molecule. Papain digestion of an IgG typically segments the antibody into two Fab fragments 
and an Fc fragment. Selis et al. have reported the digestion of trastuzumab using this method 
to produce a pure supply of trastuzumab Fab.217 In contrast, Castañeda et al. reported that 
direct cleavage of trastuzumab with papain generates a mixture of products.218 Instead, they 
implemented a two-step procedure. First, treatment of trastuzumab with pepsin generated the 
F(ab’)2 fragment, which subsequently underwent papain digestion to generate pure 

















Figure 4.9: Methods for the digestion of trastuzumab to produce trastuzumab Fab. 
With the hope of simplifying the synthesis of the Fab, it was decided to investigate the one-
step procedure via direct papain digestion first. As such, trastuzumab was digested with 
immobilised papain from a Pierceä Fab preparation kit. Attempts to purify via protein A affinity 
chromatography were unsuccessful as the Fab appeared to also bind the protein A column. 
However, pure trastuzumab Fab was obtained after gel filtration and analysis by SDS-PAGE 
and LCMS (Figure 4.10).  
 
Figure 4.10: Analysis of trastuzumab Fab via a) SDS-PAGE, Lanes: M) molecular weight marker, 1) 








































4.10 Trastuzumab Fab Modification 
With trastuzumab Fab in hand, investigations then commenced into the rebridging potential of 
DVP linkers on this protein substrate. The single interchain disulfide of trastuzumab Fab was 
reduced by treatment with five equivalents of TCEP at 37 °C for one hour. Subsequently, the 
reduced Fab was treated with a range of DVP linkers (15, 18 or 24) in 5% DMSO in BBS (pH 
8) at 37 °C (Figure 4.11a). A small excess (10 molar equivalents) of linker enabled efficient 
rebridging of the Fab polypeptide chains in just one hour for all of the linkers, generating 
rebridged Fab conjugates 31, 32 and 33 (Figure 4.11b-g). Gratifyingly, TCEP removal was not 
required before addition of the linkers, suggesting that it did not interfere significantly in the 
conjugation reaction.  
 
 
Figure 4.11: a) DVP rebridging of trastuzumab Fab with DVPs 15, 18 and 24 and analysis by LCMS, 
Buffer conditions – BBS; sodium borate pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM), b) non-
deconvoluted MS of 31, c) deconvoluted MS of 31, expected mass 47,784 Da, d) non-deconvoluted 
MS of 32, e) deconvoluted MS of 32, expected mass 47,864 Da, f) non-deconvoluted MS of 33, and g) 
deconvoluted MS of 34, expected mass 47,856 Da. 
These promising studies suggested that Fab rebridging was complete after one hour using 
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31; R = H, R1 = H,
32: R = (CH2)4CCH, R1 = H,












faster timescale. In order to understand the rate of rebridging of the Fab light and heavy 
chains, trastuzumab Fab was first reduced and then treated with 10 or 20 molar equivalents 
of 18 (Figure 4.12a). At intervals of 5, 10, 15, 20, 30, 40 and 60 minutes, an aliquot was 
removed from each reaction, quenched with 100-fold molar excess of cysteine and conversion 
to the rebridged species quantified by LCMS. This analysis suggested that at both 10 and 20 
equivalents of 18, >90% rebridging had occurred after only 15 minutes, representative of an 
exceptionally fast rebridging reaction (Figure 4.12b). 
  
Figure 4.12: a) Studies on the rate of trastuzumab Fab rebridging after treatment with 18. Buffer 
conditions – BBS; sodium borate pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM), and b) graph of 
conversion to the rebridged Fab with varying equivalents of 18 with respect to time. 
With good conditions in hand for the rebridging of trastuzumab Fab, the chemoselectivity of 
the reaction was assessed on a protein system. Unreduced Fab contains no free thiols and 
so any modification of this protein without disulfide reduction would indicate modification of 
other amino acid residues. Unreduced trastuzumab Fab was treated with 10 equivalents of 
DVP 18 in 5% DMSO in BBS (pH 8) for two hours at 37 °C (Figure 4.13a). LCMS analysis of 
the reaction mixture revealed no modification of the protein, confirming the chemoselectivity 
of the DVP scaffold for cysteine residues (Figure 4.13b and c). 
  
Figure 4.13: a) Treatment of unreduced trastuzumab Fab with 18 and analysis by LCMS, Buffer 
conditions – BBS; sodium borate pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM),  b) non-
deconvoluted MS of reaction between unreduced Fab and 18 and c) deconvoluted MS, mass of 
unmodified Fab 47,655 Da. Small peak at higher mass than Fab is 47,910 Da and was present in the 
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4.11 Trastuzumab Modification 
The DVP linkers were shown to effectively rebridge an antibody Fab fragment, only requiring 
a small excess of rebridging linker to achieve full conversion in less than one hour. 
Investigations then commenced into DVP rebridging of an IgG molecule. As was discussed in 
Section 3.5.2, the four interchain disulfides in trastuzumab could be reduced upon treatment 
with 10 equivalents of TCEP for one hour at 37 °C. In an initial study, reduced trastuzumab 
was treated with 40 molar equivalents of simple DVP 15 in 10% DMSO in a TBS buffer (25 
mM Tris HCl pH 8, 25 mM NaCl, 0.5 mM EDTA pH 8) at 37 °C for two hours (Figure 4.14a). 
Analysis of the conjugation reactions by LCMS and reducing SDS-PAGE suggested good 
consumption of the light and heavy chains. This marked a radical improvement over 
divinylpyridine rebridging of reduced trastuzumab, which had significant quantities of 
unreacted light and heavy chain remaining after eight hours incubation and with much higher 
relative linker concentrations (Section 3.5.2). However, LCMS analysis suggested that the 
major product of the reaction was the half antibody conjugate (72,886 kDa) (Figure 4.14c and 
d). SDS-PAGE confirmed its presence, but also showed the presence of the correctly bridged 
full antibody conjugate (Figure 4.14b). It is interesting that the full antibody was only barely 
visible in the LCMS trace. This can potentially be attributed to the better ionisation ability of 
the smaller half antibody conjugate or to the ionisation parameters used in the LCMS method. 
Furthermore, the [M+2H]2+ ion of the correctly rebridged antibody would have the same mass-
to-charge ratio (m/z) as the [M+H]+ ion of the half antibody conjugate. Nevertheless, the 
combination of SDS-PAGE and LCMS analysis was found to give definitive evidence of good 




Figure 4.14: a) Synthesis of trastuzumab bioconjugate 34 as a mixture of full and half antibody via DVP 
rebrdging of reduced trastuzumab with 15, Buffer conditions – TBS; Tris HCl pH 8 (25 mM), NaCl (25 
mM), EDTA pH 8 (0.5 mM), b) SDS-PAGE analysis, Lanes: M) molecular weight marker, 1) 
trastuzumab, 2) reduced trastuzumab, 3) 34, Lane 1 is non-reduced, lanes 2 and 3 are reduced, c) non-
deconvoluted MS of 34, and d) deconvoluted MS of 34, expected mass 72,880 and 145,760 Da. 
In an attempt to overcome this potential issue of half antibody formation, a large number of 
reaction conditions were explored (Table 4.3). Unfortunately, modifications to reaction 
concentration, linker stoichiometry, organic co-solvent, co-solvent percentage and 
temperature had little effect on the ratio of half to full antibody conjugates formed in the 
reaction, as evidenced by SDS-PAGE and LCMS analysis. Morais et al. and Bahou et al. have 
recently reported optimised conditions to prevent half antibody formation with 
dibromomaleimide and dibromopyridazinedione reagents, respectively.161,166 In these cases, 
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with the antibody before TCEP addition to afford disulfide reduction. The same approach was 
also attempted with the DVP linkers, but without improvement to the ratio of half antibody 
formation (Table 4.3, entries 20-22). 
Table 4.3: Attempted conditions to prevent half antibody conjugate formation in the reaction of 
trastuzumab and 15. In all cases, no change in the ratio of half antibody to full antibody was observed. 










Time (h) Conversion 
1 2.5 37 DMSO (10) 10 1,2,4,8,24 Excellent 
2 2.5 37 DMSO (10) 20 1,2,4,8,24 Excellent 
3 2.5 37 DMSO (10) 40 1,2,4,8,24 Excellent 
4 2.5 37 DMSO (10) 60 1,2,4,8,24 Excellent 
5 2.5 37 DMSO (10) 100 1,2,4,8,24 Excellent 
6 2.5 37 DMSO (10) 200 1,2,4,8,24 Excellent 
7 2.5 37 DMSO (10) 500 1,2,4,8,24 Excellent 
8 1 37 DMSO (10) 40 1,2,4 Excellent 
9 5 37 DMSO (10) 40 1,2,4 Excellent 
10 7.5 37 DMSO (10) 40 1,2,4 Excellent 
11 2.5 37 DMSO (1) 40 1,2,4 Excellent 
12 2.5 37 DMSO (5) 40 1,2,4 Excellent 
13 2.5 37 DMSO (12) 40 1,2,4 Excellent 
14 2.5 37 DMSO (15) 40 1,2,4 Excellent 
15 2.5 25 DMSO (10) 40 1,2,4 Excellent 
16 2.5 4 DMSO (10) 40 1,2,4 Excellent 
17 2.5 37 DMF (10) 40 1,2,4 Excellent 
18 2.5 37 MeCN (10) 40 1,2,4 Excellent 
19 2.5 37 MeOH (10) 40 1,2,4 Excellent 
20a 2.5 37 DMSO (10) 40 1,2,4 Excellent 
21a 2.5 25 DMSO (10) 40 1,2,4 Excellent 
22a 2.5 4 DMSO (10) 40 1,2,4 Excellent 
a Linker (15) was added to trastuzumab and incubated for 10 minutes before the addition of TCEP (10 
molar eq.). 
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The screen of conditions tested did highlight the efficiency of the DVP rebridging reaction. 
Conversion from unmodified light and heavy chain to the half and full antibody conjugates was 
found to occur at very low linker stoichiometry (10 molar equivalents), at low antibody 
concentration (~5 µM), at low percentages of organic co-solvent, and at lower temperature. In 
addition, under all reaction conditions tested, the reaction appeared to be complete after just 
one hour. 
To further exemplify this approach, determination of the rebridging ability of alternative DVP 
reagents was also required. Accordingly, reduction of trastuzumab with TCEP and subsequent 
incubation with DVPs 18 and 24 in 10% DMSO in TBS at 37 °C for two hours resulted in good 
conversion to conjugates 35 and 36 (Figure 4.15a). Formation of both half and full antibody 






Figure 4.15: a) Synthesis of 35 and 36 from the reaction of trastuzumab with 18 and 24. Buffer 
conditions – TBS; Tris HCl pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM). b) Reducing SDS-
PAGE analysis, Lanes: M) molecular weight marker, 1) 35 2) 36, c) non-deconvoluted MS of 35, d) 
deconvoluted MS of 35, expected mass 73,040 and 146,080 Da, e) non-deconvoluted MS of 36, f) 
deconvoluted MS of 36, expected mass 73,024 and 146,048 Da. 
LCMS and SDS-PAGE analysis suggested conversion from the reduced antibody to the full 
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35: R = (CH2)4CCH, R1 = H,





















to quantify this conversion and analyse the effects of rebridging on the antibody structure, 
trastuzumab conjugate 35 was analysed by reverse phase HPLC (RP-HPLC) and size 
exclusion chromatography (SEC) at Spirogen (a biotechnology company specialising in ADC 
therapeutics, London). RP-HPLC analysis confirmed ~90% consumption of the unmodified 
light and heavy chains to both the full and half antibody conjugates in approximately a 40:50 
ratio, respectively (Figure 4.16).  
 
 
Figure 4.16: a) Analysis of the full and half antibody mixture of bridged trastuzumab 35 via RP-HPLC. 
b) RP-HPLC of trastuzumab, c) reduced trastuzumab and d) reduced 35. e) Percentage of the 
constituents of 35. This analysis was conducted at Spirogen. 
It is important to note that although undesirable, the half antibody conjugate remains highly 
useful, even as a mixture with the full antibody conjugate. Indeed, Lyon et al. have reported 
that ADCs with no interchain linkages have demonstrated exquisite in vivo activity.219 Critically, 
with DVP antibody conjugates, the light and heavy chains are covalently attached through 
rebridging of the Fab disulfide, ensuring that the region of the antibody that confers its receptor 





























chains has been lost, other non-covalent attractions such as hydrogen bonds, salt bridges and 
hydrophobic interactions will likely still hold the entire antibody together. This is evidenced by 
non-reducing and non-boiled SDS-PAGE analysis and SEC. A non-reduced SDS-PAGE 
analysis of conjugate 35 showed a single band in the gel at the same mass as unmodified 
trastuzumab (Figure 4.17a). Similarly, 35 eluted as a single peak from a SEC column at an 
identical retention time to trastuzumab (Figure 4.17b).  
 
Figure 4.17: a) Non-reducing SDS-PAGE analysis of 35, Lanes: M) molecular weight marker, 1) non-
reduced 35, b) SEC of trastuzumab and c) SEC of 35. 
4.12 Functional Antibody Modification 
The functionalisation of antibodies with biologically useful modalities (e.g. cytotoxic warheads, 
fluorophores, affinity tags) can provide extremely important tools in the study or perturbation 
of biological systems. The simple DVP reagents described thus far do not contain any 
functional payloads, the physical characteristics of which can vary greatly. For example, 
MMAE is a stable molecule that can be easily derivatised to attach to a bioconjugation linker. 
In contrast, routinely used imaging agents such as near-infrared (NIR) dyes are generally 
unstable, difficult to synthesise, and can only be purchased in low quantities (<1 mg). On this 
scale, chemical modification with a linker is challenging. However, if conjugation of the payload 
can be conducted directly on the protein of interest, low or sub-milligram quantities of reagent 
are more than sufficient. With this in mind, it was envisaged that functional modification of the 
antibody could take on two possible formats. In one approach, a pre-functionalised linker could 
be used to attach stable, modifiable payloads to the antibody. In another format, the DVP 
linkers could be used to install a bioorthogonal handle on the antibody which could be 
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4.12.1 Post-Rebridging Functionalisation 
A library of bioorthogonal reactions has now been developed that enables chemo- and site-
selective modification of proteins.43,99 One of the most commonly employed bioorthogonal 
reactions is the copper-catalysed azide-alkyne cycloaddition (CuAAC) “Click” reaction (vide 
supra). It was proposed that DVP reagents could be used to decorate an antibody with an 
alkyne or an azide handle, which would then be amenable to the attachment of the desired 
payload via CuAAC chemistry. This was seen as an attractive strategy for a number of 
reasons: 1) the CuAAC reaction has been shown to be a robust method of modifying a range 
of proteins and other biomacromolecules including DNA/RNA and polysaccharides;188,189 and 
2) a catalogue of potential payloads containing azide or alkyne groups are commercially 
available.  
4.12.1.1 Doxorubicin ADC 
Doxorubicin is a DNA intercalating agent that has seen significant use as a small molecule 
therapeutic and as a cytotoxic warhead in ADC development. Indeed, numerous ADCs armed 
with doxorubicin payloads have undergone clinical evaluation.220,221 It has been demonstrated 
that while this cytotoxin is not amenable to many chemical reactions, attachment of an azide-
containing moiety to doxorubicin through mild amide coupling conditions is tolerable.222 To this 
end, modification of its daunosamine sugar with a pendant azide group via HBTU-mediated 
amide coupling generated azide 37 in good yield (Scheme 4.11). 
 
Scheme 4.11: Synthesis of azide 37. 
With alkyne-functionalised trastuzumab 35 and azide 37 now in hand, post-rebridging 
investigations were able to commence. Accordingly, bioconjugate 35 was reacted with azide 
37 in PBS in the presence of CuSO4×H2O, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) 

































was performed and showed excellent conversion to the desired ADC 38 with a measured DAR 






(𝐴𝑏𝑠256 − 0.724 × 𝐴𝑏𝑠09:)/𝜀256
 
Figure 4.18: a) Post-conjugation CuAAC reaction between alkyne-modified trastuzumab 35 and azide 
37. b) Non-deconvoluted MS and c) deconvoluted MS of 38, expected mass 76,119 Da. d) UV-vis 
spectrum of 38, and e) calculation used to measure the DAR of 38 from the UV-vis data. A correction 
factor of 0.724 was required to account for doxorubicin absorbance at 280 nm. 
4.12.1.2 AlexaFluorä 488 Antibody-Fluorophore Conjugate  
Antibody-based imaging agents have seen a surge in interest in recent years in diagnostics 
due to the highly specific cellular imaging that can be achieved with antibody strategies.223,224 
With the aim of creating a potentially valuable imaging agent, alkyne-modified trastuzumab 35 
was reacted with commercially available AlexaFluorä 488 azide in PBS in the presence of 
CuSO4×H2O, THPTA and sodium ascorbate to yield the antibody-fluorophore conjugate (AFC) 
39 (Figure 4.19a). SDS-PAGE followed by in-gel fluorescence analysis suggested formation 












































e495 = 8,030 M-1 cm-1 
e280 = 215,380 M-1 cm-1  
Correction factor = 0.724 
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conversion to the desired conjugate with a measured fluorophore-antibody ratio (FAR) of 3.9 




       𝐹𝐴𝑅 =		 EFGHIJ/KHIJ
(EFGLMNO	6.11×EFGHIJ)/KLMN
 
Figure 4.19: a) Post-conjugation CuAAC reaction between alkyne-modified trastuzumab 35 and 
AlexaFluorä 488 azide. b) SDS-PAGE analysis of 39, Lanes: M) molecular weight marker, 1) 
Coomassie stain of 39, 2) in-gel fluorescent image of 39. c) UV-vis spectrum of 39, and d) calculation 
used to measure the FAR of 39 from the UV-vis data. A correction factor of 0.11 was used to account 
for AlexaFluorä 488 absorbance at 280 nm. 
The synthesis of a potentially useful therapeutic ADC and diagnostic AFC via post-rebridging 
CuAAC chemistry shows that DVP reagents can serve as a powerful tool for affecting tandem 
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e495 = 71,000 M-1 cm-1 
e280 = 215,380 M-1 cm-1  
Correction factor = 0.11 
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4.12.2 Pre-Rebridging Functionalisation with MMAE 
MMAE is a highly potent cytotoxin that inhibits tubulin polymerisation, thus preventing 
microtubule formation and subsequent cell division.57 It has been widely employed in ADC 
research, and is the payload used in many ADCs currently in clinical development and in the 
FDA-approved brentuximab vedotin (Adcetrisâ).33 Typically, MMAE is combined with a 
cleavable linker such as the cathepsin B-cleavable Val-Cit linker to release the free warhead 
from the antibody upon cellular internalisation. It was proposed to synthesise both cleavable 
and non-cleavable MMAE-containing ADCs, for comparison. Numerous examples of MMAE 
functionalisation with a variety of linkers have been reported, suggesting that synthesis of a 
DVP-MMAE linker-drug would be achievable prior to antibody conjugation.10,54,57 MMAE is an 
exceptionally potent cytotoxin and so extreme care should be taken during its use. Please see 
Chapter 7, General Experimental for full details on use of this chemical. 
4.12.2.1 Non-Cleavable MMAE ADC 
The design of any linker-drug molecule is crucial to ensure that one component does not 
disrupt the function of the other. This is particularly important for non-cleavable linkers as the 
two moieties will remain attached throughout the lifetime of the molecule in vivo, and it is 
important that the linker will not impede the biological mechanism of action of the warhead. It 
was hoped that a short polyethylene glycol (PEG) spacer would be sufficient to prevent 
negative interaction. Thus, modification of the MMAE N-terminus with a PEG spacer was 
achieved through an amide coupling with N3-PEG4-COOH in the presence of HBTU and 
DIPEA, providing azide-modified MMAE 40 in excellent yield (Scheme 4.12). Azide 40 was 




Scheme 4.12: Synthesis of DVP-PEG4-MMAE (41). 
Subsequently, reduction of trastuzumab was followed by treatment with linker-drug 41 (40 
equivalents) in 10% DMSO in TBS at 37 °C for two hours (Figure 4.20a). Excellent conversion 
to the rebridged non-cleavable MMAE ADC 42 was observed by LCMS and SDS-PAGE 
(Figure 4.20b-d). A mixture of the half and full antibody conjugates was again present in similar 







































































Figure 4.20: a) Synthesis of ADC 42. Buffer conditions – TBS; Tris HCl pH 8 (25 mM), NaCl (25 mM), 
EDTA pH 8 (0.5 mM). b) SDS-PAGE analysis, Lanes: M) molecular weight marker, 1) reduced 42. c) 
Non-deconvoluted MS and d) deconvoluted MS of 42, expected mass 74,994 and 149,988 Da. 
4.12.2.2 Cleavable MMAE ADC 
A range of cleavable linkers have been successfully employed in ADC research, as described 
in Section 1.5.1. The most commonly used drug release mechanism is the cathepsin B-
mediated cleavage of valine-citrulline and valine-alanine dipeptide motifs to release an 
unmodified cytotoxic warhead (vide supra). Synthetic routes to Val-Cit and Val-Ala MMAE 
linker-drugs are well described.225,226 In addition, Alloc-protected valine-alanine-4-
aminobenzyl alcohol (Alloc-Val-Ala-PABA, 43) was readily available from AstraZeneca and so 
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carbonate in the presence of diisopropylethylamine (DIPEA) (Scheme 4.13). This activated 
carbonate intermediate was subsequently reacted with MMAE in the presence of 1-
hydroxybenzotriazole hydrate (HOBt×H2O) and pyridine, providing access to 44 in 88% yield 
over two steps. Removal of the Alloc protecting group proceeded smoothly under Pd(PPh3)4 
catalysis in the presence of pyrrolidine as an allyl scavenger.227 Amide coupling of the 
unprotected amine with the carboxylic acid of DVP 24 was achieved with HBTU, HOBt×H2O 
and DIPEA to yield cleavable DVP-MMAE linker-drug 45 in excellent yield over two steps 
(Scheme 4.13). 
 
Scheme 4.13: Synthesis of cleavable linker-drug 45.  
With 45 in hand, conjugation of this linker-drug to reduced trastuzumab was attempted using 
40 equivalents of 45 in 10% DMSO in TBS at 37 °C (Figure 4.21a). Disappointingly, no 

























































Figure 4.21: a) Attempted modification of trastuzumab with 45 and b) example reducing SDS-PAGE 
analysis of the reaction showing only unreacted light and heavy chains. Lanes; M) molecular weight 
marker, 1) reaction of trastuzumab with 40 eq. of drug-linker 45. Buffer conditions – TBS; Tris HCl pH 
8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM). 
It was noted that on addition of the linker-drug solution in DMSO into the solution of reduced 
trastuzumab in TBS, a white precipitate immediately formed, suggesting that 45 was insoluble 
in this solvent system. A small screen of conditions was performed, varying the organic solvent 
(DMSO, DMF, MeCN and MeOH) and the final percentage of organic co-solvent in the reaction 
(10 and 15%) (Table 4.4). In all cases, the concentration of the drug-linker stock solution was 
adjusted so that the final percentage of organic solvent would be present immediately on 
addition. However, a white precipitate was formed in all cases and no conversion to the 
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Table 4.4: Attempted modification of trastuzumab with linker-drug 45. Conversion determined from 
SDS-PAGE analysis. 
Entry Co-solvent Co-solvent % (v/v) Conversion 
1 DMSO 10 None 
2 DMF 10 None 
3 MeCN 10 None 
4 MeOH 10 None 
5 DMSO 15 None 
6 DMF 15 None 
7 MeCN 15 None 
8 MeOH 15 None 
 
This result was somewhat surprising as the structurally similar maleimide linker-drug, mc-Val-
Cit-PABC-MMAE (Figure 4.22b) is a widely used linker-drug for synthesising cleavable MMAE 
ADCs. It was proposed that the short spacer between the DVP linker and the valine residue 
may be affecting the solubility and thus the reactivity of the linker, as the mc-Val-Cit-PABC-
MMAE has a longer alkyl chain between the maleimide and the valine. Drug-linkers 47 and 48 
were proposed as a potential solution to these solubility and reactivity issues (Figure 4.22c 
and d).  
 88 
 
Figure 4.22: a) Linker-drug 45 failed to show any reactivity with trastuzumab, b) commonly used 
maleimide reagent mc-Val-Cit-PABC-MMAE, and proposed DVP reagents c) 47 and d) 48 that are 
similar in structure to mc-Val-Cit-PABC-MMAE. MMAE highlighted in blue, cleavable motif in red and 
linker in black. 
Synthesis of the Val-Cit-PABC-MMAE fragment of proposed linker-drug 48 commenced from 
succinimide-activated amino acid Fmoc-Val-OSu, which was treated with L-citrulline to 
produce the Fmoc-protected Val-Cit dipeptide 49 in near quantitative yield (Scheme 4.14). 
Attachment of the self-immolative PABC spacer was subsequently achieved by treatment of 
the protected dipeptide 49 with 4-aminobenzyl alcohol in the presence of 2-ethoxy-1-
ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) coupling agent, to produce 50 in moderate yield. 
Activation of the benzyl alcohol was then achieved as previously described for the Val-Ala 
dipeptide by treatment with bis(4-nitrophenyl) carbonate in the presence of DIPEA. 
Conversion of the active carbonate to the desired carbamate proceeded smoothly upon 
reaction with MMAE, HOBt×H2O and pyridine, producing 51 in 39% yield over two steps. 


















































































































amine with DVP 52 (see Section 7.2.1 for synthetic details) in the presence of HBTU, 
HOBt×H2O and DIPEA, to generate the desired linker-drug 48 in 20% yield over two steps. 
Although the final deprotection and amide coupling sequence produced 48 in a relatively low 
yield, sufficient material was produced to conduct conjugation studies. 
 
Scheme 4.14: Synthesis of linker-drug 48. 
In order to compare the conjugation abilities of Val-Cit- and Val-Ala-containing linker-drugs, 
the analogous Val-Ala cleavable linker-drug 47 was also synthesised in two steps from the 
previously synthesised Alloc-Val-Ala-PABC-MMAE 44. Alloc deprotection via Pd(PPh3)4 
catalysis was followed by amide coupling of the free amine and DVP 52 in the presence of 
HBTU and DIPEA, to yield Val-Ala linker-drug 47 (Scheme 4.15). 
 








































































































The conjugation capabilities of linker-drugs 47 and 48 to trastuzumab were then investigated. 
The linker-drug conjugates were again added to reduced trastuzumab in four different organic 
co-solvents (DMSO, DMF, MeCN and MeOH), with each reaction containing 10% v/v organic 
solvent (Figure 4.23a). Disappointingly, no conversion to the desired bridged conjugates 53 
or 54 could be observed by SDS-PAGE and LCMS analysis under any of the reaction 
conditions tested (Figure 4.23b). In a similar fashion to the conjugation studies conducted with 
45, a white precipitate was formed in all reactions with 53 and 54 upon addition into the TBS 
buffer. 
 
Figure 4.23: a) Attempted modification of trastuzumab with 47 and 48. b) Example reducing SDS-
PAGE analysis of the reactions showing only unreacted light and heavy chains. Lanes, M) molecular 
weight marker, 1) example reaction of trastuzumab with Val-Cit linker-drug 48, 2) example reaction of 
trastuzumab with Val-Ala linker-drug 47. Buffer conditions – TBS; Tris HCl pH 8 (25 mM), NaCl (25 
mM), EDTA pH 8 (0.5 mM). 
Given the apparent solubility issues with the initial cleavable linkers, it was postulated that 
PEGylation of the linker-drug conjugate would potentially increase the aqueous solubility of 
the constructs. Based on this hypothesis, two linker-drug constructs were synthesised using 
commercially available hetero-bifunctional PEGylation reagents. Linker-drug conjugates 
containing four and nine PEG units were synthesised in three and five steps, respectively, 
from a common Alloc-Val-Ala-PABC-MMAE intermediate 44 (Scheme 4.16). Synthesis of 
DVP-PEG4-Val-Ala-PABC-MMAE 57 commenced with Alloc deprotection of dipeptide 44 
under standard Pd(PPh3)4 catalysis followed by HBTU-mediated amide coupling with N3-
PEG4-CO2H to give azide 56 in 70% yield over two steps. Subsequent reaction of azide 56 
with alkynyl DVP 18 under CuAAC conditions produced DVP-PEG4-Val-Ala-PABC-MMAE 57 
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Similarly, synthesis of DVP-PEG9-Val-Ala-PABC-MMAE 60 commenced by Alloc deprotection 
followed by amide coupling with FmocHN-PEG5-CO2H, producing PEGylated dipeptide 58 in 
moderate yield. Fmoc removal with piperidine was followed by another amide coupling with 
N3-PEG4-CO2H generated azide 59. The synthesis of the desired linker-drug was completed 
via a CuAAC reaction between azide 59 and alkyne 18 to give DVP-PEG9-Val-Ala-PABC-
MMAE 60 in 59% yield. 
 




































































































































Initial antibody conjugation investigations focused on DVP-PEG9-Val-Ala-PABC-MMAE 60 
due to its potentially better aqueous solubility and thus better probability of reactivity. A number 
of conditions were screened, varying the organic co-solvent, organic co-solvent percentage, 
linker equivalents and reaction concentration (Table 4.5).  
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Table 4.5: a) Attempted conjugation of trastuzumab with linker-drug 60 and b) typical reducing SDS-
PAGE analysis. Lanes; M) molecular weight marker, 1) entry 16 reaction. Buffer conditions – TBS; Tris 






60 Eq. Conc. (mg/mL) Conversion 
1 DMF 10 40 2.5 None 
2 DMSO 10 40 2.5 None 
3 MeCN 10 40 2.5 None 
4 MeOH 10 40 2.5 None 
5 DMF 15 40 2.5 None 
6 DMSO 15 40 2.5 None 
7 MeCN 15 40 2.5 None 
8 MeOH 15 40 2.5 None 
9 DMSO 20 60 2.5 Moderate 
10 DMSO 20 80 2.5 Moderate 
11 DMSO 20 100 2.5 Moderate 
12 DMSO 20 120 2.5 Moderate 
13 DMSO 20 60 5 Moderate 
14 DMSO 20 80 5 Moderate 
15 DMSO 20 100 5 Moderate 
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Varying the organic co-solvent to either DMSO, DMF, MeCN or MeOH at 10% v/v yielded no 
reaction to the desired conjugate by LCMS and SDS-PAGE analysis (Table 4.5, entries 1-4). 
Similarly, increasing the organic solvent percentage in the reaction to 15% v/v had little effect 
on reactivity (Table 4.5, entries 5-8). Disappointed by these results, an exceptionally high 
organic solvent make-up (20% v/v) was investigated. Moderate reactivity was observed with 
this high organic solvent ratio upon increasing the linker stoichiometry from 40 to 120 molar 
equivalents (Table 4.5, entries 9-12). An increase in the reaction concentration from 2.5 
mg/mL to 5 mg/mL also yielded slight improvements in reactivity (Table 4.5, entries 13-16). 
However, even under these forcing conditions, large amounts of unreacted heavy and light 
chain could still be observed by SDS-PAGE analysis and the harsh conditions required to 
observe any reactivity suggested that this linker-drug could not be used to produce an ADC 
with a cleavable payload.  
The shorter PEGylated cleavable linker-drug 57 was then examined for its antibody 
conjugation properties (Table 4.6). 
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Table 4.6: Optimisation of trastuzumab conjugation with PEGylated linker-drug 57. Buffer conditions – 










1 DMF 10 40 2.5 Moderate 
2 DMSO 10 40 2.5 Moderate 
3 MeCN 10 40 2.5 Moderate 
4 MeOH 10 40 2.5 Moderate 
5 DMF 15 40 2.5 Good 
6 DMSO 15 40 2.5 Moderate 
7 MeCN 15 40 2.5 Good 
8 MeOH 15 40 2.5 Moderate 
9 MeCN 15 60 2.5 Good 
10 MeCN 15 80 2.5 Good 
11 DMF 15 80 2.5 Excellent 
 
 
The same initial screen of conditions was tested for DVP-PEG4-Val-Ala-PABC-MMAE 57 as 
was previously attempted with linker-drug 60 by varying the organic co-solvent (DMSO, DMF, 
MeCN or MeOH) and co-solvent percentage (10 or 15% v/v) (Table 4.6, entries 1-8). 
Pleasingly, at 15% (v/v) MeCN and DMF and using 40 molar equivalents of linker-drug 57 
(Table 4.6, entries 5 and 7), good reactivity was observed and the predominant species in 
both reactions was identified as the half and full antibodies, indicative of good reactivity. 
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reaction (Table 4.6, entries 9 and 10). However, an increase in linker stoichiometry in DMF 
from 40 to 80 molar equivalents produced high levels of conversion from the reduced antibody 
to the rebridged bioconjugate 62. This was confirmed by LCMS and SDS-PAGE (Figure 4.24a-
c).  
 
Figure 4.24: Analysis of cleavable ADC 62 by a) SDS-PAGE, Lanes: M) molecular weight marker, 1) 
reduced 62. b) Non-deconvoluted MS and c) deconvoluted MS of 62, expected mass 75,636 and 
151,272 Da. 
With some modification and optimisation to the linker-drug design and bioconjugation reaction 
conditions, the DVP linkers were shown to efficiently modify trastuzumab to produce both 
cleavable and non-cleavable ADCs. Initial difficulties in synthesising an ADC with a cleavable 
linker were overcome by the introduction of a short PEG chain (PEG4) between the cleavable 
dipeptide motif and the DVP moiety.  
4.13 Biological Evaluation 
Having demonstrated the capability of a series of DVP linkers to rebridge disulfide bonds in 
antibodies with functional payloads (both cytotoxins and a fluorescent imaging agent), it was 
now important to understand the effects of modification on the biological properties of the 
synthesised conjugates. When developing any method for synthesising ADCs, a number of 
factors must be considered when evaluating the effects of conjugation on the antibody. For 
example, it is critical that the linkage formed is highly stable in circulation to ensure that the 
cytotoxic warhead is only released upon endocytosis. The effects of modification on receptor 
affinity and selectivity must also be considered. Ultimately, the conjugation methodology must 














a series of assays that were designed and developed to enable this analysis and give a 
comprehensive understanding of the characteristics of DVP-modified antibody conjugates. 
4.13.1 Stability 
The first priority was to ascertain the stability of the DVP linkage to the antibody. Small 
molecule studies described in Sections 4.3 and 4.6 indicated that the thioether linkage was 
stable at physiological pH and in the presence of other thiols such as GSH. While useful, a 
more robust and potentially biologically-relevant assay would be required to gain a clear 
understanding of the stability of the linkage under physiological conditions. It was proposed 
that analysis of the stability in plasma would generate data reflective of the potential circulatory 
stability of the conjugates. Human plasma contains a large number of proteins, the most 
abundant of which is human serum albumin (HSA). HSA constitutes approximately 50% of all 
serum proteins and its main functions involve the transport of hormones, fatty acids, and other 
nutrients throughout the body.228 Approximately 70% of HSA contains one free thiol (Cys34) 
that could potentially react with any free linker if a retro-conjugate addition occurred to release 
the linker-drug. Indeed, the free thiol of Cys34 has been exploited in many instances to 
generate albumin-drug conjugates or other biotherapeutics.229,230  
A stability assay was designed that would enable analysis by SDS-PAGE, which would be 
able to separate the complex mixture of proteins present in human plasma including HSA (~66 
kDa) from the full antibody (~150 kDa) or half antibody (~75 kDa) conjugates. Fluorescent 
antibody conjugate 39 was deemed to be ideally suited for this analysis. Using this AFC, SDS-
PAGE analysis of human plasma containing 39 could be monitored by in-gel fluorescence 
imaging and compared to Coomassie staining of the gel. This comparison would reveal if the 
linker-fluorophore had been released or transferred to HSA. In contrast, if an unfunctionalised 
DVP linker conjugate or even an ADC was analysed, it would not be possible to observe if the 
linker had been released from the antibody via this analytical method. To this end, AFC 39 
was incubated in human plasma at 37 °C for two weeks (Figure 4.25a). Aliquots were removed 
on days 0, 1, 3, 5, 7, 9, 11 and 14, and analysed by SDS-PAGE (Figure 4.25b and c). 
Gratifyingly, in-gel fluorescent imaging followed by Coomassie staining demonstrated almost 
no transfer of the fluorescent linker-drug conjugate to HSA or any of the other plasma proteins 




Figure 4.25: Stability evaluation of DVP bioconjugates by a) incubation of fluorescent trastuzumab 
bioconjugate 39 in human plasma for two weeks and analysis by SDS-PAGE. b) Coomassie stained 
SDS-PAGE analysis, c) in-gel fluorescence analysis, Lanes: M) molecular weight marker, 39) AFC 39, 
P) human plasma. Numbers above the remaining lanes indicate the day of incubation when aliquot was 
removed from the reaction. 
This analysis confirmed the exquisite stability profile of the DVP linker system and enabled 
further investigation into the biological profile of the antibody conjugates. 
4.13.2 Binding Affinity 
The effect of DVP rebridging on the binding affinity of trastuzumab for its native HER2 receptor 
was then investigated. DVP rebridging introduces a seven-atom linkage between the disulfide-
derived thiols. It is possible to envisage that this bridge would change the tertiary structure of 

























rebridging could improve the binding affinity of the antibody for its receptor. Recent work by 
Martínez-Saez et al. demonstrated that a disulfide rebridged trastuzumab using a dibromo-
oxetane reagent had a lower dissociation constant (KD) for HER2 than its native, disulfide-
containing counterpart.231 To determine the binding affinity of the modified antibodies in 
comparison to the unmodified antibody, an enzyme-linked immunosorbent assay (ELISA) was 
devised. Accordingly, the binding affinity of trastuzumab DVP bioconjugates 34, 35 and 36 to 
the HER2 receptor were analysed by ELISA. Encouragingly, no significant difference was 
observed between any of the trastuzumab conjugates and unmodified trastuzumab (Figure 
4.26). The binding affinity results are suggestive that rebridging with DVP reagents does not 
have any effect on the affinity of modified trastuzumab antibodies for the HER2 receptor.  
 
Figure 4.26: a) DVP-modified trastuzumab bioconjugates analysed for HER2 binding affinity by ELISA. 
b) Comparison of binding affinity of trastuzumab, 34, 35 and 36. Error bars represent the standard 
deviation of technical quadruplicates.  
4.13.3 Cellular Selectivity 
Pleased by the retained binding affinity of our modified ADCs for HER2, we then moved on to 
determine if selectivity was also retained. There is a huge number of receptors present on the 
cell surface making it virtually impossible to carry out ELISA analysis on all of these and 
compare binding affinities. However, flow cytometry could be used to determine the cellular 
selectivity of fluorescent antibody conjugates. Upon treatment with AFC 39, comparison of the 
labelling of HER2-positive cell lines with labelling of HER2-negative cell lines could be used 
to elucidate the receptor selectivity of the DVP bioconjugate. To this end, two HER2-positive 
cell lines (SKBR3 and BT474) and two HER2-negative cell lines (MCF7 and T47D) were 
incubated with AFC 39 (50 nM) for one hour at 37 °C. The cells were collected, washed and 
analysed by fluorescence-activated cell sorting (FACS) (Figure 4.27a-d). Pleasingly, this 
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cell lines. In contrast, the MCF7 and T47D lines showed almost no fluorescent signal on any 
cells (Figure 4.27e). Cellular images obtained from the flow cytometry investigations also 
confirmed the high levels of selectivity observed for the HER2-positive cell lines (Figure 4.27f). 
 
Figure 4.27: FACS analysis of 39 labelling of a) SKBR3 cells, b) BT474 cells, c) MCF7 cells and d) 
T47D cells. e) Percentage of cells labelled in the four cell lines after incubation with 39, and f) imaging 
of the four cell lines shows 39 labelling of HER2-positive cells (SKBR3 and BT474), with no observed 
labelling of HER2-negative cell lines (MCF7 and T47D). DRAQ5 is a nuclear stain. 
4.13.4 Cytotoxicity 
The stability, receptor affinity and cellular selectivity data obtained inspired confidence that the 
DVP ADCs could be evaluated for their cytotoxic potential. First, appraisal of non-cleavable 
DVP ADC 42 to selectively kill HER2-positive cells was undertaken. SKBR3, BT474, MCF7 
and T47D cell lines were treated with varying concentrations of 42, trastuzumab and MMAE. 
After 96 hours incubation, a CellTiter-Gloâ assay was used to measure the number of viable 
cells present for each concentration of the different compounds tested. Pleasingly, ADC 42 
demonstrated exquisite potency against both SKBR3 and BT474 cell lines, whilst displaying 
no activity against MCF7 or T47D lines at the concentrations tested (Figure 4.28a). The ADC 
had IC50 values of ~62 pM and ~275 pM against SKBR3 and BT474 cell lines, respectively. In 
contrast, MMAE was exceptionally potent against all four cell lines, regardless of HER2 
expression (Figure 4.28b), while trastuzumab alone displayed almost no activity against any 
of the cell lines (Figure 4.28c).  
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Figure 4.28: Cell viability of HER2-positive (SKBR3 and BT474) and HER2-negative cell lines after 96-
hour treatment with a) 42, b) MMAE and c) trastuzumab. Each treatment had three technical replicates 
with the results represented as the average of three biological replicates from independent passages 
of each cell line. Data reported as the mean of the three biological replicates and error bars represent 
s.e.m. 
To confirm the potency and selectivity observed with the 96-hour cell viability assay, cell 
growth was monitored for six days after treatment of all four cell lines with ADC 42. Confirming 
the CellTiter-Gloâ assay results, the ADC displayed a high degree of potency against both 
SKBR3 and BT474 cell lines, whilst no significant activity was observed against the HER2-
negative MCF7 and T47D cell lines (Figure 4.29a-d). 
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Figure 4.29: Cell growth curves after incubation with ADC 42 for six days in a) SKBR3, b) BT474, c) 
MCF7 and d) T47D cell lines. 
Finally, the potency of cathepsin-cleavable ADC 62 was evaluated in a HER2-positive and 
HER2-negative cell line. Treatment of SKBR3 and MCF7 cell lines with 62 was followed by 
CellTiter-Gloâ cell viability determination after 96 hours incubation. ADC 62 showed 
exceptional potency against SKBR3 cells, with little cytotoxicity observed in MCF7 cells at the 
concentrations tested (Figure 4.30a). The ADC had a calculated IC50 of ~15 pM against the 
SKBR3 cell line. Growth of the cells was also monitored over four days and similarly showed 
high levels of activity in SKBR3 cells with no significant activity observed in MCF7 cells (Figure 





Figure 4.30: a) Cell viability of SKBR3 and MCF7 cells after 96-hour treatment with 62 and four-day 
cell growth analysis of 62 in b) SKBR3 cells and c) MCF7 cells. Viability data reported as the mean of 
three biological replicates from independent passages of each cell line and error bars represent s.e.m. 
4.14 Modification of PfRadA-dCys 
The synthesis of ADCs via DVP cysteine rebridging was shown to proceed in a site-selective 
and efficient manner. Functionalised antibodies demonstrated an excellent biological profile 
with outstanding stability, receptor affinity and selectivity, and highly potent and selective 
cytotoxicity. It was also hoped that DVP reagents could be used to modify non-antibody 
proteins. To this end, PfRadA-dCys was treated with a slight excess (15 molar equivalents) of 
unfunctionalised DVP linkers 15, 18 and 24 for one hour at 37 °C (Figure 4.31a). Subsequent 







Figure 4.31: a) Modification of PfRadA-dCys with 15, 18 and 24. LCMS analysis of the resulting 
bioconjugates 63, 64, and 65; b) non-deconvoluted MS of 63, c) deconvoluted MS of 63, expected 
mass 25,451 Da, d) non-deconvoluted MS and e) deconvoluted MS of 64, expected mass 25,531 Da; 
f) non-deconvoluted MS and g) deconvoluted MS of 65, expected mass 25,523 Da. Buffer conditions – 
TBS; Tris HCl pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM), guanidine hydrochloride (3 M). 
In contrast to the divinylpyridine modification of PfRadA-dCys described in Section 3.4, no 
evidence of double alkylation was observed when treated with higher equivalents of 18 and 
left for an extended reaction time. This result indicated that the increased rebridging efficiency 
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Figure 4.32: a) Modification of PfRadA-dCys with high molar equivalents of 18 and LCMS analysis of 
the reaction; b) non-deconvoluted MS and c) deconvoluted MS of the reaction mixture, expected mass 
25,531 Da. No evidence of double alkylation, expected mass, 25,758 Da. Buffer conditions – TBS; Tris 
HCl pH 8 (25 mM), NaCl (25 mM), EDTA pH 8 (0.5 mM), guanidine hydrochloride (3 M). 
4.15 Conclusions 
In this chapter, the development of a divinylpyrimidine (DVP) linker system was described. In 
the first instance, assessment of the reactivity, chemoselectivity and stability of the thioether 
conjugates was undertaken on the vinylpyrimidine scaffold in a series of small molecule model 
systems. Having completed analysis on the monovinylpyrimidine system, synthetic 
procedures for the production of a series of DVP reagents were then developed.  
Initial protein chemistry studies utilising simple, unfunctionalised DVP linkers demonstrated 
their excellent rebridging efficiency in the modification a trastuzumab Fab. Modification of a 
trastuzumab antibody was then extensively investigated. DVP reagents were shown to 
rebridge the reduced interchain disulfides in trastuzumab with an excellent reactivity profile 
and only a small excess of linker required. It was discovered that a mixture of half and full 
antibody conjugates was formed due to intrachain misbridging of the heavy chain cysteine 
residues. Although undesired, further analysis showed that the non-covalent interactions were 
likely to keep the antibody intact as a single entity. Furthermore, receptor binding data and 
cellular selectivity analysis confirmed that rebridging with DVP reagents did not affect receptor 
recognition of the trastuzumab conjugates for their native HER2 receptor. Crucially, 
assessment of the stability of a fluorescent antibody imaging agent revealed that the 
bioconjugates had near-perfect stability in human plasma over multiple weeks. In addition, 
both cleavable and non-cleavable ADCs synthesised via DVP conjugation displayed highly 
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Finally, the DVP linkers were also used to cross-link cysteine residues in PfRad-dCys. This 
collective data highlights the utility of the DVP platform to generate highly stable and functional 
protein bioconjugates via cysteine bridging chemistry.232 
  
 107 
Chapter 5 – 
Dual-Functional Divinylpyrimidine Linkers 
5.1 Introduction 
In classic ADC or AFC synthesis, one linker molecule is used to attach one molecule of drug 
or fluorescent dye. In contrast, generic protein modification often involves the functionalisation 
of a protein with multiple payloads, either via a dual-functional linker or via modification of 
orthogonal protein sites.233 Only a handful of strategies for the bis-modification of antibodies 
have been reported. In one example, Levengood et al. described the use of an orthogonal 
cysteine protecting group strategy to synthesise a high DAR ADC with eight MMAE payloads 
and eight MMAF payloads in an aim to overcome auristatin resistance mechanisms (Figure 
5.1a).234 In another approach, Xiao et al. have reported the synthesis of a theranostic ADC via 
conjugation of an AlexaFluorä 488 fluorescent tag and an MMAF cytotoxin. In this strategy, 
the unnatural amino acid p-acetylphenylalanine and an azido-lysine amino acid were 
incorporated into the heavy and light chains of an antibody via genetic engineering. 
Subsequent oxime formation via reaction of the ketone-containing amino acid with an amino-
oxy tagged MMAF (nAF) followed by a SPAAC reaction with an AlexaFluorä 488 cyclooctyne 
derivative yielded the fluorescent ADC (Figure 5.1b).144 
Similarly, Maruani et al. have described the use of the pyridazinedione reagents to modify 
both Fabs and IgG molecules with cytotoxic warheads, fluorescent tags and PEG chains. In 
this method, the complementarity of the CuAAC and SPAAC reactions has been exploited to 
first modify an antibody with an azide modified payload via a SPAAC reaction. A subsequent 
CuAAC reaction was then used to decorate the antibody with an alternate payload, generating 
fluorescent ADCs or Fab-drug/fluorophore conjugates with extended half-lives due to 
PEGylation (Figure 5.1c).165 The pyridazinedione reagents were also used to synthesise a 
different type of theranostic agent, which combines photodynamic therapy with in vivo imaging 
capabilities.235 Finally, an approach developed by Puthenveetil and co-workers details a solid 
phase method, whereby a THIOMAB antibody was firstly immobilised on a Protein A-modified 
bead. Subsequent deglycosylation of the antibody with PNGase F was followed by the 
attachment of a strained bicyclononyne (BCN) to the exposed glutamine 295 residue in the 
antibody heavy chains. A maleimide-modified BODIPY reagent could then be used to modify 
the engineered cysteine residues on the light chains and an azide-modified Cy5.5 dye reacted 
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with the BCN alkyne in a SPAAC reaction to generate the bis-fluorophore modified antibody 
(Figure 5.1d).236 This strategy was also used to synthesise a theranostic Fab-drug conjugate. 
Dual-modification of an antibody or antibody fragment in this way could potentially be used to 
attach a number of useful payloads. Incorporation of two different cytotoxins with alternate 
mechanisms of action would potentially decrease the occurrence of resistance; attachment of 
a cytotoxin and an imaging agent would generate a fluorescent ADC; or modification with a 
cytotoxin and a PEG group would enable modulation of the physicochemical properties of the 
ADC or other biotherapeutic.  
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Figure 5.1: a) Orthogonal cysteine protection enables attachment of two different payloads with the 
same maleimide linker, b) genetic engineering of unnatural amino acids with bioorthogonally reactive 
azide and acetyl groups. Modified from Xiao et al.,144 c) pyridazinedione reagents containing strained 
and unstrained alkynes can react in orthogonal SPAAC and CuAAC reactions, respectively and d) 
combination of THIOMAB with glycan remodelling enables attachment of different fluorescent dyes.  
It was hypothesised that the DVP linkers could be used to synthesise valuable bis-
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We proposed that the synthetic routes used to synthesise original DVPs could also be used 
to synthesise dual-functional divinylpyrimidine (df-DVP) reagents. The SNAr reaction 
developed in Section 4.5 to attach desired functional groups was shown to work well with both 
primary and secondary amine nucleophiles. With this knowledge at hand, it was postulated 
that a secondary amine would give two synthetic vectors to incorporate the desired orthogonal 
functionalities to achieve dual-modification of an antibody (Figure 5.2b).  
 
Figure 5.2: a) potential modified antibodies that could be synthesised with dual-functional DVP linkers 
and b) synthetic route used in Section 4.5 to synthesise mono-functional DVP reagents and the 
proposed chemistry that would enable the synthesis of dual-functional DVP reagents. 
5.2 Synthesis of a df-DVP Linker 
In order to implement the proposed synthetic strategy, a secondary amine containing two 
orthogonal functional groups was required. In Chapter 4, both carboxylic acid and alkyne 
functional groups were shown to be compatible with the attachment of multiple different 
payloads. In addition, the alkynyl DVP 18 demonstrated excellent post-rebridging reactivity in 
a series of on-antibody CuAAC modifications. Combination of an alkyne with a carboxylic acid 
on the same DVP linker would enable hetero-bifunctional modification of a protein through 
both pre- and post-rebridging functionalisation. Exploration of commercially available 
secondary amines did not yield any promising candidates. However, it was thought that the 
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amination approach with a primary amine and an appropriately functionalised aldehyde was 
deemed to be an attractive strategy. No useful alkynyl aldehydes were found to be 
commercially available. However, oxidation of an alkynyl alcohol and subsequent reductive 
amination with an appropriate amino acid could be conducted to yield the desired secondary 
amine. To this end, 5-hexyn-1-ol was treated with pyridinium chlorochromate (PCC) in CH2Cl2 
following a known literature procedure (Table 5.1, entry 1).237 However, TLC analysis of the 
reaction suggested a number of products had been formed in the reaction. Dess-Martin 
periodinane (DMP) oxidation of the same substrate had also been previously reported and 
was attempted accordingly (Table 5.1, entry 2).238 Again, TLC analysis of the crude reaction 
mixture also suggested that multiple products had been formed. Undeterred, a Parikh-Doering 
reaction using a sulfur trioxide complex with pyridine (SO3×Py), pyridine (Py), DMSO and 
DIPEA was attempted on the alcohol (Table 5.1, entry 3).239 Pleasingly, a single spot was 
observed on TLC analysis of the reaction mixture which was confirmed to be the desired 
oxidation product via 1H NMR of the crude reaction mixture. Acidic work-up conditions 
provided the desired aldehyde 68 which was immediately subjected to reductive amination 
conditions. 
Table 5.1: Optimisation of the oxidation of 5-hexyn-1-ol to aldehyde 68. 
 
Entry Reagents Solvent Temp. Time (h) 
1 PCC CH2Cl2 0 °C to rt 17 ha 
2 DMP CH2Cl2 0 °C to rt 2 h 
3 SO3×Py, Py, DIPEA, DMSO CH2Cl2 –40 to –20 °C 4 h 
a monitored by TLC after 2, 4, 6, 8 and 17 hours. 
Ethyl 4-aminobutyrate was selected as the amino acid to condense with the aldehyde. A small 
screen of conditions for the reductive amination between this substrate and aldehyde 68 and 
was carried out (Table 5.2). First, attempts to form the imine by pre-mixing crude aldehyde 68 
and the amine before the addition of sodium borohydride yielded the desired secondary amine 
69 in just 8% yield, over two steps (Table 5.2, entry 1). Use of milder reductants, such as 
NaBH(OAc)3 or NaBH3CN, enabled immediate addition of the reductant and gave much 





entries 2 and 3). Use of NaBH(OAc)3 gave the cleanest conversion to secondary amine 69 
with an isolated yield of 40% over two steps. 
Table 5.2: Optimisation of the reductive amination reaction between aldehyde 68 and ethyl 4-
aminobutyrate hydrochloride to yield amine 69. 
 
Entry Reductant Pre-stir 4 Å MS Solvent Base Yielda 
1 NaBH4 16 h No MeOH NEt3 8% 
2 NaBH(OAc)3 2 min Yes CH2Cl2/MeOH NEt3 40% 
3 NaBH3CN 2 min Yes CH2Cl2/MeOH NEt3 31% 
a over two steps 
Synthesis of the df-DVP reagent could now proceed using the same synthetic strategy 
previously described in Section 4.5. First, SNAr reaction of 2,4,6-trichloropyrimidine with amine 
69 proceeded smoothly in the presence of NEt3 to produce 70 in 35% yield (Scheme 5.1). 
Subsequent installation of the vinyl groups was achieved via Suzuki chemistry to yield DVP 
71 in moderate yield. Finally, hydrolysis of ethyl ester 71 with LiOH×H2O generated the desired 


















Scheme 5.1: Synthetic route used to produce df-DVP 72. 
To ensure that the addition of extra functionality around the DVP core did not affect the 
conjugation performance of the scaffold, df-DVP 72 was reacted with reduced trastuzumab in 
10% DMSO in TBS for two hours at 37 °C (Figure 5.3a). Pleasingly, excellent conversion to 








































Figure 5.3: a) Reaction between trastuzumab and df-DVP 72 to produce bioconjugate 73 as a mixture 
of full and half antibody. b) SDS-PAGE analysis, Lanes; M) molecular weight marker, 1) reduced 
bioconjugate 73, showing both full and half antibody conjugates. c) Non-deconvoluted MS and d) 
deconvoluted MS of 73, expected mass 73,214 Da. Buffer conditions – TBS; Tris HCl pH 8 (25 mM), 
NaCl (25 mM), EDTA pH 8 (0.5 mM). 
5.3 MMAE-Functionalised df-DVP 
Theranostic agents are so-called due to their ability to treat and diagnose disease states 
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development and use than antibody based theranostics, potentially due to the complexity of 
synthesising these agents.241–247 
Having completed the synthesis and analysed the antibody conjugation capabilities of a 
simple, unfunctionalised df-DVP, efforts then moved toward synthesis of biologically-
functional hetero-bis-modified antibodies. As an initial proof-of-concept study, it was aimed to 
firstly synthesise a theranostic ADC by attachment of a cytotoxin such as MMAE and an 
imaging agent such as AlexaFluorä 488. It was envisaged that MMAE could be attached via 
the carboxylic acid moiety of 72 before antibody conjugation and subsequent post-rebridging 
attachment of the dye via a CuAAC reaction.  
Functionalisation of df-DVP 72 with an MMAE payload was firstly undertaken. It was thought 
that a cleavable trigger would be required to release free MMAE upon internalisation as the 
sterically bulky linker and imaging agent may impede its mechanism of action if a non-
cleavable linker was used. To this end, previously synthesised Fmoc-protected linker-drug 58 
was deprotected with piperidine and reacted with df-DVP 72 in the presence of HBTU, 
HOBt×H2O and DIPEA to yield df-DVP-MMAE linker-drug 74 in 40% yield over two steps 
(Scheme 5.2). 
 
Scheme 5.2: Synthesis of linker-drug 74 from protected compound 58 via Fmoc deprotection and 

































































With a viable route to linker-drug 74 in hand, conjugation of this compound to trastuzumab 
was then investigated (Table 5.3a). Initial conditions involved varying the organic co-solvent 
(DMSO, DMF or MeCN) and co-solvent percentage (10-25%) (Table 5.3, entries 1-9). In all 
cases, no evidence of the desired conjugate 75 was observed by LCMS and SDS-PAGE 
analysis, with the linker-drug 74 appearing to have poor aqueous solubility under all of the 
conditions tested (Table 5.3b). Attempts to aid the solubility of the linker-drug by decreasing 
the reaction concentration (1 mg/mL) were also unsuccessful (Table 5.3, entries 10-12). 
Table 5.3: a) Conditions tested in the attempted reaction between trastuzumab and 74. b) Typical 
reducing SDS-PAGE analysis of the reactions showing primarily unmodified light and heavy chains. 
Lanes: M) molecular weight marker, 1) entry 1, 2) entry 2, 3) entry 3. Buffer conditions – TBS; Tris HCl 
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Entry Co-solvent Co-solvent % (v/v) Conc. (mg/mL) Conversion 
1 DMF 10 2.5 None 
2 DMF 12 2.5 None 
3 DMF 15 2.5 None 
4 DMSO 10 2.5 None 
5 DMSO 12 2.5 None 
6 DMSO 15 2.5 None 
7 MeCN 15 2.5 None 
8 MeCN 20 2.5 None 
9 MeCN 25 2.5 None 
10 DMF 15 1.0 None 
11 DMSO 15 1.0 None 
12 MeCN 15 1.0 None 
 
It was proposed that an alternate synthetic strategy to allow more facile modification of the 
solubility profile of the linker-drug would potentially be beneficial. It was envisaged that df-DVP 
72 could still be used in these investigations. A CuAAC reaction between an azide-modified 
MMAE fragment and df-DVP 72 could be used to install the cytotoxic component. 
Subsequently, amide bond formation with a tuneable amino alkyne could be used to install the 
desired bioorthogonal handle for post-rebridging modification. Accordingly, cleavable MMAE 
fragment 56 was subjected to a CuAAC reaction with df-DVP 72 to provide carboxylic acid 76 
in moderate yield. Finally, amide formation was carried out by reaction of carboxylic acid 76 
with 3-butynylamine hydrochloride in the presence of HBTU, HOBt×H2O and DIPEA, 
generating the desired linker-dug 77 in 53% yield (Scheme 5.3).  
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Scheme 5.3: Synthetic sequence used for the synthesis of df-DVP 77. 
Having successfully synthesised linker-drug 77, conjugation to trastuzumab was investigated. 
Disappointingly, despite extensive screening of reaction conditions, including organic co-
solvent, co-solvent percentage, and reaction concentration, no significant rebridging of the 

































































































Table 5.4: a) Conditions tested in the attempted reaction between trastuzumab and 77. b) Typical 
reducing SDS-PAGE analysis of the reactions showing primarily unmodified light and heavy chains. 
Lanes: M) molecular weight marker, 1) entry 1, 2) entry 2, 3) entry 3. Buffer conditions – TBS; Tris HCl 
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Entry Co-solvent Co-solvent % (v/v) Conc. (mg/mL) Conversion 
1 DMF 10 2.5 None 
2 DMF 12 2.5 None 
3 DMF 15 2.5 None 
4 DMF 20 2.5 None 
5 DMF 15 1.0 None 
6 DMF 15 5.0 None 
7 DMSO 15 1.0 None 
8 DMSO 15 2.5 None 
9 DMSO 15 5.0 None 
10 MeCN 15 1.0 None 
11 MeCN 15 2.5 None 
12 MeCN 15 5.0 None 
 
5.4 Conclusions 
The synthesis of a DVP linker with orthogonally reactive functional groups was described in 
this chapter. The simple dual-functional linker 72 displayed similar reactivity with trastuzumab 
as previously described DVP linkers. This suggested that the extra functionality and additional 
steric bulk around the DVP core did not affect the conjugation capabilities of the DVP scaffold. 
A number of cytotoxin-modified reagents were then synthesised. While disappointing results 
were obtained in terms of reactivity of these compounds with reduced trastuzumab, the 
evidence we gathered pointed toward a solubility issue of the highly lipophilic Val-Ala-PABC-
MMAE construct, rather than to a fundamental reactivity problem inherent in the nature of our 
molecules. It is thus envisioned that slight modification of the synthetic strategy would yield 
more favourable results (vide infra). 
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Chapter 6 – 
Conclusions and Future Work 
6.1 Conclusions 
An outstanding problem in the field of ADC research is the lack of easily transferrable 
methodologies that enable the synthesis of homogeneous and stable ADCs. The large amount 
of resources that have been invested in developing such techniques have undoubtedly had 
success. However, the strategies developed typically require extensive engineering or 
alteration of the native antibody structure to achieve the desired attributes. As such, methods 
that are capable of modifying native antibodies to generate stable and homogeneous ADCs 
are desirable. Disulfide rebridging reagents have emerged as an attractive technique to 
achieve this objective; reagents in this class have shown promise for generating 
homogeneous ADCs from non-engineered antibodies. However, only a limited number of such 
reagents have been described and the effects of using rebridging linkers with different 
scaffolds is not yet known. 
This thesis describes the development of a novel cysteine bridging method for the production 
of ADCs. At the outset, the primary objectives were to deliver a methodology that; 1) enabled 
the construction of homogeneous ADCs with robust pharmacology, 2) generated ADCs with 
high levels of plasma stability to prevent premature payload release during circulation and 3) 
could be used to modify native antibodies to mitigate the requirement of unnatural amino acid 
incorporation or glycan modification.  
Preliminary studies in this area, described in Chapter 3, focused on a divinylpyridine scaffold. 
Several reports have described the use of monovinylpyridine linkers to selectively modify 
proteinogenic cysteine residues to generate highly stable bioconjugates. In the first instance, 
small molecule model systems demonstrated that divinylpyridine reagents were synthetically 
tractable, and that the conjugates formed from reaction with cysteines were highly stable. 
Subsequent evaluation of divinylpyridine cysteine cross-linking on a non-antibody protein 
(PfRadA-dCys) surrogate system suggested that protein modification with these reagents 
would be possible, as evidenced by cross-linking of two engineered cysteines. However, 
attempts to effectively rebridge the reduced disulfides of a mAb with these linkers were found 
to be generally inefficient, with only modest conversion to the rebridged antibody observed. 
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To overcome this issue, it was hypothesised that improvement of the conjugation reaction rate 
of this scaffold may generate a rebridging reagent that would enable the efficient synthesis of 
ADCs. It was postulated that increasing the electron deficiency of the divinyl-heteroaryl motif 
by switching from a pyridine to a pyrimidine core would increase the conjugation rate 
sufficiently to accomplish this, which is detailed in Chapter 4. As such, small molecule model 
investigations demonstrated the significantly enhanced reactivity of divinylpyrimidine reagents 
over divinylpyridine linkers. Critically, vinylpyrimidine conjugates displayed high levels of 
stability, analogous to those observed with vinylpyridine conjugates. Subsequently, the ability 
of a series of DVP linkers to rebridge reduced disulfides in antibodies and antibody fragments 
was then assessed, which revealed that these reagents efficiently (90–95%) rebridged the 
free cysteines in these proteins under a range of conditions. Functional modification of a 
trastuzumab antibody with relevant payloads such as cytotoxic warheads or fluorescent 
imaging agents was also achieved. These functionalities could be introduced by pre-
functionalisation of the DVP linker or in a post-rebridging bioorthogonal CuAAC after DVP-
mediated installation of an alkyne handle on the antibody. Biological evaluation of the DVP 
bioconjugates was then conducted. Studies toward investigating the stability of the antibody 
conjugates demonstrated that DVP reagents generated a linkage that was highly stable for at 
least two weeks in human plasma. Furthermore, the bioconjugates demonstrated almost 
identical affinity for the HER2 receptor compared to unmodified trastuzumab, high levels 
cellular selectivity and exquisite potency against HER2-positive cell lines. Moreover, the DVP 
reagents were also shown to be compatible with the modification of non-antibody protein 
scaffolds, as evidenced by the efficient cross-linking of two cysteine residues in a monomeric 
RadA protein. 
Finally, as an extension of these studies, a dual-functional DVP reagent was synthesised. 
Synthetic investigations revealed that modification of either alkyne or carboxylic acid handles 
with functional payloads could be achieved orthogonally to one another and to the vinyl 
groups. Preliminary antibody conjugation studies were unsuccessful; however, this was 
potentially due to the poor aqueous solubility of the linker-drug molecules. Nevertheless, the 
df-DVP will potentially be a valuable tool, facilitating the synthesis of bis-functionalised 
biomolecules. 
Overall, this work describes the development of a novel linker platform that enables the site-
selective modification of native antibodies, to generate highly stable and functional ADCs. 
Efficient modification of PfRadA-dCys also highlighted the potential use of these reagents for 
other purposes aside from ADC synthesis. 
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6.2 Future Work 
6.2.1 In vivo Evaluation of ADCs 
This thesis describes the evaluation of DVP-synthesised ADCs in a series of in vitro assays, 
demonstrating their stability, selectivity and potency. However, in vivo evaluation of these 
ADCs is required to fully understand their biological profile. In order to achieve this, appropriate 
HER2-positive mouse xenograft models (cell lines and patient-derived) could be used to 
investigate the efficacy, tolerability and pharmacokinetics of cleavable and non-cleavable DVP 
ADCs.  
6.2.2 Preventing Half Antibody Formation 
The primary obstacle encountered with DVP-mediated antibody modification was the 
formation of the half antibody conjugate as the major product of the disulfide rebridging 
reaction. As discussed in detail in Chapter 4, whilst not detrimental to their application, it would 
be preferable to have a single molecular species formed in the reaction by sole conversion to 
the full antibody conjugate. In order to overcome this issue, a number of avenues could be 
explored. 
6.2.2.1 Increasing Rate of Conjugation 
A remarkable increase in antibody rebridging efficiency was achieved when moving from a 
vinylpyridine to a vinylpyrimidine scaffold due to an increase in scaffold reactivity. Similarly, it 
might be expected that increasing the reactivity of the scaffold further could lead to increased 
rebridging efficiency. It is postulated that an increase in reaction rate may potentially also 
favour full antibody formation.248 To this end, a more electron deficient scaffold such as a 
divinyltriazine could be explored. As such, it is envisaged that divinyltriazine reagents such as 
79 could be evaluated for their antibody rebridging capabilities (Figure 6.1). 
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Figure 6.1: Potential divinyltriazine reagent 79. 
6.2.2.2 Varying Cross-Linking Reagent Length 
DVP linkers generate a conjugate with seven atoms between cysteine sulfur atoms. It is 
possible that alteration of the distance between the sulfur atoms could be utilised to favour 
either half or full antibody formation. Accordingly, bis-monovinylpyrimidines of the general 
structure A (Figure 6.2) would give conjugates with greater distance between sulfur atoms. 
Conversely, an alkynylpyrimidine of general structure B (Figure 6.2) could be used to generate 
bioconjugates with only a one-atom bridge between sulfur atoms. In this case, a double 
addition mechanism into the terminal alkyne carbon would produce the rebridged 
bioconjugate. In both cases, triazine variants could also be explored. 
 
Figure 6.2: Bis-monovinylpyrimidines A and alkynylpyrimdines B would potentially favour full antibody 
formation. 
6.2.3 Metal-Free Post-Rebridging Conjugation 
In this thesis, combining CuAAC chemistry with DVP rebridging was shown to be highly 
effective at modifying trastuzumab with functional payloads. However, there are 
disadvantages to using transition metal-catalysed reactions for the production of 
biotherapeutics, such as potential residual metal contaminants, metal-catalysed oxidation of 
the protein and poor synthetic yields. To circumvent these issues, modification of the protein 
through DVP rebridging with bioorthogonal functional groups such as strained alkynes/alkenes 
or tetrazines could enable metal-free functionalisation of the antibody (Figure 6.3). Tetrazines 
have been widely used in the bioorthogonal modification of biomacromolecules via an inverse 


































cyclopropenes, trans-cyclooctenes).249–251 Combining this chemistry with the DVP technology, 
linkers such as tetrazine 80 or strained alkyne 81 could be explored. 
 
Figure 6.3: Potential metal-free bioconjugation linkers such as tetrazine-functionalised DVP 80 and 
strained alkyne-functionalised DVP 81. 
6.2.4 Dual-Functional DVPs 
A number of possible strategies could be investigated to overcome the poor reactivity of the 
df-DVP linkers described in Chapter 5. First, modification of the linker to include two 
compatible bioorthogonal groups would enable rebridging with a potentially more soluble df-
DVP reagent, followed by bioorthogonal chemistry to attach the desired payloads. An alkyne- 
and tetrazine-modified DVP such as 82 would be amenable to this sequence (Figure 6.4a). 
Alternatively, a reversal of the conjugation order by attachment of an imaging agent to the 
linker before rebridging followed by bioorthogonal attachment of the cytotoxin post-conjugation 
could potentially mitigate these issues. Indeed, small, polar fluorescent dyes such as 
nitrobenzofurazans (NBD) have been used in the generation of AFCs and as such could aid 
the reactivity of the described df-DVP linkers (Figure 6.4b).151,252 
 
Figure 6.4: Potential strategies to overcome the poor reactivity of the df-DVP drug-linkers by using a 
df-DVP containing two bioorthogonal handles such as 82 or small polar imaging agents such as an 
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6.2.5 Peptide Stapling 
Protein-protein interactions (PPIs) govern many cellular processes. However, they have 
classically been deemed undruggable due to their large and shallow binding interfaces, 
making it difficult to design small molecule inhibitors.253 Peptide molecules have proven to be 
attractive candidates for the interrogation and perturbation of these interfaces. However, linear 
peptides typically suffer from poor physiological properties such as poor membrane 
permeability and low levels of circulatory stability.254 A process known as peptide stapling, 
whereby two amino acids in the peptide sequence are covalently linked has been extensively 
used to improve these characteristics and thus the overall pharmacological profile of the 
peptide. Many of the most commonly used macrocyclisation techniques utilise bioorthogonal 
chemistry to link unnatural amino acids containing complementary reactive groups.255,256 
Stapling of cysteine residues enables peptide macrocyclisation without the need to synthesise 
or purchase unnatural amino acids.257–259 In this context, DVP linkers could potentially serve 
as valuable tools in the development of peptide therapeutics (Figure 6.5). Functionalisation of 
the peptide with cell-penetrating peptides, fluorescent tags or additional drug molecules would 
also be possible in a facile manner, as demonstrated in this work in the synthesis of ADCs. 
 













   cell-penetrating peptide
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Chapter 7 – 
Experimental 
General Experimental 
All solvents and reagents were used as received unless otherwise stated. Ethyl acetate, 
methanol, dichloromethane, acetonitrile and toluene were distilled from calcium hydride. 
Diethyl ether was distilled from a mixture of lithium aluminium hydride and calcium hydride. 
Petroleum ether refers to the fraction between 40 – 60 °C upon distillation. Tetrahydrofuran 
was dried using Na wire and distilled from a mixture of lithium aluminium hydride and calcium 
hydride with triphenylmethane as indicator. 
Non-aqueous reactions were conducted under a stream of dry nitrogen using oven-dried 
glassware. All temperatures below 0 °C were maintained using an acetone-dry ice bath. 
Temperatures of 0 °C were maintained using an ice-water bath. Room temperature (rt) refers 
to ambient temperature. 
Yields refer to spectroscopically and chromatographically pure compounds unless otherwise 
stated. Reactions were monitored by thin layer chromatography (TLC) or liquid 
chromatography mass spectrometry (LCMS). TLC was performed using glass plates pre-
coated with Merck silica gel 60 F254 and visualised by quenching of UV fluorescence (λmax = 
254 nm) or by staining with potassium permanganate. Retention factors (Rf) are quoted to 
0.01. LCMS was carried out using a Waters ACQUITY H-Class UPLC with an ESCi Multi-
Mode Ionisation Waters SQ Detector 2 spectrometer using MassLynx 4.1 software; ESI refers 
to the electrospray ionisation technique; LC system: solvent A: 2 mM NH4OAc in H2O/MeCN 
(95:5); solvent B: MeCN; solvent C: 2% formic acid; column: ACQUITY UPLC® CSH C18 (2.1 
mm × 50 mm, 1.7 μm, 130 Å) at 40 °C; gradient: 5 – 95 % B with constant 5 % C over 1 min 
at flow rate of 0.6 mL/min; detector: PDA eλ Detector 220 – 800 nm, interval 1.2 nm. 
Flash column chromatography (FCC) was carried out using slurry-packed Merck 9385 
Kieselgel 60 SiO2 (230-400 mesh) under a positive pressure of nitrogen. 
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Analytical high performance liquid chromatography (HPLC) was performed on Agilent 1260 
Infinity machine, using a Supelcosil™ ABZ+PLUS column (150 mm × 4.6 mm, 3 μm) with a 
linear gradient system (solvent A: 0.05% (v/v) TFA in H2O; solvent B: 0.05% (v/v) TFA in 
MeCN) over 15 min at a flow rate of 1 mL/min, and UV detection (λmax = 220 – 254 nm).  
Preparative HPLC was performed on Agilent 1260 Infinity machine, using a Supelcosil™ 
ABZ+PLUS column (250 mm × 21.2 mm, 5 μm) with a linear gradient system (solvent A: 0.1% 
(v/v) TFA in H2O; solvent B: 0.05% (v/v) TFA in MeCN) over 20 min at a flow rate of 20 mL/min, 
and UV detection (λmax = 220 – 254 nm).  
Melting points (m.p.) were obtained using a Büchi Melting Point B-545 melting point apparatus 
and are uncorrected. 
Infrared (IR) spectra were recorded neat on a Perkin-Elmer Spectrum One spectrometer with 
internal referencing. Selected absorption maxima (νmax) are reported in wavenumbers (cm-1). 
Proton and carbon nuclear magnetic resonance (NMR) were recorded using an internal 
deuterium lock on Bruker DPX-400 (400 MHz, 101 MHz), Bruker Avance 400 QNP (400 MHz, 
101 MHz) and Bruker Avance 500 Cryo Ultrashield (500 MHz, 126 MHz). In proton NMR, 
chemical shifts (δH) are reported in parts per million (ppm), to the nearest 0.01 ppm and are 
referenced to the residual non-deuterated solvent peak (CDCl3: 7.26, DMSO-d6: 2.50, CD3OD: 
3.31, D2O: 4.79). Coupling constants (J) are reported in Hertz (Hz) to the nearest 0.1 Hz. Data 
are reported as follows: chemical shift, multiplicity (s = singlet; d = doublet; t = triplet; q = 
quartet; qn = quintet; sx = sextet; sep = septet; m = multiplet; or as a combination of these, 
e.g. dd, dt etc.), integration, coupling constant(s) and assignment. Proton assignments are 
reported in reference to alphabetical labelling of protons in the structures. In carbon NMR, 
chemical shifts (δC) are quoted in ppm, to the nearest 0.1 ppm, and are referenced to the 
residual non-deuterated solvent peak (CDCl3: 77.16, DMSO-d6, 39.52, CD3OD: 49.00). 
Carbon assignments are reported in reference to alphabetical labelling of carbons in the 
structures. 1H NMR and 13C NMR spectra assignments are supported by DEPT-135 editing, 
COSY (2D, 1H-1H correlations), HSQC (2D, one bond 1H-13C correlations), HMBC (2D, multi-
bonds 1H-13C correlations), or by analogy to fully interpreted spectra of related compounds.  
High resolution mass spectrometry (HRMS) measurements were recorded with a Micromass 
Q-TOF mass spectrometer or a Waters LCT Premier Time of Flight mass spectrometer. Mass 
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values are reported within the error limits of ±5 ppm mass units. ESI refers to the electrospray 
ionisation technique. 
Protein LCMS was performed on a Xevo G2-S TOF mass spectrometer coupled to an Acquity 
UPLC system using an Acquity UPLC BEH300 C4 column (1.7 μm, 2.1 × 50  mm). H2O  with  
0.1%  formic  acid  (solvent  A)  and  95%  MeCN  and  5%  water  with 0.1% formic acid 
(solvent B), were used as the mobile phase at a flow rate of 0.2 mL/min. The gradient was 
programmed as follows: 95% A for 0.93 min, then a gradient to 100% B over 4.28 min, then 
100% B for 1.04 minutes, then a gradient to 95% A over 1.04 min. The electrospray source 
was operated with a capillary voltage of 2.0 kV and a cone voltage of 40 V. Nitrogen was used 
as the desolvation gas at a total flow of 850 L/h. Total mass spectra were reconstructed from 
the ion series using the MaxEnt algorithm preinstalled on MassLynx software (v4.1 from 
Waters) according to the manufacturer’s instructions. Trastuzumab samples were 
deglycosylated with PNGase F (New England Biolabs) prior to LCMS analysis unless 
otherwise stated. 
Extreme care was taken when conducting any reactions containing MMAE or its derivatives. 
All handling was conducted in a fumehood while wearing full personal protective equipment 
(safety glasses, labcoat and nitrile gloves). Reactions were conducted on small scale with <75 
µmol MMAE used in all instances. Safety notices should be placed on the front of the 
fumehood during operation. All aqueous waste should be treated with sodium hypochlorite for 
a minimum of 24 hours before disposal. All organic waste should be disposed of immediately 
in the appropriate waste containers. Any spillages should be cleaned up immediately. Tissue 
waste should be double bagged and cable-tied before disposal as ‘Toxic Waste’. A competent 
person should be made aware of the intended use before beginning any experiments. 
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7.1 Chapter 3: Divinylpyridine Linkers 
7.1.1 Synthetic Procedures 
2-amino-4-vinylpyridine (1) 
 
2-amino-4-bromopyridine (250 mg, 1.45 mmol), potassium vinyltrifluoroborate (290 mg, 2.17 
mmol), Pd(dppf)Cl2×CH2Cl2 (118 mg, 0.145 mmol) and potassium carbonate (599 mg, 4.34 
mmol) in THF/H2O (10:1, 5.5 mL) were heated to 70 °C for 16 h. Upon completion, the reaction 
mixture was filtered through Celiteâ and the solvent removed in vacuo. The resulting residue 
was purified by flash column chromatography (FCC) (5% MeOH/CH2Cl2 with 0.5% Et3N) to 
yield 2-amino-4-vinylpyridine 1 (155 mg, 1.29 mmol, 89%) as a brown solid.  
Rf 0.19 (SiO2; 5% MeOH/CH2Cl2 with 1% Et3N); m.p. 53-55 °C; νmax (neat/cm-1) 3436, 1630, 
1603, 1543, 1494; δH (400 MHz, CD3OD) 7.82 (d, 1H, J = 5.6 Hz, Ha), 6.70 (dd, 1H, J = 5.6, 
1.4 Hz, Hb), 6.60 (dd, 1H, J = 17.6, 10.9 Hz, Hf), 6.56 (s, 1H, Hd), 5.94 (dd, 1H, J = 17.6, 0.8 
Hz, Hgt), 5.42 (dd, 1H, J = 10.9, 0.8 Hz, Hgc); δC (101 MHz, CD3OD) 161.4 (Ce), 148.5 (Cc), 
147.9 (Ca), 136.5 (Cf), 118.5 (Cg), 111.1 (Cb), 107.7 (Cd); HRMS (ESI) m/z found [M+H]+ 












4-amino-2-bromopyridine (250 mg, 1.45 mmol), potassium vinyltrifluoroborate (290 mg, 2.17 
mmol), Pd(dppf)Cl2×CH2Cl2 (118 mg, 0.145 mmol) and potassium carbonate (599 mg, 4.34 
mmol) in THF/H2O (10:1, 5.5 mL) were heated to 70 °C for 16 h. Upon completion, the reaction 
mixture was filtered through Celiteâ and the solvent removed in vacuo. The resulting residue 
was purified by FCC (5% MeOH/CH2Cl2 with 0.5% Et3N) to yield 4-amino-2-vinylpyridine 2 
(148 mg, 1.23 mmol, 85%) as a brown oil.  
Rf 0.26 (SiO2; 5% MeOH/CH2Cl2 with 1% Et3N); νmax (neat/cm-1) 3329, 3208, 1636, 1595, 
1560, 1487; δH (400 MHz, CD3OD) 7.92 (d, 1H, J = 5.8 Hz, Ha), 6.70 (d, 1H, J = 2.4 Hz, Hd), 
6.63 (dd, 1H, J = 17.6, 11.0 Hz, Hf), 6.47 (dd, 1H, J = 5.8, 2.4 Hz, Hb), 6.00 (dd, 1H, J = 17.6, 
1.1 Hz, Hgt), 5.40 (dd, 1H, J = 11.0, 1.1 Hz, Hgc); δC (101 MHz, CD3OD) 157.6 (Cc), 156.5 
(Ce), 149.1 (Ca), 137.6 (Cf), 118.1 (Cg), 109.3 (Cb), 107.3 (Cd); HRMS (ESI) m/z found 
[M+H]+ 121.0759, C7H9N2+ required 121.0760. 
Methyl S-(2-(2-aminopyridin-4-yl)ethyl)-N-(tert-butoxycarbonyl)-L-cysteinate (3) 
 
To a solution of N-tert-butoxycarbonyl-L-cysteine methyl ester (48.9 mg, 0.208 mmol) in 
sodium phosphate buffer (0.5 M, pH 8, 2.91 mL) was added a solution of amine 1 (125 mg, 
1.04 mmol) in MeCN (1.25 mL). The mixture was heated to 37 °C for 180 min. Upon 
completion, the reaction mixture was diluted with H2O (5 mL) and the product extracted with 
EtOAc (4 × 10 mL). The combined organic fractions were dried (MgSO4) and the crude purified 
by FCC (5% MeOH/CH2Cl2) to yield yield methyl S-(2-(2-aminopyridin-4-yl)ethyl)-N-(tert-































Rf 0.20 (SiO2; 5% MeOH/CH2Cl2); νmax (neat/cm-1) 3324, 1703, 1665, 1624, 1514; δH (400 
MHz, CD3OD) 7.78 (d, 1H, J = 5.4 Hz, Ha), 6.52 (dd, 1H, J = 5.4, 1.2 Hz, Hb), 6.47 (s, 1H, 
Hd), 4.36-4.32 (m, 1H, Hi), 3.73 (s, 3H, Hk), 2.97 (dd, 1H, J = 13.9, 5.3 Hz, Hh) 2.85-2.74 (m, 
5H, Hf, Hg, Hh) 1.44 (s, 9H, Hn); δC (101 MHz, CD3OD) 173.2 (Cj), 160.9 (Cc), 153.2 (Ce), 
147.8 (Cl), 147.5 (Ca), 114.7 (Cb), 110.0 (Cd) 80.8 (Cm), 55.2 (Ci), 52.8 (Ck) 36.4 (Ch), 34.7 
(Cg), 33.3 (Cf), 28.7 (Cn); HRMS (ESI) m/z found [M+H]+ 356.1636, C16H26N3O432S1+ required 
356.1639. 
Methyl S-(2-(4-aminopyridin-2-yl)ethyl)-N-(tert-butoxycarbonyl)-L-cysteinate (4) 
 
To a solution of N-tert-butoxycarbonyl-L-cysteine methyl ester (12.9 mg, 54.8 μmol) in sodium 
phosphate buffer (0.5 M, pH 8, 770 μL) was added a solution of amine 2 (32.9 mg, 274 μmol) 
in MeCN (330 μL). The mixture was heated to 37 °C for 4 h. Upon completion, the reaction 
mixture was diluted with H2O (5 mL) and the product extracted with EtOAc (4 × 10 mL). The 
combined organic fractions were dried (MgSO4) and the crude purified by FCC (5-10% 
MeOH/CH2Cl2) to yield methyl S-(2-(4-aminopyridin-2-yl)ethyl)-N-(tert-butoxycarbonyl)-
L-cysteinate 4 (18.6 mg, 52.3 μmol, 96%) as a pale yellow oil.  
Rf 0.20 (SiO2; 10% MeOH/CH2Cl2); νmax (neat/cm-1) 3359, 2980, 1740, 1695, 1632, 1606, 
1515; δH (400 MHz, CDCl3) 8.04 (d, 1H, J = 5.6 Hz, Ha), 6.55-6.53 (m, 2H, Hb and Hd), 5.58 
(d, 1H, J = 7.8 Hz, NH), 4.51-4.50 (m, 1H, Hi), 3.74 (s, 3H, Hk), 2.98-2.91 (m, 6H, Hf, Hg and 
Hh), 1.43 (s, 9H, Hn); δC (101 MHz, CDCl3) 171.7 (Cj), 157.7 (Cc), 155.5 (Ce or Cl), 155.4 (Ce 
or Cl), 146.6 (Ca), 108.9 (Cb or Cd) 108.1 (Cb or Cd), 80.3 (Cm), 53.6 (Ci), 52.7 (Ck), 36.7 
(Cf or Cg or Ch), 34.7 (Cf or Cg or Ch), 32.0 (Cf or Cg or Ch), 28.5 (Cn); HRMS (ESI) m/z 





















2,6-divinylpridine-4-carboxylic acid (5) 
 
2,6-dibromopyridine-4-carboxylic acid (300 mg, 1.07 mmol), potassium vinyltrifluoroborate 
(430 mg, 3.21 mmol), Pd(dppf)Cl2×CH2Cl2 (188 mg, 0.230 mmol) and potassium carbonate 
(887 mg, 6.42 mmol) in THF/H2O (10:1, 6.6 mL) were heated to 70 °C for 15 h. Upon 
completion, the reaction mixture was filtered through Celiteâ and the solvent removed in 
vacuo. The resulting residue was purified by FCC (10% MeOH/CH2Cl2 with 1% AcOH) to yield 
2,6-divinylpridine-4-carboxylic acid 5 (180 mg, 1.03 mmol, 96%) as a brown solid.  
Rf 0.41 (SiO2; 10% MeOH/CH2Cl2); m.p. 121-123 °C; νmax (neat/cm-1) 2927, 1715, 1592, 1556, 
1424; δH (400 MHz, CD3OD) 7.84 (s, 2H, Hb), 6.90 (dd, 2H, J = 17.5, 10.9 Hz, Hd), 6.30 (dd, 
2H, J = 17.5, 1.0 Hz, Het), 5.56 (dd, 2H, J = 10.9, 1.0 Hz, Hec); δC (101 MHz, CD3OD) 168.0 
(Cf), 157.7 (Ca), 141.4 (Cc), 137.5 (Cd), 120.3 (Cb), 120.0 (Ce); HRMS (ESI) m/z found 
[M+H]+ 176.0698, C10H10N1O2+ required 176.0706. 
N-(but-3-yn-1-yl)-2,6-divinylisonicotinamide (6) 
 
To a solution of carboxylic acid 5 (30.0 mg, 0.171 mmol) in DMF (2.00 mL) was added DIPEA 
(0.147 mL, 0.855 mmol) followed by HBTU (78.0 mg, 0.206 mmol). The mixture was stirred at 
rt for 5 min. But-3-ynylamine hydrochloride (90.0 mg, 0.855 mmol) was added and the mixture 
stirred for 3 h. Upon completion, the reaction mixture was diluted with H2O (10 mL) and the 
product extracted in CH2Cl2 (4 × 10 mL) and dried (MgSO4). The organic fractions were 
concentrated and the crude residue purified by FCC (20% EtOAc/PE) to yield N-(but-3-yn-1-






















Rf 0.27 (SiO2; 40% EtOAc/PE); νmax (neat/cm-1) 3297, 1647, 1544, 1425; δH (400 MHz, CDCl3) 
7.49 (s, 2H, Hb), 6.86 (dd, 2H, J = 17.4, 10.7 Hz, Hd), 6.33 (dd, 2H, J = 17.4, 1.2 Hz, Het), 
5.56 (dd, 2H, J = 10.7, 1.2 Hz, Hec), 3.63 (q, 2H, J = 6.2 Hz, Hg), 2.54 (td, 2H, J = 9.6, 2.7 Hz, 
Hh), 2.07 (t, 1H, J = 2.7 Hz, Hj); δC (101 MHz, CDCl3) 166.0 (Cf), 156.3 (Ca), 142.8 (Cc), 136.3 
(Cd), 119.7 (Ce), 117.1 (Cb), 81.2 (Ci), 70.5 (Cj), 38.5 (Cg), 19.3 (Ch); HRMS (ESI) m/z found 
[M+H]+ 227.1180, C14H15N2O1+ required 227.1184. 
2,6-bis(2-(((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)- 
thio)ethyl)isonicotinic acid (7) 
 
A mixture of 2,6-divinylpyridine-4-carboxylic acid 5 (8.97 mg, 51.2 μmol) and N-tert-
butoxycarbonyl-L-cysteine methyl ester (26.5 mg, 113 μmol) in 30% MeCN/sodium phosphate 
buffer (0.5 M, pH 8, 1.02 mL) was heated to 37 °C for 14 h. Upon completion, the mixture was 
diluted with H2O (5 mL) and the product extracted with CH2Cl2 (4 × 10 mL). The combined 
organic fractions were dried (MgSO4) and the crude purified by FCC (5-10% MeOH/CH2Cl2) 
to yield 2,6-bis(2-(((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-thio)ethyl)iso-
nicotinic acid 7 (26.8 mg, 41.5 μmol, 81%) as a clear oil.  
Rf 0.26 (SiO2; 10% MeOH/CH2Cl2); νmax (neat/cm-1) 3363, 1742, 1694, 1555, 1505; δH (400 
MHz, CD3OD) 7.64 (s, 2H, Hb), 4.34-4.23 (m, 2H, Hh), 3.72 (s, 6H, Hj), 3.11-3.08 (m, 4H, He), 
2.97-2.92 (m, 6H, Hf and Hg), 2.86-2.82 (m, 2H, Hg), 1.43 (s, 18H, Hm); δC (101 MHz, CD3OD) 
173.2 (Ci), 170.5 (Cd), 161.6 (Ca), 157.8 (Ck) 144.0 (Cc), 122.0 (Cb), 80.8 (Cl), 55.2 (Ch), 
52.8 (Cj), 38.9 (Ce), 34.7 (Cg), 33.1 (Cf), 28.7 (Cm); HRMS (ESI) m/z found [M+H]+ 646.2437, 




















7.1.2 Monovinylpyridine Rate Studies 
2-amino-4-vinylpyridine (1) 
 
To a solution of N-Boc-Cys-OMe (5.00 mg, 21.2 μmol) in MeCN (127 μL) and NaPi (297 μL, 
0.5 M, pH 8) was added amine 1 (21.2 μmol, 42.4 μmol, 106 μmol, 212 μmol or 424 μmol) 
and the reaction mixture stirred at 37 °C. Aliquots were removed from the reaction at 15 min 




To a solution of N-Boc-Cys-OMe (3.50 mg, 14.9 μmol) in MeCN (89.0 μL) and NaPi (209 μL, 
0.5 M, pH 8) was added amine 2 (14.9 μmol, 29.8 μmol, 74.5 μmol, 149 μmol or 298 μmol) 
and the reaction mixture stirred at 37 °C. Aliquots were removed from the reaction at 15 min 
intervals up to 2 h, then at 30 min intervals up to 4 h. Reaction progress was monitored by 
TLC. 
N NH2 BocHN CO2Me
HS
30% MeCN/NaPi 
(pH 8, 0.5 M)











(pH 8, 0.5 M)






7.1.3 Divinylpyridine Stability Studies 
 
To a solution of carboxylic acid 7 (4.30 mg, 6.70 μmol) in CD3OD (280 μL) and deuterated 
NaPi (420 μL, 50 mM, pH 7.4) was added reduced L-glutathione (6.20 mg, 20.1 μmol). The 
mixture was incubated at rt and analysed by 1H NMR after 24, 100 and 200 h. 
7.2 Chapter 4: Divinylpyrimidine Linkers 
7.2.1 Synthetic Procedures 
2-amino-4-vinylpyrimidine (11) 
 
A solution of 2-amino-4-chloropyrimidine (300 mg, 2.32 mmol), potassium vinyltrifluoroborate 
(931 mg, 6.95 mmol), Pd(dppf)Cl2×CH2Cl2 (189 mg, 0.232 mmol) and potassium carbonate 
(1.92 g, 13.9 mmol) in THF/H2O (10:1, 7.7 mL) was heated to 70 °C for 16 h. Upon completion, 
the reaction mixture was filtered through Celiteâ and the solvent removed in vacuo. The 
resulting residue was purified by FCC (40% EtOAc/PE) to yield 2-amino-4-vinylpyrimidine 11 
(195 mg, 1.61 mmol, 70%) as an off-white solid.  
Rf 0.12 (SiO2; 40% EtOAc/PE); m.p. 83-86 °C; νmax (neat/cm-1) 3318, 1648, 1546, 1466, 1403; 
δH (400 MHz, CDCl3) 8.26 (d, 1H, J = 5.2 Hz, Ha), 6.65 (d, 1H, J = 5.2 Hz, Hb), 6.58 (dd, 1H, 
J = 17.4, 10.6 Hz, He), 6.37 (dd, 1H, J = 17.4, 1.3 Hz, Hft), 5.64 (dd, 1H, J = 10.6, 1.3 Hz, Hfc), 
5.20 (s, 2H, NH2); δC (101 MHz, CDCl3) 163.9 (Cc), 162.7 (Cd), 158.4 (Ca), 135.4 (Ce), 123.0 























A solution of amine 11 (15.0 mg, 124 μmol), N-(tert-butoxycarbonyl)-L-cysteine methyl ester 
(29.2 mg, 124 μmol) in 30% MeCN/sodium phosphate buffer (pH 8, 50 mM, 2.48 mL) was 
stirred at 37 °C for 15 min. Upon completion, the mixture was diluted with H2O (10 mL), 
extracted with EtOAc (4 × 10 mL), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified by FCC (50-100% EtOAc/PE) to yield methyl S-(2-(2-aminopyrimidin-4-
yl)ethyl)-N-tert-butoxycarbonyl)-L-cysteinate 12 (39.6 mg, 111 μmol, 90%) as a clear oil.  
Rf 0.10 (SiO2; 50% EtOAc/PE); νmax (neat/cm-1) 3334, 2977, 1741, 1704, 1616, 1562, 1457; 
δH (400 MHz, CDCl3) 8.17 (d, 1H, J = 5.3 Hz, Ha), 6.49 (d, 1H, J = 5.3 Hz, Hb), 5.70 (d, 1H, J 
= 7.5 Hz, NH), 5.13 (s, 2H, NH2), 4.60-4.56 (m, 1H, Hh), 3.74 (s, 3H, Hj), 3.03-2.96 (m, 2H, 
Hg), 2.95-2.81 (m, 4H, He, Hf), 1.44 (s, 9H, Hm); δC (101 MHz, CDCl3) 171.9 (Ci), 169.3 (Cc), 
163.1 (Cd), 158.3 (Ca), 155.4 (Ck), 111.0 (Cb), 80.4 (Cl), 53.7 (Ch), 52.7 (Cj), 37.5 (Ce), 34.7 





A solution of N-benzylmaleimide (100 mg, 0.534 mmol), N-(tert-butoxycarbonyl)-L-cysteine 
methyl ester (151 mg, 0.641 mmol) and triethylamine (74.0 μL, 0.534 mmol) was stirred at 37 









































residue purified by FCC (35% EtOAc/PE) to yield methyl S-(1-benzyl-2,5-dioxopyrrolidin-3-yl)-
N-(tert-butoxycarbonyl)-L-cysteinate 13 (210 mg, 0.497 mmol, 93%) as a white solid.  
Rf 0.16 (SiO2; 35% EtOAc/PE); m.p. 73-77 °C; νmax (neat/cm-1) 2982, 1744, 1700, 1498, 1434; 
δH (400 MHz, CDCl3) 7.37-7.28 (m, 10H, Hn, Ho and Hp), 5.54 (d, 1H, J = 7.6 Hz, NH), 5.32 
(d, 1H, J = 7.6 Hz, NH), 4.70-4.56 (m, 6H, Hf and Hl), 3.94-3.91 (m, 1H, Hh), 3.84-3.81 (m, 
1H, Hh), 3.77-3.76 (m, 6H, Hd), 3.57-3.53 (m, 1H, Hg), 3.41-3.36 (m, 1H, Hg), 3.17-3.07 (m, 
3H, Hg and Hj), 2.98-2.92 (m, 1H, Hg), 2.52-2.42 (m, 2H, Hj), 1.44 (s, 18H, Ha); δC (101 MHz, 
CDCl3) 176.4, 176.3 (Ci or Ck), 174.2, 174.0 (Ci or Ck), 171.4 (Ce), 155.4, 155.3 (Cc), 2 ´ 
135.4 (Cm), 128.9, 128.8, 2 ´ 128.2 (Cn, Co, Cp), 80.5 (Cb), 53.7, 52.9 (Cd), 52.9, 52.7 (Cf), 
2 ´ 42.8 (Cl), 39.3, 38.6 (Ch), 36.1, 35.8 (Cj), 34.7, 34.3 (Cg), 2 ´ 28.4 (Ca); HRMS (ESI) m/z 
found [M+H]+ 423.1576, C20H27N2O632S1+ required 423.1584. 
2-amino-4,6-divinylpyrimidine (15) 
 
A solution of 2-amino-4,6-dichloropyrimidine (200 mg, 1.22 mmol), potassium 
vinyltrifluoroborate (490 mg, 3.66 mmol), Pd(dppf)Cl2×CH2Cl2 (100 mg, 0.122 mmol) and 
potassium carbonate (1.01 g, 7.32 mmol) in THF/H2O (10:1, 3.3 mL) was heated to 70 °C for 
18 h. Upon completion, the reaction mixture was filtered through Celiteâ and the solvent 
removed in vacuo. The resulting residue was purified by FCC (20-40% EtOAc/PE) to yield 2-
amino-4,6-divinylpyrimidine 15 (152 mg, 1.03 mmol, 85%) as an off-white solid.  
Rf 0.29 (SiO2; 50% EtOAc/PE); m.p. 81-83 °C; νmax (neat/cm-1) 3213, 1567, 1536, 1415; δH 
(500 MHz, DMSO-d6) 6.81 (s, 1H, Hc), 6.57 (dd, 2H, J = 17.4, 10.7 Hz, Hd), 6.54 (s, 2H, NH2), 
6.32 (dd, 2H, J = 17.4, 1.5 Hz, Het), 5.58 (dd, 2H, J = 10.7, 1.5 Hz, Hec); δC (126 MHz, DMSO-
d6) 163.6 (Cb), 163.4 (Ca), 136.1 (Ce), 121.5 (Cd), 104.7 (Cc); HRMS (ESI) m/z found [M+H]+ 











To a solution of amine 15 (50.0 mg, 0.340 mmol) in DMF (1.5 mL) was added 6-iodo-1-hexyne 
(223 μL, 1.69 mmol) followed by the slow addition of sodium hydride (60% in mineral oil, 68.0 
mg, 1.69 mmol). The reaction mixture was stirred at rt for 15 h, then diluted with H2O (15 mL) 
and extracted with CH2Cl2 (3 × 15 mL). The combined organic fractions were washed with 
brine, dried (MgSO4) and concentrated in vacuo. The crude residue was purified by FCC (20% 
EtOAc/PE) to yield N-(hex-5-yn-1-yl)-4,6-divinylpyrimidin-2-amine 18 (40.0 mg, 0.176 mmol, 
52%) as a clear oil.  
Rf 0.36 (SiO2; 25% EtOAc/PE); νmax (neat/cm-1) 3298, 2936, 1635, 1539, 1458, 1420; δH (500 
MHz, CDCl3) 6.58 (dd, 2H, J = 17.4, 10.6 Hz, Hd), 6.53 (s, 1H, Hc), 6.38 (d, 2H, J = 17.4 Hz, 
Het), 5.58 (dd, 2H, J = 10.6, 1.4 Hz, Hec), 5.29 (s, 1H, NH), 3.51 (q, 2H, J = 6.6 Hz, Hf), 2.25 
(td, 2H, J = 10.5, 2.7 Hz, Hi), 1.95 (t, 1H, J = 2.7 Hz, Hk), 1.78-1.72 (m, 2H, Hg), 1.67-1.61 (m, 
2H, Hh); δC (126 MHz, CDCl3) 163.7 (Cb), 162.4 (Ca), 135.8 (Cd), 121.9 (Ce), 105.7 (Cc), 
84.4 (Cj), 68.7 (Ck), 41.0 (Cf), 28.9 (Cg), 25.9 (Ch), 18.3 (Ci); HRMS (ESI) m/z found [M+H]+ 
228.1497, C14H18N3+ required 228.1495. 
Ethyl N-(4,6-dichloropyrimidin-2-yl)-N-methylglycinate (21) 
 
To a solution of 2,4,6-trichloropyrimidine (1.00 g, 5.45 mmol) in acetone (6 mL) at 0 °C was 
added sarcosine ethyl ester hydrochloride (1.01 g, 6.54 mmol) followed by the slow addition 
of triethylamine (1.90 mL, 13.6 mmol) and the reaction mixture stirred at 0 °C for 90 min. Upon 
completion, the solvent was removed in vacuo then redissolved in H2O (20 mL) and extracted 



























in vacuo and the crude residue purified by FCC (2-20% EtOAc/PE) to yield ethyl N-(4,6-
dichloropyrimidin-2-yl)-N-methylglycinate 21 (266 mg, 1.01 mmol, 19%) as a white solid.  
Rf 0.34 (SiO2; 10% EtOAc/PE); m.p. 40-42 °C; νmax (neat/cm-1) 1747, 1567, 1511, 1413, 1198; 
δH (400 MHz, CDCl3) 6.59 (s, 1H, Hc), 4.33 (s, 2H, He), 4.21 (q, 2H, J = 7.2 Hz, Hg), 3.23 (s, 
3H, Hd), 1.28 (t, 3H, J = 7.2 Hz, Hh); δC (101 MHz, CDCl3) 169.5 (Cf), 2 ´ 161.4 (Ca and Cb), 
108.8 (Cc), 61.4 (Cg), 51.4 (Ce), 36.8 (Cd), 14.4 (Ch); HRMS (ESI) m/z found [M+H]+ 
264.0299, C9H1235Cl2N3O2+ required 264.0301. 
Ethyl N-(4,6-divinylpyrimidin-2-yl)-N-methylglycinate (23) 
 
Dichloropyrimidine 21 (204 mg, 0.722 mmol), potassium vinyltrifluoroborate (517 mg, 3.86 
mmol), Pd(dppf)Cl2×CH2Cl2 (94.6 mg, 0.116 mmol) and potassium carbonate (641 mg, 4.63 
mmol) in THF/H2O (10:1, 5.5 mL) were heated to 70 °C for 16 h. Upon completion, the reaction 
mixture was filtered through Celiteâ and the solvent removed in vacuo. The resulting residue 
was purified by FCC (0-4% EtOAc/PE) to yield ethyl N-(4,6-divinylpyrimidin-2-yl)-N-
methylglycinate 23 (182 mg, 0.736 mmol, 95%) as a pale yellow oil.  
Rf 0.30 (SiO2; 10% Et OAc/PE); νmax (neat/cm-1); 1747, 1560, 1540, 1508, 1401, 1196; δH (400 
MHz, CDCl3) 6.59 (dd, 2H, J = 17.2, 10.5 Hz, Hd), 6.49 (s, 1H, Hc), 6.38 (d, 2H, J = 17.2 Hz, 
Het), 5.53 (dd, 2H, J = 10.5, 1.0 Hz, Hec), 4.36 (s, 2H, Hg), 4.18 (q, 2H, J = 7.2 Hz, Hi), 3.32 
(s, 3H, Hf), 1.23 (t, 3H, J = 7.2 Hz, Hj); δC (101 MHz, CDCl3) 171.1 (Ch), 2 ´ 162.2 (Ca and 
Cb), 136.2 (Cd), 121.3 (Ce), 105.7 (Cc), 60.8 (Ci), 51.8 (Cg), 36.6 (Cf), 14.4 (Cj); HRMS (ESI) 

















To a solution of ester 23 (40.0 mg, 0.162 mmol) in THF/H2O (1:1, 2 mL) was added LiOH×H2O 
(14.9 mg, 0.178 mmol) and the reaction mixture stirred at rt for 18 h. Upon completion, the 
mixture was diluted with H2O (10 mL) and washed with Et2O (10 mL). The aqueous phase 
was neutralised with 1M HCl and extracted with CH2Cl2 (4 × 20 mL). The combined organic 
fractions were dried (MgSO4) and concentrated in vacuo. The crude residue was triturated 
with PE to yield N-(4,6-divinylpyrimidin-2-yl)-N-methylglycine 24 (29.0 mg, 0.132 mmol, 82%) 
as a pale yellow solid.  
m.p. 92-95 °C; νmax (neat/cm-1) 2935, 1705, 1630, 1536, 1395, 1243, 1220; δH (400 MHz, 
CD3OD) 6.67-6.60 (m, 3H, Hc and Hd), 6.40 (dd, 2H, J = 17.4, 1.5 Hz, Het), 5.55 (dd, 2H, J = 
10.6, 1.5 Hz, Hec), 4.36 (s, 2H, Hg), 3.28 (s, 3H, Hf); δC (101 MHz, CD3OD) 174.6 (Ch), 164.8 
(Cb), 163.4 (Ca), 137.2 (Cd), 121.8 (Ce), 106.1 (Cc), 52.1 (Cg), 36.7 (Cf); HRMS (ESI) m/z 





A solution of DVP 15 (10.0 mg, 68.0 μmol), N-(tert-butoxycarbonyl)-L-cysteine methyl ester 
(40.0 mg, 170 μmol) in 30% MeCN/sodium phosphate buffer (pH 8, 50 mM, 1.36 mL) was 
stirred at 37 °C for 2 h. Upon completion, the mixture was diluted with H2O (10 mL), extracted 





























purified by FCC (70% EtOAc/PE) to yield dimethyl 3,3’-(((2-aminopyrimidine-4,6-
diyl)bis(ethane-2,1-diyl))bis(sulfanediyl))(2S,2’S)bis(2-((tert-butoxycarbonyl)amino)propan-
oate) 25 (23.0 mg, 37.0 μmol, 55%) as a clear oil.  
Rf 0.33 (SiO2; 70% EtOAc/PE); νmax (neat/cm-1) 3359, 2977, 1742,1703, 1615, 1579, 1560, 
1503, 1437; δH (400 MHz, CD3OD) 6.54 (s, 1H, Hc), 4.37-4.34 (m, 2H, Hg), 3.73 (s, 6H, Hi), 
2.99-2.79 (m, 12H, Hd, He, Hf) 1.44 (s, 18H, Hl); δC (101 MHz, CD3OD) 173.2 (Ch), 171.1 
(Cb), 164.7 (Ca), 157.8 (Cj), 110.5 (Cc), 80.8 (Ck), 55.1 (Cg), 52.9 (Ci), 38.5 (Cd), 34.6 (Cf), 






A solution of DVP 18 (10.0 mg, 44.0 μmol), N-(tert-butoxycarbonyl)-L-cysteine methyl ester 
(25.9 mg, 110 μmol) in 30% MeCN/sodium phosphate buffer (pH 8, 50 mM, 880 μL) was 
stirred at 37 °C for 1 h. Upon completion, the mixture was diluted with H2O (10 mL), extracted 
with CH2Cl2 (4 × 10 mL), dried (MgSO4) and concentrated in vacuo. The crude residue was 
purified by FCC (EtOAc) to yield dimethyl 3,3'-(((2-(hex-5-yn-1-ylamino)pyrimidine-4,6-
diyl)bis(ethane-2,1-diyl))bis(sulfanediyl))(2R,2'R)-bis(2-((tert-butoxycarbonyl)amino)- 
propanoate) 26 (28.0 mg, 40.0 μmol, 91%) as a clear oil.  
Rf 0.07 (SiO2; 70% EtOAc/PE); νmax (neat/cm-1) 2976, 2344, 1744, 1711, 1642, 1565; δH (500 
MHz, CDCl3) 6.25 (s, 1H, Hc), 5.54-5.41 (m, 2H, 2 ´ NH), 5.14 (s, 1H, NH), 4.61-4.54 (m, 2H, 
Hg), 3.74 (s, 6H, Hi), 3.45-3.41 (m, 2H, Hm), 2.98 (d, 4H, J = 5.1 Hz, Hf), 2.91-2.86 (m, 4H, 
Hd), 2.78-2.75 (m, 4H, He), 2.23 (td, 2H, J = 10.5, 2.5 Hz, Hp), 1.95 (t, 1H, J = 2.5 Hz, Hr), 
1.73-1.72 (m, 2H, Hn), 1.65-1.59 (m, 2H, Ho), 1.44 (s, 18H, Hl); δC (126 MHz, CDCl3) 171.7 

























52.7 (Ci), 40.9 (Cm), 37.7 (Cd), 34.8 (Cf), 31.0 (Ce), 2 ´ 28.4 (Cn and Cl), 25.9 (Co), 18.3 




A solution of DVP 24 (5.00 mg, 22.8 μmol), N-(tert-butoxycarbonyl)-L-cysteine methyl ester 
(13.4 mg, 57.0 μmol) in 30% MeCN/sodium phosphate buffer (pH 8, 50 mM, 456 μL) was 
stirred at 37 °C for 1 h. Upon completion, the mixture was diluted with H2O (10 mL), extracted 
with CH2Cl2 (4 × 10 mL), dried (MgSO4) and concentrated in vacuo. The crude residue was 
purified by FCC (70-100% EtOAc/PE then 1% AcOH/EtOAc) to yield N-(4,6-bis(2-(((R)-2-
((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-thio)ethyl)pyrimidin-2-yl)-N-
methylglycine 27 (8.60 mg, 12.5 μmol, 55%) as a clear oil.  
Rf 0.17 (SiO2; 70% EtOAc/PE); νmax (neat/cm-1) 2974, 1704, 1561, 1509; δH (500 MHz, 
CD3OD) 6.46 (s, 1H, Hc), 4.34-4.32 (m, 4H, Hg and Hn), 3.72 (s, 6H, Hi), 3.24 (s, 3H, Hm), 
2.97-2.91 (m, 6H, Hd and Hf), 2.85-2.81 (m, 6H, Hd and He), 1.44 (s, 18H, Hl); δC (126 MHz, 
CD3OD) 174.7 (Co), 173.3 (Ch), 170.1 (Cb), 163.5 (Ca), 157.8 (Cj), 109.6 (Cc), 80.8 (Ck), 
55.2 (Cg), 52.8 (Cn), 52.2 (Ci), 38.7 (Cd), 36.7 (Cm), 34.7 (Cf), 31.6 (Ce), 28.7 (Cl); HRMS 
























To a solution of doxorubicin hydrochloride (10.9 mg, 20.0 μmol) in DMF (1.10 mL) was added 
DIPEA (7.00 μL, 40.0 μmol) followed by HBTU (9.10 mg, 24.0 μmol). The mixture was stirred 
at rt for 5 min. 14-azido-3,6,9,12-tetraoxatetradecanoic acid (N3-PEG4-COOH, 0.5 M in TBME, 
44.5 μL, 20.0 mmol) was added and the mixture stirred for 3 h. Upon completion, the reaction 
mixture was diluted with H2O (10 mL) and the product extracted in CH2Cl2 (4 × 10 mL) and 
dried (MgSO4). The organic fractions were concentrated and the crude residue purified by 
FCC (5-10% MeOH/EtOAc) to yield Dox-PEG4-N3 37 (13.5 mg, 16.8 μmol, 84%) as an orange 
solid.  
Rf 0.22 (SiO2; 10% MeOH/CH2Cl2); νmax (neat/cm-1) 2922, 2106, 1724, 1654, 1619, 1578, 
1535, 1411; δH (500 MHz, CDCl3) 8.04 (d, 1H, J = 7.9 Hz, Hd), 7.78 (t, 1H, J = 7.9 Hz, Hc), 
7.39 (d, 1H, J = 7.9 Hz, Hb), 5.51 (d, 1H, J = 3.8 Hz, Hv), 5.30-5.29 (m, 1H, Hp), 4.77 (d, 2H, 
J = 3.1 Hz, Hu), 4.61 (s, 1H, OH), 4.22-4.16 (m, 1H, Hy), 4.13 (q, 1H, J = 6.5 Hz, Hw), 4.08 
(s, 3H, Hg), 3.93 (m, 2H, 1 × CH2 of ac-aj), 3.72-3.63 (m, 15H, x and 7 × CH2 of ac-aj), 3.40 
(t, 2H, J = 5.0 Hz, ak), 3.28 (dd, 1H, J = 18.8, 1.7 Hz, Hs), 3.04 (s, 1H, Hs), 2.37 (d, 1H, J = 
14.7 Hz, Hq), 2.16 (dd, 1H, J = 14.7, 4.0 Hz, Hq), 1.93 (td, 1H, J = 19.8, 5.0 Hz, Hz), 1.80 (dd, 
1H, J = 13.4, 5.0 Hz, Hz), 1.29 (d, 3H, J = 6.5 Hz, aa);  δC (126 MHz, CDCl3) 214.1 (Ct), 187.3 
(Ch), 186.9 (Ci), 169.4 (Cab), 161.2 (Ca), 156.4 (Co), 155.9 (Cl), 135.9 (Ce), 135.7 (Cc), 133.8 
(Cm), 133.8 (Cn), 121.1 (Cf), 120.0 (Cd), 118.6 (Cb), 111.7 (Ck or Cj), 111.5 (Ck or Cj), 101.1 
(Cv), 76.8 (under CDCl3 peak, Cr), 71.1, 70.9, 70.7, 70.6, 70.6, 70.4, 70.2, 70.2 (8 × CH2 of 
ac-aj), 69.8 (Cp), 69.3 (Cx), 67.6 (Cw), 65.7 (Cu), 56.8 (Cg), 50.8 (Cak), 45.0 (Cy), 35.8 (Cq), 




















































A solution of N3-PEG4-COOH (50.0 μL, 25.1 μmol, 0.5 M in TBME, 90%), HBTU (12.7 mg, 
33.4 μmol) and DIPEA (17.5 μL, 100 μmol) in DMF (0.5 mL) was stirred at rt for 15 min. To 
this was added a solution of MMAE (12.0 mg, 16.7 μmol) in DMF (0.5 mL) and the reaction 
mixture stirred at rt for 18 h. Upon completion, the solvent was removed under a stream of N2 
and the crude residue was purified by FCC (0-5% MeOH/CH2Cl2) to yield N3-PEG4-MMAE 40 
(14.6 mg, 14.9 μmol, 90%) as a clear oil.  
Rf 0.48 (SiO2; 10% MeOH/CH2Cl2); νmax (neat/cm-1) 3423, 2926, 2109, 1629, 1454, 1098; δH 
(500 MHz, CDCl3) 7.77-7.75 (m, 1H), 7.70-7.68 (m, 1H), 7.40-7.37 (m, 2H), 7.31-7.27 (m, 2H), 
4.90 (s, 1H), 4.71-4.53 (m, 3H), 4.38-4.20 (m, 3H), 4.16-4.08 (m, 2H), 3.89-3.86 (m, 1H), 3.75-
3.63 (m, 13H), 3.52-3.43 (m, 5H), 3.37 (s, 3H), 3.25-3.23 (m, 2H), 3.05-3.00 (m, 2H), 2.94-
2.89 (m, 2H), 2.55-2.38 (m, 2H), 2.34-2.20 (m, 2H), 2.11-1.97 (m, 4H), 1.88 (s, 2H), 1.72 (s, 
1H), 1.47 (t, 2H, J = 6.4 Hz), 1.38 (d, 2H, J = 6.5 Hz), 1.25-1.22 (m, 5H), 1.00 (d, 3H, J = 7.5 
Hz), 0.94-0.71 (m, 18H); δC (126 MHz, CDCl3) 174.2, 173.3, 171.1, 169.5, 140.3, 128.5, 128.3, 
126.7, 126.5, 117.0, 111.6, 82.2, 76.1, 70.2, 69.9, 69.6, 66.8, 61.3, 60.3, 57.8, 54.9, 50.9, 
50.5, 50.4, 48.3, 48.1, 46.9, 45.3, 37.4, 32.1, 31.0, 29.9, 26.3, 25.8, 25.2, 23.6, 22.8, 19.4, 
19.1, 18.7, 17.5, 17.2, 16.0, 14.9, 10.8, 10.0; HPLC (5-95% MeCN/H2O over 20 min) retention 






















To a degassed solution of azide 40 (4.90 mg, 5.00 μmol) and alkyne 18 (2.30 mg, 10.0 μmol) 
in CH2Cl2 (0.25 mL) was added a degassed solution of CuSO4×5H2O (1.50 mg, 6.00 μmol), 
THPTA (4.40 mg, 10.0 μmol) and sodium ascorbate (5.00 mg, 25.0 μmol) in H2O/tBuOH (0.5 
mL, 1:1) and the reaction mixture stirred at rt for 2 h. Upon completion, the reaction was diluted 
with H2O (15 mL) and extracted with CH2Cl2 (5 × 15 mL). The combined organic fractions were 
dried (MgSO4), concentrated in vacuo and the crude residue purified by FCC (0-10% 
MeOH/CH2Cl2) to yield DVP-PEG4-MMAE 41 (1.80 mg, 1.50 μmol, 30%) as a clear oil.  
Rf 0.28 (SiO2; 7.5% MeOH/CH2Cl2); νmax (neat/cm-1) 3301, 2926, 1632, 1544, 1452, 1098; δH 
(500 MHz, CDCl3) 7.45-7.38 (m, 1H), 7.38-7.37 (m, 2H), 7.34-7.31 (m, 3H), 6.57 (dd, 2H, J = 
17.2, 10.7 Hz), 6.52 (s, 1H), 6.34 (dd, 2H, J = 17.2, 1.4 Hz), 5.55 (dd, 2H, J = 10.7, 1.4 Hz), 
5.16 (s, 1H), 4.95-4.95 (m, 1H), 4.75-4.71 (m, 1H), 4.69-4.63 (m, 1H), 4.57-4.47 (m, 3H), 4.26-
4.23 (m, 2H), 4.18-4.15 (m, 3H), 4.08-4.03 (m, 1H), 3.86-3.83 (m, 3H), 3.76-3.73 (m, 1H), 
3.68-3.65 (m, 3H), 3.62-3.58 (m, 9H), 3.52-3.48 (m, 3H), 3.41-3.37 (m, 4H), 3.33-3.33 (m, 1H), 
3.30 (s, 3H), 3.14-3.11 (m, 1H), 3.01-2.99 (m, 2H), 2.87-2.85 (m, 2H), 2.77-2.74 (m, 2H), 2.48-
2.30 (m, 4H), 2.27-2.21 (m, 2H), 2.11-1.93 (m, 5H), 1.85-1.81 (m, 2H), 1.80-1.75 (m, 2H), 
1.72-1.66 (m, 3H), 1.39-1.33 (m, 1H), 1.02 (d, 3H, J = 6.7 Hz), 0.96 (d, 3H, J = 6.8), 0.91-0.88 
(m, 6H), 0.84-0.80 (m, 9H); δC (126 MHz, CDCl3) 174.7, 170.7, 170.4, 169.7, 169.0, 163.8, 
162.8, 148.0, 141.3, 136.1, 128.4, 128.2, 127.4, 126.5, 122.0, 121.5, 105.6, 85.7, 82.1, 75.9, 
70.6, 70.2, 69.8, 66.2, 62.6, 61.0, 60.3, 58.1, 54.0, 51.8, 50.2, 47.9, 45.0, 41.2, 37.9, 33.6, 
32.0, 31.1, 29.8, 29.4, 27.1, 26.0, 25.6, 25.1, 23.4, 22.8, 19.4, 18.7, 18.0, 16.1, 14.6; HPLC 
(5-95% MeCN/H2O over 20 min) retention time 10.309 min; HRMS (ESI) m/z found [M+Na]+ 
























A solution of Alloc-Val-Ala-PABA 43 (100 mg, 0.265 mmol), bis(4-nitrophenyl) carbonate (121 
mg, 0.397 mmol) and DIPEA (231 μL, 1.33 mmol) was stirred at rt for 13 h. Upon completion, 
the mixture was concentrated under a stream of N2. The crude residue was redissolved in 
CH2Cl2 (20 mL) and saturated aqueous NaHCO3 (25 mL), the layers separated and the 
aqueous phase extracted with further CH2Cl2 (3 × 20 mL). The combined organic fractions 
were dried (MgSO4) and concentrated to yield Alloc-Val-Ala-PABA-PNP 65 as a pale yellow 
solid, which was carried forward without further purification.  
δH (400 MHz, CDCl3) 8.81 (s, 1H), 8.30-8.26 (m, 2H), 7.62 (d, 2H, J = 8.3 Hz), 7.40-7.37 (m, 
4H), 6.95 (d, 1H, J = 7.0 Hz), 5.97-5.88 (m, 1H), 5.46 (d, 1H, J = 7.7 Hz), 4.71 (qn, 1H, J = 7.1 
Hz), 4.65-4.56 (m, 2H), 4.11 (t, 1H, J = 6.7 Hz), 2.98 (DMF), 2.91 (DMF), 2.18 (sx, 2H, J = 2.2 















A solution of MMAE (40.0 mg, 74.0 μmol), Alloc-Val-Ala-PAB-PNP 65 (36.0 mg, 50.1 μmol), 
1-hydroxybenzotriazole hydrate (HOBt×H2O, 16.6 mg, 123 μmol) and pyridine (50.0 μL, 614 
μmol) in DMF (0.5 mL) was stirred at rt for 2 h. Upon completion, the reaction mixture was 
concentrated under a stream of N2 and the crude residue purified by FCC (0-6% 
MeOH/CH2Cl2) to yield Alloc-Val-Ala-PABC-MMAE 44 (49.5 mg, 44.1 μmol, 88%) as a white 
solid. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 12.237 min; HRMS (ESI) m/z found 
[M+H]+ 1121.6819, C59H93N8O13+ required 1121.6857. 
DVP(1C)-Val-Ala-PABC-MMAE (45) 
 
A solution of Alloc-Val-Ala-PABC-MMAE 44 (37.0 mg, 33.0 μmol), Pd(PPh3)4 (2.00 mg, 1.65 
μmol) and pyrrolidine (5.50 μL, 66.0 μmol) in CH2Cl2 (0.6 mL) was stirred at rt for 1 h. Upon 
completion, the reaction mixture was diluted with CH2Cl2 (15 mL) and NaHCO3 (sat. aq., 15 
mL). The layers were separated and the aqueous phase was extracted with further CH2Cl2 (3 
× 20 mL). The combined organic fractions were dried (MgSO4), concentrated in vacuo and the 

















































HPLC (5-95% MeCN/H2O over 20 min) retention time 11.795 min. HRMS (ESI) m/z found 
[M+H]+ 1037.6610, C55H89N8O11+ required 1037.6645. 
A solution of the deprotected amine 55 (7.50 mg, 7.23 μmol), DVP 24 (4.00 mg, 18.1 μmol), 
HBTU (5.50 mg, 14.5 μmol), HOBt×H2O (2.00 mg, 14.5 μmol) and DIPEA (6.30 μL, 36.2 μmol) 
in DMF (0.5 mL) was stirred at rt for 2 h. Upon completion, the solvent was removed under a 
stream of N2 and the crude residue was purified by FCC (0-8% MeOH/CH2Cl2) to yield 
DVP(1C)-Val-Ala-PABC-MMAE 45 (8.00 mg, 6.46 μmol, 89%) as a clear oil.  
HPLC (5-95% MeCN/H2O over 20 min) retention time 12.237 min; HRMS (ESI) m/z found 
[M+H]+ 1238.7537, C66H100N11O12+ required 1238.7547. 
Ethyl 4-((4,6-dichloropyrimidin-2-yl)amino)butanoate (66) 
 
A solution of 2,4,6-trichloropyrimidine (1.00 g, 5.45 mmol), ethyl 4-aminobutyrate 
hydrochloride (1.10 g, 6.54 mmol) and triethylamine (1.90 mL, 13.6 mmol) in acetone (20 mL) 
was stirred at 0 °C for 2 h. Upon completion, the reaction was concentrated in vacuo and the 
residue redissolved in H2O (20 mL) and CH2Cl2 (20 mL). The layers were separated and the 
aqueous phase was extracted with further CH2Cl2 (3 × 20 mL). The combined organic fractions 
were dried (MgSO4), concentrated in vacuo and the crude residue purified by FCC (5-30% 
EtOAc/PE) to yield ethyl 4-((4,6-dichloropyrimidin-2-yl)amino)butanoate 66 (420 mg, 1.51 
mmol, 28%) as a white solid. 
Rf 0.33 (SiO2; 20% EtOAc/PE); νmax (neat/cm-1) 2981, 1735, 1569, 1513, 1450; δH (400 MHz, 
CD3OD) 6.65 (s, 1H, Hc), 4.12 (q, 2H, J = 7.2 Hz, Hh), 3.40 (t, 2H, J = 7.0 Hz, Hd), 2.38 (t, 
2H, J = 7.0 Hz, Hf), 1.89 (t, 2H, J = 7.0 Hz, He), 1.24 (t, 3H, J = 7.2 Hz, Hi); δC (101 MHz, 
CD3OD) 175.1 (Cg), 163.4 (Ca and Cb), 108.8 (Cc), 61.6 (Ch), 41.6 (Cd), 32.3 (Cf), 25.5 (Ce), 

















Ethyl 4-((4,6-divinylpyrimidin-2-yl)amino)butanoate (67) 
 
A solution of dichloropyrimidine 66 (200 mg, 0.719 mmol), potassium vinyltrifluoroborate (482 
mg, 3.60 mmol), Pd(dppf)Cl2×CH2Cl2 (88.1 mg, 0.108 mmol) and potassium carbonate (596 
mg, 4.31 mmol) in THF/H2O (10:1, 5.5 mL) was heated to 70 °C for 15 h. Upon completion, 
the reaction mixture was filtered through Celite® and the solvent removed in vacuo. The 
resulting residue was purified by FCC (20% EtOAc/PE) to yield ethyl 4-((4,6-divinylpyrimidin-
2-yl)amino)butanoate 67 (181 mg, 0.693 mmol, 96%) as a pale yellow oil. 
Rf 0.18 (SiO2; 20% EtOAc/PE); νmax (neat/cm-1) 2971, 1734, 1636, 1543, 1418, 1371; δH (400 
MHz, CD3OD) 6.69 (s, 1H, Hc), 6.61 (dd, 2H, J = 17.4, 10.7 Hz, Hd), 6.37 (d, 2H, J = 17.4 Hz, 
Het), 5.57 (dd, 2H, J = 10.7, 1.5 Hz, Hec), 4.10 (q, 2H, J = 7.2 Hz, Hj), 3.48 (t, 2H, J = 7.1 Hz, 
Hf), 2.40 (t, 2H, J = 7.1 Hz, Hh), 1.92 (qn, 2H, J = 7.1 Hz, Hg), 1.22 (t, 3H, J = 7.2 Hz, Hk); δC 
(101 MHz, CD3OD) 175.4 (Ci), 165.3 (Cb), 164.1 (Ca), 137.1 (Cd), 122.0 (Ce), 105.8 (Cc), 
61.5 (Cj), 41.5 (Cf), 32.6 (Ch), 26.1 (Cg), 14.5 (Ck); HRMS (ESI) m/z found [M+H]+ 262.1541, 
C14H20N3O2+ required 262.1550. 
4-((4,6-divinylpyrimidin-2-yl)amino)butanoic acid (52) 
 
A solution of ester 67 (160 mg, 0.612 mmol) and LiOH×H2O (56.6 mg, 1.35 mmol) in THF/H2O 
(6 mL, 1:1) was stirred at rt for 20 h. Upon completion, the reaction was diluted with H2O (10 
mL) and washed with Et2O (15 mL) and concentrated in vacuo. The residue was suspended 
in MeOH, filtered and the filtrate concentrated in vacuo to yield 4-((4,6-divinylpyrimidin-2-






























νmax (neat/cm-1) 3311, 2935, 1711, 1636, 1542, 1418, 1348, 1320; δH (400 MHz, D2O) 6.84 (s, 
1H, Hc), 6.63 (dd, 2H, J = 17.5, 10.9 Hz, Hd), 6.31 (d, 2H, J = 17.5 Hz, Het), 5.71 (d, 2H, J = 
10.9 Hz, Hec), 3.40 (t, 2H, J = 7.3 Hz, Hf), 2.29 (t, 2H, J = 7.3 Hz, Hh), 1.88 (qn, 2H, J = 7.3 
Hz, Hg); δC (101 MHz, D2O) 183.1 (Ci), 164.7 (Cb), 162.3 (Ca), 134.8 (Cd), 123.2 (Ce), 104.7 




A solution of crude amine 55 (12.0 mg, 11.6 μmol), DVP 52 (6.80 mg, 29.0 μmol), HBTU (8.80 
mg, 23.2 μmol), HOBt×H2O (3.10 mg, 23.2 μmol) and DIPEA (13.6 μL, 58.0 μmol) in DMF (1 
mL) was stirred at rt for 16 h. Upon completion, the reaction was concentrated under a stream 
of N2 and the crude residue purified by FCC (0-8% MeOH/CH2Cl2) to yield DVP(3C)-Val-Ala-
PABC-MMAE 47 (4.10 mg, 3.27 μmol, 28%) as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 10.764 min; HRMS (ESI) m/z found 
[M+H]+ 1252.7711, C67H102N11O12+ required 1252.7704. 
Fmoc-Val-Cit-OH (49) 
 
To a solution of Fmoc-Val-OSu (1.00 g, 2.29 mmol) and NaHCO3 (260 mg, 3.09 mmol) in H2O 





















































THF (4 mL) was added, the reaction warmed to rt and stirred for 28 h. Upon completion, the 
reaction was adjusted to pH 10 with saturated aqueous K2CO3 and washed with EtOAc (2 × 
50 mL). The aqueous layer was acidified to pH 4 with 15% aqueous citric acid and the formed 
gelatinous mixture was filtered. The wet cake was redissolved in THF/MeOH (50 mL), TBME 
(100 mL) was added and the mixture was stirred at rt for 16 h. The mixture was filtered and 
the filtrate concentrated in vacuo to yield Fmoc-Val-Cit-OH 49 (1.12 g, 2.25 mmol, 98%) as an 
off-white solid. 
νmax (neat/cm-1) 3385, 2935, 1691, 1641, 1536, 1446, 1342; δH (400 MHz, DMSO-d6) 7.89 (d, 
2H, J = 7.7 Hz, Hb), 7.75 (t, 2H, J = 7.3 Hz, He), 7.41 (t, 2H, J = 7.7 Hz, Hc), 7.34-7.30 (m, 
2H, Hd), 5.36 (s, 1H, NH), 4.31-4.19 (m, 3H, Hg and Hh), 4.17-4.13 (m, 1H, Hn), 3.94-3.87 
(m, 1H, Hj), 2.97-2.92 (m, 2H, Hq), 1.98 (app sx, 1H, J = 6.8 Hz, Hk), 1.74-1.65 (m, 1H, Ho), 
1.61-1.52 (m, 1H, Ho), 1.46-1.34 (m, 2H, Hp), 0.89 (d, 3H, J = 6.8 Hz, Hl), 0.86 (d, 3H, J = 6.8 
Hz, Hl); δC (101 MHz, DMSO-d6) 173.5 (Cs), 171.3 (Cm), 158.8 (Cr), 156.1 (Ci), 144.0 (Ca), 
140.7 (Cf), 127.7 (Cc), 127.1 (Cd), 125.4 (Ce), 120.1 (Cb), 65.7 (Ch), 59.9 (Cj), 51.9 (Cn), 
46.7 (Cg), 38.8 (Cq), 30.6 (Ck), 28.4 (Co), 26.7 (Cp), 19.2 (Cl), 18.3 (Cl); HRMS (ESI) m/z 
found [M+H]+ 497.2394, C26H33N4O6+ required 497.2395. 
Fmoc-Val-Cit-PABA (50) 
 
A solution of dipeptide 49 (600 mg, 1.21 mmol), 4-aminobenzyl alcohol (PABA, 298 mg, 2.42 
mmol) and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ, 598 mg, 2.42 mmol) in 
CH2Cl2/MeOH (12.6 mL, 2:1) was stirred at rt for 21 h. Upon completion, the mixture was 
diluted with Et2O (30 mL), sonicaated briefly, filtered and washed with Et2O to yield Fmoc-Val-
Cit-PABA 50 (428 mg, 0.710 mmol, 59%) as an off-white solid.  
νmax (neat/cm-1) 3258, 1691, 1642, 1590, 1538, 1448; δH (400 MHz, DMSO-d6) 9.98 (s, 1H, 
NH), 8.12 (d, 1H, J = 7.5 Hz, NH), 7.89 (d, 2H, J = 7.6 Hz, Hb), 7.74 (t, 2H, J = 8.1 Hz, He), 



































2H, J = 8.4 Hz, Hv), 6.00 (t, 1H, J = 5.8 Hz, NH), 5.41 (s, 2H, NH2), 5.09 (t, 1H, J = 5.5 Hz, 
OH), 4.43-4.39 (m, 3H, Hn and Hx), 4.33-4.20 (m, 3H, Hg and Hh), 3.95-3.91 (m, 1H, Hj), 
3.06-2.89 (m, 2H, Hq), 2.04-1.95 (m, 1H, Hk), 1.74-1.55 (m, 2H, Ho), 1.50-1.32 (m, 2H, Hp), 
0.89-0.84 (m, 6H, Hl); δC (101 MHz, DMSO-d6) 171.3 (Cm), 170.4 (Cs), 158.9 (Cr), 156.1 (Ci), 
143.9, (Ca or Cf), 140.7 (Ca or Cf), 137.5 (Ct or Cw), 137.4 (Ct or Cw), 127.7 (Cc), 127.1 (Cd), 
126.9 (Cv), 125.4 (Ce), 120.1 (Cb), 118.9 (Cu), 65.7 (Ch), 62.6 (Cx), 60.1 (Cj), 53.1 (Cn), 46.7 
(Cg), 38.6 (Cq), 30.5 (Ck), 29.5 (Co), 26.8 (Cp), 19.2 (Cl), 18.3 (Cl); HRMS (ESI) m/z found 
[M+H]+ 602.2968, C33H40N5O6+ required 602.2973. 
Fmoc-Val-Cit-PABC-MMAE (51) 
 
A solution of Fmoc-Val-Cit-PABA 50 (200 mg, 0.332 mmol), bis(4-nitrophenyl) carbonate (202 
mg, 0.665 mmol) and DIPEA (86.8 μL, 0.498 mmol) was stirred at rt for 3 h. Upon completion, 
the mixture was concentrated under a stream of N2. The crude residue was precipitated with 
EtOAc (3 mL) and Et2O (30 mL), allowed to stand for 30 min and then filtered to yield Fmoc-
Val-Cit-PAB-PNP as a light brown solid, which was carried through without further purification. 
A solution of MMAE (25.0 mg, 34.8 μmol), Fmoc-Val-Cit-PAB-PNP (53.4 mg, 69.6 μmol), 
HOBt×H2O (9.40 mg, 69.6 μmol) and pyridine (28.2 μL, 348 μmol) in DMF (1.5 mL) was stirred 
at rt for 17 h. Upon completion, the reaction mixture was concentrated under a stream of N2. 
The crude residue was dissolved in CH2Cl2/MeOH (30 mL, 3:2), filtered and the filtrate purified 
by FCC (0-10% MeOH/CH2Cl2) to yield Fmoc-Val-Cit-PABC-MMAE 51 (22.0 mg, 16.4 μmol, 
47%) as a white solid. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 13.281 min; HRMS (ESI) m/z found 


























A solution of Fmoc-Val-Cit-PABC-MMAE 51 (20.0 mg, 14.9 μmol) and piperidine (7.40 μL, 
74.3 μmol) in DMF (1 mL) was stirred at rt for 2 h. Upon completion, the reaction mixture was 
concentrated under a stream of N2 and carried forward without further purification. 
A solution of H-Val-Cit-PABC-MMAE (5.00 mg, 4.45 μmol), DVP 52 (2.60 mg, 11.1 μmol), 
HBTU (3.40 mg, 8.90 μmol), HOBt×H2O (1.20 mg, 8.90 μmol) and DIPEA (3.90 μL, 22.3 μmol) 
in DMF (1 mL) was stirred at rt for 14 h. Upon completion, the reaction was concentrated under 
a stream of N2 and the crude residue purified by preparative HPLC to yield DVP(3C)-Val-Cit-
PABC-MMAE 48 (1.20 mg, 0.896 μmol, 20%) as a white solid. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 10.156 min; HRMS (ESI) m/z found 
[M+H]+ 1338.8167, C70H108N13O13+ required 1338.8184. 
Fmoc-PEG5-Val-Ala-PABC-MMAE (58) 
 
A solution of crude amine 55 (8.00 mg, 7.70 μmol), Fmoc-18-amino-4,7,10,13,16-
pentaoxaoctadecanoic (FmocHN-PEG5-COOH, 5.00 mg, 9.30 μmol), HBTU (5.90 mg, 15.4 
μmol) and DIPEA (2.70 μL, 15.4 μmol) in DMF (0.5 mL) was stirred at rt for 2 h. Upon 
completion, the reaction was diluted with H2O (15 mL) and extracted with CH2Cl2 (5 × 10 mL). 





















































residue purified by FCC (0-9% MeOH/CH2Cl2) to yield Fmoc-PEG5-Val-Ala-PABC-MMAE 58 
(7.70 mg, 4.97 μmol, 65%) as a clear oil.  
HPLC (5-95% MeCN/H2O over 20 min) retention time 13.203 min; HRMS (ESI) m/z found 
[M+Na]+ 1572.8883, C83H123N9O1923Na1+ required 1572.8827. 
N3-PEG9-Val-Ala-PABC-MMAE (59) 
 
To a solution of protected amine 58 (6.50 mg, 4.20 μmol) in DMF (0.5 mL) was added 
piperidine (2.10 μL, 21.0 μmol) and the reaction mixture stirred for 22 h at rt. Upon completion, 
the reaction mixture was concentrated under a stream of N2 and the crude amine carried 
forward without further purification. 
A solution of the deprotected amine, N3-PEG4-COOH (16.8 μL, 8.40 μmol, 0.5 M in TBME, 
90%), HBTU (3.20 mg, 8.40 μmol) and DIPEA (1.50 μL, 8.40 μmol) and the reaction mixture 
stirred at rt for 4 h. Upon completion, the solvent was removed under a stream of N2 and the 
crude residue was purified by FCC (0-9% MeOH/CH2Cl2) to yield N3-PEG9-Val-Ala-PABC-
MMAE 59 (6.20 mg, 3.90 μmol, 93%) as a clear oil.  
HPLC (5-95% MeCN/H2O over 20 min) retention time 11.252 min; HRMS (ESI) m/z found 






























To a degassed solution of azide 59 (5.50 mg, 3.50 μmol) and alkyne 18 (1.60 mg, 7.00 μmol) 
in CH2Cl2 (0.25 mL) was added a degassed solution of CuSO4×5H2O (1.00 mg, 4.20 μmol), 
THPTA (3.00 mg, 7.00 μmol) and sodium ascorbate (3.50 mg, 17.5 μmol) in H2O/tBuOH (0.5 
mL, 1:1) and the reaction mixture stirred at rt for 20 h. Upon completion, the reaction was 
diluted with H2O (15 mL) and extracted with CH2Cl2 (5 × 15 mL). The combined organic 
fractions were dried (MgSO4), concentrated in vacuo and the crude residue purified by FCC 
(0-10% MeOH/CH2Cl2) to yield DVP-PEG9-Val-Ala-PABC-MMAE 60 (6.30 mg, 3.47 μmol, 
99%) as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 10.599 min; HRMS (ESI) m/z found 
[M+Na]+ 1837.0746, C92H147N15O2223Na+ required 1837.0737. 
N3-PEG4-Val-Ala-PABC-MMAE (56) 
 
A solution of crude amine 55 (10.5 mg, 10.1 μmol), N3-PEG4-COOH (40.4 μL, 20.2 μmol, 0.5 
M in TBME, 90%), HBTU (7.70 mg, 20.2 μmol) and DIPEA (3.50 μL, 20.2 μmol) in DMF (0.5 
mL) was stirred at rt for 2 h. Upon completion, the solvent was removed under a stream of N2 
and the crude residue was purified by FCC (0-8% MeOH/CH2Cl2) to yield N3-PEG4-Val-Ala-
PABC-MMAE 56 (9.10 mg, 7.02 μmol, 70%) as a white solid.  
HPLC (5-95% MeCN/H2O over 20 min) retention time 11.921 min; HRMS (ESI) m/z found 























































To a degassed solution of azide 56 (8.00 mg, 6.20 μmol) and alkyne 18 (2.80 mg, 12.4 μmol) 
in CH2Cl2 (0.5 mL) was added a degassed solution of CuSO4×5H2O (1.90 mg, 7.40 μmol), 
THPTA (5.40 mg, 12.4 μmol) and sodium ascorbate (6.10 mg, 31.0 μmol) in H2O/tBuOH (1 
mL, 1:1) and the reaction mixture stirred at rt for 13 h. Upon completion, the reaction was 
diluted with H2O (15 mL) and extracted with CH2Cl2 (5 × 15 mL). The combined organic 
fractions were dried (MgSO4), concentrated in vacuo and the crude residue purified by FCC 
(0-8% MeOH/CH2Cl2) to yield DVP-PEG4-Val-Ala-PABC-MMAE 57 (5.60 mg, 3.67 μmol, 59%) 
as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 10.966 min; HRMS (ESI) m/z found 
[M+H]+ 1523.9174, C79H123N14O16+ required 1523.9236. 
7.2.2 Monovinylpyrimidine Rate Studies 
 
To a solution of amine 11 in 30% CD3CN/deuterated NaPi (700 μL of a 20 mM stock solution) 
in an NMR tube was added a solution of N-Boc-Cys-OMe in 30% CD3CN/deuterated NaPi 
(700 μL of a 100 mM, 200 mM or 300 mM stock solution). A timer was started as the mixture 
was shaken vigorously and rapidly inserted in a 500 MHz Bruker NMR machine. Scans were 
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7.2.3 Monovinylpyrimidine Stability Studies 
 
To a solution of amine 12 (5.20 mg, 14.6 μmol) in CD3CN (389 μL) and deuterated NaPi (584 
μL, 50 mM, pH 7.4) was added reduced L-glutathione (13.4 mg, 43.7 μmol). The mixture was 
incubated at rt and analysed by 1H NMR at 24 h intervals for 14 days. 
7.2.4 Maleimide Stability Studies 
 
To a solution of succinimide 13 (5.90 mg, 14.0 μmol) in CD3CN (400 μL) and deuterated NaPi 
(600 μL, 50 mM, pH 7.4) was added reduced L-glutathione (12.9 mg, 42.0 μmol). The mixture 
was incubated at rt and analysed by 1H NMR at 24 h intervals for 14 days. 
7.2.5 Monovinylpyrimidine Chemoselectivity Studies 
 
A solution of amine 11 (12.0 mg, 99.0 μmol), N-Boc-Cys-OMe (7.80 mg, 33.0 μmol) and N-
Boc-Lys-OMe×HCl (9.70 mg, 33.0 μmol) in 30% MeCN/NaPi (1.98 mL, 50 mM, pH 8) was 
stirred at 37 °C for 2 h. Aliquots were removed from the reaction at 0 and 2 h and analysed by 
HPLC. 
40% CD3OD/NaPi 























(pH 8, 50 mM)
















7.2.6 Divinylpyrimidine Stability 
 
To a solution of amine 25 (4.70 mg, 7.61 μmol) in CD3CN (280 μL) and deuterated NaPi (420 
μL, 50 mM, pH 7.4) was added reduced L-glutathione (7.00 mg, 22.8 μmol). The mixture was 
incubated at rt and analysed by 1H NMR at 24 h intervals for 14 days. 
 
To a solution of carboxylic acid 27 (4.00 mg, 5.80 μmol) in CD3OD (309 μL) and deuterated 
NaPi (464 μL, 50 mM, pH 7.4) was added reduced L-glutathione (5.40 mg, 17.4 μmol). The 
mixture was incubated at rt and analysed by 1H NMR at 24 h intervals for 14 days. 
7.2.7 Divinylpyrimidine Chemoselectivity Studies 
2-amino-4,6-divinylpyrimidine (15) 
 
A solution of amine 15 (4.00 mg, 27.0 μmol), N-Boc-Cys-OMe (2.10 mg, 9.10 μmol) and N-
Boc-Lys-OMe×HCl (2.70 mg, 9.10 μmol) in 30% MeCN/NaPi (540 μL, 50 mM, pH 8) was stirred 
at 37 °C for 4 h. Aliquots were removed from the reaction at 0, 2 and 4 h and analysed by 










































(pH 8, 50 mM)







A solution of alkyne 18 (2.70 mg, 11.9 μmol), N-Boc-Cys-OMe (1.00 mg, 4.00 μmol) and N-
Boc-Lys-OMe×HCl (1.20 mg, 4.00 μmol) in 30% MeCN/NaPi (238 μL, 50 mM, pH 8) was stirred 
at 37 °C for 4 h. Aliquots were removed from the reaction at 0, 2 and 4 h and analysed by 
HPLC and LCMS. 
N-(4,6-divinylpyrimidin-2-yl)-N-methylglycine (24) 
 
A solution of carboxylic acid 24 (4.00 mg, 18.2 μmol), N-Boc-Cys-OMe (1.50 mg, 6.10 μmol) 
and N-Boc-Lys-OMe×HCl (1.80 mg, 6.10 μmol) in 30% MeCN/NaPi (364 μL, 50 mM, pH 8) 
was stirred at 37 °C for 4 h. Aliquots were removed from the reaction at 0, 2 and 4 h and 
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7.3 Chapter 5: Dual-functional Divinylpyrimidine 
7.3.1 Synthetic Procedures 
Ethyl 4-(hex-5-yn-1-ylamino)butanoate (69) 
 
A solution of sulfur trioxide pyridine complex (2.44 g, 15.3 mmol) and pyridine (1.24 mL, 15.3 
mmol) in CH2Cl2 (5 mL) was stirred at rt for 5 min. To this solution was added DIPEA (2.67 
mL, 15.3 mmol) and DMSO (3.62 mL, 51.0 mmol) and stirred at rt for 5 min. The mixture was 
cooled to –40 °C and to this was added 5-heyn-1-ol (500 mg, 5.10 mmol). The reaction was 
stirred for 2 h warming slowly to –20 °C. Upon completion, the reaction was acidified to pH 3 
with 1 M HCl and diluted with CH2Cl2 (10 mL). The layers were separated and the aqueous 
phase was extracted with further CH2Cl2 (2 × 20 mL). The combined organic fractions were 
washed with brine (2 × 50 mL), dried (MgSO4) and concentrated in vacuo. The crude oil was 
immediately redissolved in MeOH (4 mL). A separate solution of ethyl 4-aminobutyrate 
hydrochloride (1.28 g, 7.65 mmol), triethylamine (1.07 mL, 7.65 mmol) and 4 Å molecular 
sieves in CH2Cl2 (12 mL) was stirred at rt for 5 min. To this solution was added the aldehyde 
(68) solution, followed by NaBH(OAc)3 (3.24 g, 15.3 mmol) and the reaction mixture stirred at 
room temperature for 3 h. Upon completion, the reaction mixture was filtered, diluted with 
NaHCO3 (sat. aq., 15 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined organic layers 
were washer with brine (50 mL), dried (MgSO4) and concentrated in vacuo. The crude residue 
was purified by FCC (0-12% MeOH/CH2Cl2) to yield ethyl 4-(hex-5-yn-1-ylamino)butanoate 69 
(430 mg, 2.04 mmol, 40%) as a clear oil. 
Rf 0.16 (SiO2; 10% MeOH/CH2Cl2); νmax (neat/cm-1) 3455, 2931, 2148, 1730, 1660; δH (400 
MHz, CD3OD) 4.12 (q, 2H, J = 7.1 Hz, Hk), 2.64-2.59 (m, 4H, Hf and Hg), 2.36 (t, 2H, J = 7.5 
Hz, Hi), 2.23-2.19 (m, 3H, Ha and Hc), 1.81 (qn, 2H, J = 7.5 Hz, Hh), 1.68-1.51 (m, 4H, Hd 
and He), 1.25 (t, 3H, J = 7.1 Hz, Hl); δH (101 MHz, CD3OD) 175.1 (Cj), 84.7 (Cb), 69.7 (Ca), 
61.5 (Ck), 50.0 (Cf or Cg), 49.8 (Cf or Cg), 32.8 (Ci), 29.3 (Cd or Ce), 27.4 (Cd or Ce), 25.5 
















Ethyl 4-((4,6-dichloropyrimidin-2-yl)(hex-5-yn-1-yl)amino)butanoate (70) 
 
A solution of 2,4,6-trichloropyrimidine (327 μL, 2.84 mmol), amine 69 (720 mg, 3.41 
mmol) and triethylamine (792 μL, 5.68 mmol) in acetone (10 mL) was stirred at 0 °C 
for 2 h. Upon completion, the reaction was concentrated in vacuo and the residue 
redissolved in H2O (10 mL), NaHCO3 (sat. aq., 10 mL) and CH2Cl2 (20 mL). The layers 
were separated and the aqueous phase was extracted with further CH2Cl2 (3 × 20 
mL). The combined organic fractions were dried (MgSO4), concentrated in vacuo and 
the crude residue purified by FCC (0-40% EtOAc/PE) to yield ethyl 4-((4,6-
dichloropyrimidin-2-yl)(hex-5-yn-1-yl)amino)butanoate 70 (353 mg, 0.985 mmol, 35%) as a 
white solid. 
Rf 0.44 (SiO2; 20% EtOAc/PE); νmax (neat/cm-1) 3302, 2945, 2175, 1729, 1571, 1529; 
δH (400 MHz, CD3OD) 6.64 (s, 1H, Ha), 4.11 (q, 2H, J = 7.1 Hz, Hn), 3.60 (qn, 4H, J 
= 7.2 Hz, Hd and Hj), 2.35 (t, 2H, J = 7.2 Hz, Hl), 2.26-2.20 (m, 3H, Hg and Hi), 1.93 
(qn, 2H, J = 7.2 Hz, Hk), 1.78-1.70 (m, 2H, He), 1.52 (qn, 2H, J = 7.2 Hz, Hf), 1.24 (t, 
3H, J = 7.1 Hz, Ho); δH (101 MHz, CD3OD) 174.9 (Cm), 162.8 (Cb or Cc), 162.3 (Cb 
or Cc), 108.2 (Ca), 84.7 (Ch), 69.8 (Ci), 61.6 (Cn), 48.3 (Cd or Cj), 48.0 (Cd or Cj), 
32.2 (Cl), 27.5 (Ce), 26.8 (Cf), 23.8 (Ck), 18.8 (Cg), 14.5 (Co); HRMS (ESI) m/z found 























Ethyl 4-((4,6-divinylpyrimidin-2-yl)(hex-5-yn-1-yl)amino)butanoate (71) 
 
A solution of dichloropyrimidine 70 (23.0 mg, 64.2 μmol), potassium vinyltrifluoroborate (43.0 
mg, 321 μmol), Pd(dppf)Cl2×CH2Cl2 (8.00 mg, 9.63 μmol) and potassium carbonate (53.0 mg, 
385 μmol) in THF/H2O (10:1, 1.1 mL) was heated to 70 °C for 20 h. Upon completion, the 
reaction mixture was filtered through Celite® and the solvent removed in vacuo. The resulting 
residue was purified by FCC (5% EtOAc/PE) to yield ethyl 4-((4,6-divinylpyrimidin-2-yl)(hex-
5-yn-1-yl)amino)butanoate 71 (11.5 mg, 33.7 μmol, 53%) as a pale yellow oil. 
Rf 0.51 (SiO2; 15% EtOAc/PE); νmax (neat/cm-1) 2935, 2194, 1736, 1543; δH (400 MHz, 
CD3OD) 6.62 (dd, 2H, J = 17.3, 10.5 Hz, Hp), 6.56 (s, 1H, Ha), 6.39 (dd, 2H, J = 17.3, 1.8 Hz, 
Hqt), 5.52 (dd, 2H, J = 10.5, 1.8 Hz, Hqc), 4.09 (q, 2H, J = 7.2 Hz, Hn), 3.70-3.63 (m, 4H, Hd 
and Hj), 2.36-2.33 (m, 2H, Hl), 2.26-2.21 (m, 2H, Hg), 2.18 (t, 1H, J = 2.7 Hz, Hi), 2.01-1.93 
(m, 2H, Hk), 1.80-1.64 (m, 2H, He), 1.58-1.50 (m, 2H, Hf), 1.21 (t, 3H, J = 7.2 Hz, Ho); ; δC 
(101 MHz, CD3OD) 175.3 (Cm), 164.8 (Cb), 163.1 (Cc), 137.5 (Cp), 121.3 (Cq), 105.5 (Ca), 
84.9 (Ch), 69.6 (Ci), 61.5 (Cn), 48.0 (Cd or Cj), 47.7 (Cd or Cj), 32.5 (Cl), 27.9 (Ce), 27.1 (Cf), 
























4-((4,6-divinylpyrimidin-2-yl)(hex-5-yn-1-yl)amino)butanoic acid (72) 
 
A solution of ester 71 (8.00 mg, 23.4 μmol) and LiOH×H2O (4.00 mg, 93.8 μmol) in THF/H2O 
(0.5 mL, 1:1) was stirred at rt for 21 h. Upon completion, the reaction was diluted with H2O (10 
mL) and washed with Et2O (10 mL). The aqueous phase was neutralised with 1M HCl and 
extracted with CH2Cl2 (4 × 20 mL). The combined organic fractions were dried (MgSO4) and 
concentrated in vacuo to yield 4-((4,6-divinylpyrimidin-2-yl)(hex-5-yn-1-yl)amino)butanoic acid 
72 (6.30 mg, 20.1 μmol, 86%) as a pale yellow oil. 
νmax (neat/cm-1) 2927, 2117, 1705, 1539; δH (400 MHz, CD3OD) 6.62 (dd, 2H, J = 17.3, 10.6 
Hz, Hn), 6.56 (s, 1H, Ha), 6.40 (dd, 2H, J = 17.3, 1.8 Hz, Hot), 5.52 (dd, 2H, J = 10.6, 1.8 Hz, 
Hoc), 3.68 (q, 4H, J = 7.2 Hz, Hd and Hj), 2.33 (t, 2H, J = 7.2 Hz, Hl), 2.23 (td, 2H, J = 10.5, 
2.6 Hz, Hg), 2.18 (t, 1H, J = 2.6 Hz, Hi), 1.95 (qn, 2H, J = 7.2 Hz, Hk), 1.81-1.74 (m, 2H, He), 
1.55 (qn, 2H, J = 7.2 Hz, Hf); δH (101 MHz, CD3OD) 178.2 (Cm), 164.8 (Cb), 163.1 (Cc), 137.5 
(Cn), 121.3 (Co), 105.4 (Ca), 84.9 (Ch), 69.6 (Ci), 48.1 (Cd or Cj), 47.9 (Cd or Cj), 32.3 (Cl), 
28.0 (Ce), 27.1 (Cf), 24.4 (Ck), 18.9 (Cg); HRMS (ESI) m/z found [M+H]+ 314.1873, 























To a solution of protected amine 58 (9.30 mg, 6.00 μmol) in DMF (0.5 mL) was added 
piperidine (2.10 μL, 21.0 μmol) and the reaction mixture stirred for 22 h at rt. Upon completion, 
the reaction mixture was concentrated under a stream of N2 and the crude amine carried 
forward without further purification. 
A solution of crude amine, df-DVP 72 (3.80 mg, 12.0 μmol), HBTU (4.60 mg, 12.0 μmol), 
HOBt×H2O (2.00 mg, 12.0 μmol) and DIPEA (2.10 μL, 12.0 μmol) was stirred at rt for 2 h. Upon 
completion, the reaction was diluted with H2O (15 mL) and extracted with CH2Cl2 (5 × 15 mL). 
The combined organic fractions were washed with brine, dried (MgSO4), concentrated in 
vacuo and the crude residue purified by FCC (0-8% MeOH/CH2Cl2) to yield df-DVP-alkyne-
PEG5-Val-Ala-PABC-MMAE 74 (3.90 mg, 2.40 μmol, 40%) as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 12.056 min; HRMS (ESI) m/z found 
[M+H]+ 1623.9996, C86H135N12O18+ required 1624.0012. 
df-DVP-acid-PEG4-Val-Ala-PABC-MMAE (76) 
 
To a degassed solution of azide 56 (25.0 mg, 19.3 μmol) and alkyne 72 (12.1 mg, 38.6 μmol) 
in CH2Cl2 (1 mL) was added a degassed solution of CuSO4×5H2O (5.80 mg, 23.2 μmol), 
THPTA (16.8 mg, 38.6 μmol) and sodium ascorbate (19.2 mg, 96.5 μmol) in H2O/tBuOH (2 



























































removed under a stream of N2 and the crude residue purified by FCC (0-10% MeOH/CH2Cl2) 
to yield df-DVP-acid-PEG4-Val-Ala-PABC-MMAE 76 (17.1 mg, 10.6 μmol, 55%) as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 11.320 min; HRMS (ESI) m/z found 
[M+H]+ 1609.9619, C83H129N14O18+ required 1609.9604. 
df-DVP-amide-alkyne-PEG4-Val-Ala-PABC-MMAE (77) 
 
A solution of carboxylic acid 76 (6.30 mg, 3.90 μmol), but-3-ynylamine hydrochloride 
(0.800 mg, 7.80 μmol), HBTU (3.00 mg, 7.80 μmol), HOBt×H2O (1.30 mg, 7.80 μmol) 
and DIPEA (1.40 μL, 7.80 μmol) was stirred at rt for 4 h. Upon completion, the reaction 
was diluted with H2O (15 mL) and extracted with CH2Cl2 (5 × 20 mL). The combined 
organic fractions were dried (MgSO4), concentrated in vacuo and the crude residue 
purified by FCC (0-8% MeOH/CH2Cl2) to yield df-DVP-amide-alkyne-PEG4-Val-Ala-
PABC-MMAE 77 (3.40 mg, 2.05 μmol, 53%) as a clear oil. 
HPLC (5-95% MeCN/H2O over 20 min) retention time 11.154 min; HRMS (ESI) m/z 
































7.4 Protein Chemistry 
7.4.1 Chapter 3: Divinylpyridine 
PfRadA-dCys Preparation 
Synthetic DNA Production 
The synthetic gene of the PfRadA C-terminal ATPase domain containing the desired cysteine 
mutations was constructed from DNA oligos using overlap-extension PCR. Oligos of 
approximately 25 bases (Sigma) were designed to include the cysteine mutations. Primers 
were present in the polymerase chain reaction (PCR) at a concentration of 1 μg/μL. PCR was 
conducted with Phusion polymerase (Thermo Scientific), and products were purified from 
agarose gel using a Gel Extraction kit (Qiagen). PCR products and pBAT4 vector were 
digested using NcoI and XhoI (New England Biolabs) for at least two hours at 37 °C, 
dephosphorylated with Shrimp alkaline phosphatase (SAP) (Agilent Technologies) and gel 
purified. The gene insert was ligated into the plasmid using a Quick Ligase Kit (New England 
Biolabs). The construct was then transformed into DH5α strain E. coli by heat shock at 42 °C. 
Transformants were selected using 100 μg/mL ampicillin in Luria-Bertani (LB) medium. 
Plasmid was extracted from 2 mL overnight cell cultures using a Miniprep Spin kit (Qiagen). 
The insert was verified by restriction digest analysis and DNA sequencing. 
Expression and Purification 
The plasmids containing the desired insert were transformed into the BL21(DE3)-pUBS520 
strain of E. coli and soluble expression of mutated proteins was confirmed in a small scale 
expression test. For large scale expression, cells were streaked from previously stored 
glycerol stocks on ampicillin- and kanamycin-supplemented LB agar plates. Colonies were 
grown overnight at 37 °C and used to inoculate 1 L cultures of LB media with ampicillin (100 
μg/mL) and kanamycin (25 μg/mL). After 4.5 hours incubation at 37 °C (OD600 = 0.7 – 1.0), 
cells were induced with IPTG (400 mM). Further incubation at 37 °C was carried out for 3 
hours, followed by centrifugation of the cultures. The cell pellet was resuspended in 20 mM 
MES pH 6.0. Cells were lysed using EmulsiFlex C5 homogeniser (Avestin). The cell lysate 
was heated to 65 °C for 10 minutes followed by centrifugation. The clarified supernatant was 
loaded onto a 5 mL HiTrap SP-Sepharose HP column using an ÄKTA purifier 10 
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chromatography system (GE Healthcare). The protein was eluted using ion exchange elution 
buffer (20 mM MES pH 6.0, 0.5 mM EDTA, 1 M NaCl) gradient of 0 – 0.5 M NaCl. Appropriate 
fractions were concentrated to 2 mL using an Amicon-Ultra centrifugal filter (10000 MWCO, 
Merck Millipore). To the concentrated sample was added TCEP (~180 μL, 10% v/v) which was 
subsequently loaded onto a Superdex 75 16/60 gel filtration (GF) column equilibrated with GF 
buffer (20 mM MES pH 6.0, 1 mM EDTA, 100 mM NaCl, 0.1 mM TCEP) using an ÄKTA purifier 
10 chromatography system. The protein was eluted using GF buffer. Fractions containing 
purified PfRadA-dCys were concentrated to 2 mL using an Amicon-Ultra centrifugal filter 
(10000 MWCO, Merck Millipore) and protein purity analysed by 15% SDS-PAGE. 
PfRadA-dCys 5 modification 
 
To a solution of PfRadA-dCys (15 μL, 2.94 mg/mL) in TBS (50 mM Tris HCl pH 8, 100 mM 
NaCl) was added TCEP (5 eq.). The mixture was vortexed and incubated at 37 °C for 1 h. A 
solution of 5 (10 mM in DMSO) was added (35 eq.), the reaction adjusted to 5% DMSO (v/v) 
and the reaction mixture incubated at 37 °C for 4 h. An aliquot was removed from the reaction, 





























To a solution of trastuzumab (5 μL, 36.4 μM, 5.41 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 
mM NaCl, 0.5 mM EDTA) was added TCEP (10 eq.). The mixture was vortexed and incubated 
at 37 °C for 1 h. Excess TCEP was removed by repeated diafiltration into fresh TBS buffer 
using an Amicon-Ultra centrifugal filter (10000 MWCO, Merck Millipore) and concentrated to 
1.35 μM (100 μL). To this solution was added 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) in 
10% DMSO/TBS buffer (final concentration of 54 μM, 40 eq.) and the mixture incubated at 
room temperature for 10 min. UV-visible spectrometry revealed an absorption of 0.28 at 280 
nm and 0.15 at 412 nm. The number of free thiols was calculated to be 8.15 using the following 
formula:160 





ε412 = 14,150 M-1 cm-1 
ε280 = 215,389 M-1 cm-1 
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Trastuzumab 5 General Procedure 
 
To a solution of trastuzumab (2.50, 5.00 or 7.50 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 mM 
NaCl, 0.5 mM EDTA) or BBS (25 mM sodium borate pH 8, 25 mM NaCl, 0.5 mM EDTA) was 
added TCEP (10 eq.). The mixture was vortexed and incubated at 37 °C for 1 h. A solution of 
5 (10 mM in DMSO) was added (40, 60, 100, 200 or 500 molar eq.) and the reaction mixture 
incubated at 37 °C for 8 h. An aliquot was removed from the reaction after 2, 4 and 8 hours, 
diluted with PBS and analysed by LCMS and SDS-PAGE. 
SDS-PAGE 
Non-reducing Tris-Glycine SDS-PAGE with 12% acrylamide (15% for PfRadA-dCys) with 4% 
stacking gel was performed as standard. Broad range molecular weight marker (10-200 kDa, 
New England BioLabs) was run in all gels. Samples (10 μL of 0.4 mg/mL) were prepared with 
reducing loading dye (10 μL, containing b-mercaptoethanol) and heated to 95 °C for 5 min. 
Gels were run at constant voltage (200 V) for 48 min in 1 ´ Laemmli running buffer (LRB). All 
gels were stained with Coomassie dye or ZnCl2/imidazole staining and imaged on a Syngene 
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7.4.2 Chapter 4: Divinylpyrimidine 
Trastuzumab Fab Preparation 
Trastuzumab Fab was prepared using the Pierce™ Fab Preparation Kit (ThermoFisher). 
Briefly, 0.25 mL of immobilised papain was washed with Digestion Buffer containing 
cysteine×HCl to activate the enzyme. Trastuzumab (500 μL, 2.95 mg/mL) in Digestion Buffer 
was added to the immobilised papain and incubated with gentle mixing at 37 °C for 16 h. The 
digest was isolated from the papain and the Fab purified using a Nab Protein A Plus Spin 
Column followed by preparative size-exclusion chromatography (25 mM sodium borate pH 8, 
100 mM NaCl, 0.5 mM EDTA). The isolated Fab was aliquoted and stored at -20 °C until use.  
Trastuzumab Fab General Modification Procedure 
 
To a solution of trastuzumab Fab (10 μL, 27 μM, 1.28 mg/mL) in BBS (25 mM sodium borate 
pH 8, 25 mM NaCl, 0.5 mM EDTA) was added TCEP (5 eq.). The mixture was vortexed and 
incubated at 37 °C for 1 h. A solution of 15, 18 or 24 (10 mM in DMSO) was added (final 
concentration of 270 μM, 10 eq.) and the reaction mixture incubated at 37 °C for 1 h. The 
excess reagents were removed by repeated diafiltration into fresh BBS using an Amicon-Ultra 
centrifugal filter (10000 MWCO, Merck Millipore). Samples were either stored at 4 °C or flash 
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Trastuzumab Fab Reduction Control 
 
To a solution of trastuzumab Fab (5 μL, 29.6 μM, 1.41 mg/mL) in BBS (25 mM sodium borate 
pH 8, 25 mM NaCl, 0.5 mM EDTA) was added solution of DVP 18 (10 mM in DMSO, final 
concentration of 296 μM, 10 eq.). The reaction mixture was vortexed and incubated at 37 °C 
for 2 h. LCMS analysis revealed that no reaction had occurred.  
Trastuzumab Fab Rate Studies 
 
To a solution of trastuzumab Fab (5 μL, 51 μM, 2.39 mg/mL) in BBS (25 mM sodium borate 
pH 8, 25 mM NaCl, 0.5 mM EDTA) was added TCEP (5 eq.). The mixture was vortexed and 
incubated at 37 °C for 1 h. A solution of DVP 18 (10 mM in DMSO) was added (final 
concentration equal to 10 or 20 equivalents) and the reaction mixture incubated at 37 °C. At t 
= 0, 5, 10, 15, 20, 30, 40 and 60 min, 0.5 μL was removed from each reaction, diluted with 
MilliQ water (9 μL) and quenched with 100 eq. of cysteine (5 mM in DMSO). LCMS analysis 
was then used to quantify conversion. 
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Trastuzumab General Modification Procedure 
 
To a solution of trastuzumab (10 μL, 17 μM, 2.5 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 mM 
NaCl, 0.5 mM EDTA) was added TCEP (10 eq.). The mixture was vortexed and incubated at 
37 °C for 1 h. A solution of 15, 18 or 24 (10 mM in DMSO) was added (final concentration of 
680 μM, 40 eq.) and the reaction mixture incubated at 37 °C for 2 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Samples were either stored at 4 °C or flash frozen and stored at -
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Trastuzumab-DVP (35) Dox-PEG4-N3 (37) CuAAC 
  
To a solution of trastuzumab-DVP 35 (70 μL, 12.5 μM, 1.86 mg/mL) in PBS was added Dox-
PEG4-N3 37 (5 mM in DMSO, final concentration of 150 μM), CuSO4×5H2O (final concentration 
of 250 μM), THPTA (final concentration of 1.25 mM) and sodium ascorbate (final concentration 
of 1.88 mM). The mixture was vortexed and incubated at 37 °C for 2 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Sample was either stored at 4 °C or flash frozen and stored at -20 










































Trastuzumab-DVP (35) AlexaFluorä 488 CuAAC 
 
To a solution of trastuzumab-DVP 35 (55 μL, 13.7 μM, 2.05 mg/mL) in PBS was added 
AlexaFluorä 488 Azide (ThermoFisher) (5 mM in DMSO, final concentration of 164.4 μM), 
CuSO4×5H2O (final concentration of 274 μM), THPTA (final concentration of 1.37 mM) and 
sodium ascorbate (final concentration of 2.06 mM). The mixture was vortexed and incubated 
at 37 °C for 4 h. The excess reagents were removed by repeated diafiltration into PBS using 
an Amicon-Ultra centrifugal filter (10000 MWCO, Merck Millipore). Sample was either stored 



































Trastuzumab 41 Modification 
 
To a solution of trastuzumab (30 μL, 25.5 μM, 3.81 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 
mM NaCl, 0.5 mM EDTA) was added TCEP (10 eq.). The mixture was vortexed and incubated 
at 37 °C for 1 h. A solution of linker-drug 41 (10 mM in DMSO) was added (final concentration 
of 1.02 mM, 40 eq.) and the reaction mixture incubated at 37 °C for 2 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Sample was either stored at 4 °C or flash frozen and stored at -20 
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Trastuzumab 57 Modification 
 
To a solution of trastuzumab (100 μL, 27.0 μM, 2.5 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 
mM NaCl, 0.5 mM EDTA) was added TCEP (10 eq.). The mixture was vortexed and incubated 
at 37 °C for 1 h. A solution of linker-drug 57 (10 mM in DMSO) was added (final concentration 
of 2.04 mM, 80 eq.) and the reaction mixture incubated at 37 °C for 2 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Sample was either stored at 4 °C or flash frozen and stored at -20 
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DVP-Antibody Ratio and Antibody Concentration Calculations 
 
 
MMAE does not display significant absorbance at 280 nm, thus the DAR and antibody 
concentration can be calculated using the following formulas. DVP conjugate 25 has an 
absorption maximum at 298 nm; a correction factor of 0.61 is used to account for DVP 
absorbance at 280 nm260, and a correction factor of 0.1 is used to account for trastuzumab 
absorbance at 298 nm. 
𝐷𝐴𝑅 =		
𝐴𝑏𝑠295/𝜀295
(𝐴𝑏𝑠256 − [0.61 × 𝐴𝑏𝑠295] + [0.1	 ×	𝐴𝑏𝑠256])/𝜀256
 
𝐴𝐷𝐶	(𝑚𝑔 𝑚𝐿)⁄ = 		
𝐴𝑏𝑠256 − (0.61	 ×	𝐴295) + (0.1	 ×	𝐴𝑏𝑠256)
1.46  
e280 = 215,380 M-1 cm-1 











PfRadA-dCys General Modification Procedure 
 
To a solution of PfRadA-dCys (10 μL, 2.94 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 mM 
NaCl, 0.5 mM EDTA, 3 M guanidine hydrochloride) was added TCEP (5 eq.). The mixture was 
vortexed and incubated at 37 °C for 1 h. A solution of DVPs 15, 18 or 24 (10 mM in DMSO) 
was added (15 eq.) and the reaction mixture incubated at 37 °C for 1 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Samples were either stored at 4 °C or flash frozen and stored at -





37 oC, 1 h
15, 18,  24 






63; R = H, R1 = H,
64: R = (CH2)4CCH, R1 = H,








7.4.3 Chapter 5: Dual-functional Divinylpyrimidine 
Trastuzumab 72 Modification 
 
To a solution of trastuzumab (10 μL, 27.0 μM, 2.5 mg/mL) in TBS (25 mM Tris HCl pH 8, 25 
mM NaCl, 0.5 mM EDTA) was added TCEP (10 eq.). The mixture was vortexed and incubated 
at 37 °C for 1 h. A solution of df-DVP 72 (10 mM in DMSO) was added (final concentration of 
1.08 mM, 40 eq.) and the reaction mixture incubated at 37 °C for 2 h. The excess reagents 
were removed by repeated diafiltration into PBS using an Amicon-Ultra centrifugal filter (10000 
MWCO, Merck Millipore). Sample was either stored at 4 °C or flash frozen and stored at -20 
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7.5 Biological Evaluation 
7.5.1 Plasma Stability 
A solution of trastuzumab-AlexaFluorä 488, 39 (70 μL, 2.10 μM) in PBS was diluted with 15 
μL of reconstituted human plasma (Sigma) and 70 μL of PBS. To this solution was added 
reduced L-glutathione (final concentration of 1 μM) and mixture incubated at 37 °C for 14 days. 
Aliquots were removed after 0, 1, 3, 5, 7, 9, 11 and 14 days, flash frozen and stored at -20 °C 
until analysis. SDS-PAGE was followed by in-gel fluorescence and Coomassie brilliant blue 
staining. 
7.5.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
A 96-well plate was coated with 100 μL of a 0.25 μg/mL solution of HER2 (Sino Biological, 
His-tagged) overnight at 4 °C. Coating solutions were removed and each well washed with 
PBS (2 × 200 μL). Each well was then blocked with 1% BSA in PBS (200 μL) for 1 h at room 
temperature. The blocking solution was then removed and each well washed with PBS (3 × 
200 μL). Wells were treated with a serial dilution of trastuzumab and trastuzumab-DVP 
conjugates 34, 35 and 36 in PBS (100 μL of 30 nM, 10 nM, 3.33 nM, 1.11 nM, 0.37 nM, 0.12 
nM, 0 nM) and incubated at room temperature for 2 h. The conjugate solutions were removed 
and each well was washed with 0.1% Tween 20 in PBS (2 × 200 μL) followed by PBS (3 × 
200 μL). Next, 100 μL of detection antibody (1:1000 dilution of a mouse anti-human IgG-HRP, 
ThermoFisher) in PBS was added to each well and incubated at room temperature for 1 h. 
Each well was washed with 0.1% Tween 20 in PBS (2 × 200 μL) followed by PBS (3 × 200 
μL). Finally, an OPD solution [100 μL of a solution prepared by dissolving 1 capsule in 9 mL 
H2O and 1 mL stable peroxide substrate buffer (10×), ThermoFisher] was added to each well. 
After 10-15 minutes, 4M HCl(aq) (50 μL) was added to each well to quench the reaction. 
Absorbance was measured at 490 nm and 590 nm. Measurements were performed in 
quadruplicate and three independent repeats were performed.165 
7.5.3 Cells Lines 
HER2-positive SKBR3 and BT474 cells were obtained from the American Type Culture 
Collection (ATCC) and HER2-negative MCF7 and T47D cells were obtained from the 
European Collection of Authenticated Cell Cultures (ECACC) and ATCC, respectively. SKBR3 
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cells were maintained in high glucose McCoy’s 5A medium, supplemented with 10% heat-
inactivated foetal-bovine serum (FBS), 50 U/mL penicillin and 50 μg/mL streptomycin. MCF7 
cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
heat-inactivated FBS, 2 mM L-glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin. 
BT474 and T47D cell lines were maintained in RPMI1640 medium supplemented with 10% 
heat-inactivated FBS, 2 mM L-glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin. All 
cell lines were incubated at 37 °C with 5% CO2. 
7.5.4 Live Cell Labelling by Fluorescence-Activated Cell Sorting (FACS) 
SKBR3, BT474, MCF7 and T47D cell lines were seeded in 6-well plates at 106 cells/well and 
allowed to adhere for 24 h at 37 °C with 5% CO2. Cells were treated with 50 nM 39, 
AlexaFluor™488 azide or PBS in complete growth medium for 1 h at 37 °C. Next, growth 
medium was removed, the cells were washed with PBS to remove unbound antibodies and 
the cells were detached with Accutase® cell dissociation reagent (StemPro), washed with 
PBS, pelleted and resuspended in PBS (100 μL). Analysis was conducted on an Amnis® 
ImageStream® imaging flow cytometer (Merck Millipore). DRAQ5™ (ThermoFisher) was used 
as a nuclear stain. 
7.5.5 Cell Viability  
Cells were seeded in 96-well plates for 24 h at 37 °C with 5% CO2. SKBR3 cells were seeded 
at 15,000 cells/well, BT474 cells were seeded at 20,000 cells/well, MCF7 cells were seeded 
at 7,500 cells/well and T47D cells were seeded at 10,000 cells/well. Serial dilutions of ADCs 
42 or 62, trastuzumab and MMAE were added to the cells in complete growth medium and 
incubated at 37 °C with 5% CO2 for 96 h. Cell viability was measured using CellTiter-Glo 
viability assay (Promega) according to the manufacturer’s instructions. Cell viability was 
plotted as a percentage of untreated cells. Each measurement was taken in triplicate and 
three independent repeats were performed from different cell passages. 
7.5.6 Cell Growth Assay 
Cells were seeded in 96-well plates for 24 h at 37 °C with 5% CO2. SKBR3 cells were seeded 
at 15,000 cells/well, BT474 cells were seeded at 20,000 cells/well, MCF7 cells were seeded 
at 7,500 cells/well and T47D cells were seeded at 10,000 cells/well. Serial dilutions of 42 or 
 183 
62 were added to the cells in complete growth medium and incubated at 37 °C with 5% CO2 
for four or six days in an IncuCyte®. Cell growth was measured every four hours and is given 
as percentage confluence. Each concentration was measured in triplicate and error bars 




1 A. S. Ahmad, N. Ormiston-Smith and P. D. Sasieni, Br. J. Cancer, 2015, 112, 943–
947. 
2 H. P. Rang, M. M. Dale, J. M. Ritter and P. K. Moore, in Pharmacology, Elsevier, 5th 
edn., 2003, pp. 693–696. 
3 A. Urruticoechea, R. Alemany, J. Balart, A. Villanueva, F. Viñals and G. Capellá, Curr. 
Pharm. Des., 2010, 16, 3–10. 
4 B. A. Chabner and T. G. Roberts, Nat. Rev. Cancer, 2005, 5, 65–72. 
5 V. T. DeVita and E. Chu, Cancer Res., 2008, 68, 8643–8653. 
6 S. Dasari and P. Bernard Tchounwou, Eur. J. Pharmacol., 2014, 740, 364–378. 
7 K. Barabas, R. Milner, D. Lurie and C. Adin, Vet. Comp. Oncol., 2008, 6, 1–18. 
8 C. M. Spencer and D. Faulds, Drugs, 1994, 48, 794–847. 
9 M. Moudi, R. Go, C. Y. S. Yien and M. Nazre, Int. J. Prev. Med., 2013, 4, 1231–1235. 
10 R. V. J. Chari, M. L. Miller and W. C. Widdison, Angew. Chemie - Int. Ed., 2014, 53, 
3796–3827. 
11 C. S. Ross-Innes, R. Stark, A. E. Teschendorff, K. A. Holmes, H. R. Ali, M. J. 
Dunning, G. D. Brown, O. Gojis, I. O. Ellis, A. R. Green, S. Ali, S. F. Chin, C. Palmieri, 
C. Caldas and J. S. Carroll, Nature, 2012, 481, 389–393. 
12 S. J. Johnston and J. S. Carroll, Biochim. Biophys. Acta - Rev. Cancer, 2015, 1855, 
183–192. 
13 V. C. Jordan, Nat. Rev. Drug Discov., 2003, 2, 205–213. 
14 R. Baskar, K. A. Lee, R. Yeo and K. W. Yeoh, Int. J. Med. Sci., 2012, 9, 193–199. 
15 D. Adams, A. Gonzalez-Duarte, W. D. O’Riordan, C.-C. Yang, M. Ueda, A. V. Kristen, 
I. Tournev, H. H. Schmidt, T. Coelho, J. L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. 
Planté-Bordeneuve, M. M. Mezei, J. M. Campistol, J. Buades, T. H. Brannagan, B. J. 
Kim, J. Oh, Y. Parman, Y. Sekijima, P. N. Hawkins, S. D. Solomon, M. Polydefkis, P. 
J. Dyck, P. J. Gandhi, S. Goyal, J. Chen, A. L. Strahs, S. V. Nochur, M. T. Sweetser, 
P. P. Garg, A. K. Vaishnaw, J. A. Gollob and O. B. Suhr, N. Engl. J. Med., 2018, 379, 
11–21. 
16 C. Chakraborty, A. R. Sharma, G. Sharma, C. G. P. Doss and S. S. Lee, Mol. Ther. - 
Nucleic Acids, 2017, 8, 132–143. 
 185 
17 X. Shen and D. R. Corey, Nucleic Acids Res., 2018, 46, 1584–1600. 
18 V. Prasad, Nat. Rev. Clin. Oncol., 2018, 15, 11–12. 
19 C. Fellmann, B. G. Gowen, P. C. Lin, J. A. Doudna and J. E. Corn, Nat. Rev. Drug 
Discov., 2017, 16, 89–100. 
20 A. C. Komor, A. H. Badran and D. R. Liu, Cell, 2017, 168, 20–36. 
21 H. Kaplon and J. M. Reichert, MAbs, 2019, 11, 219–238. 
22 P. Ehrlich, BMJ, 1913, 2, 353–359. 
23 S. M. Lehar, T. Pillow, M. Xu, L. Staben, K. K. Kajihara, R. Vandlen, L. DePalatis, H. 
Raab, W. L. Hazenbos, J. Hiroshi Morisaki, J. Kim, S. Park, M. Darwish, B. C. Lee, H. 
Hernandez, K. M. Loyet, P. Lupardus, R. Fong, D. Yan, C. Chalouni, E. Luis, Y. 
Khalfin, E. Plise, J. Cheong, J. P. Lyssikatos, M. Strandh, K. Koefoed, P. S. 
Andersen, J. A. Flygare, M. Wah Tan, E. J. Brown and S. Mariathasan, Nature, 2015, 
527, 323–328. 
24 H. Bouchard, C. Viskov and C. Garcia-Echeverria, Bioorganic Med. Chem. Lett., 
2014, 24, 5357–5363. 
25 S. Xu, Pharm. Res., 2015, 32, 3577–3583. 
26 M. Ritchie, L. Tchistiakova and N. Scott, MAbs, 2013, 5, 13–21. 
27 K. C. Nicolaou and S. Rigol, Angew. Chemie - Int. Ed., , 
DOI:10.1002/anie.201903498. 
28 H. L. Perez, P. M. Cardarelli, S. Deshpande, S. Gangwar, G. M. Schroeder, G. D. Vite 
and R. M. Borzilleri, Drug Discov. Today, 2014, 19, 869–881. 
29 A. Beck, J.-F. Haeuw, T. Wurch, L. Goetsch, C. Bailly and N. Corvaïa, Discov. Med., 
2010, 10, 329–339. 
30 F. R. Appelbaum and I. D. Bernstein, Blood, 2017, 130, 2373–2376. 
31 V. Chudasama, Drug Discov. Today Technol., 2018, 30, 1–2. 
32 J. Katz, J. E. Janik and A. Younes, Clin. Cancer Res., 2011, 17, 6428–6436. 
33 P. D. Senter and E. L. Sievers, Nat. Biotechnol., 2012, 30, 631–637. 
34 S. M. Ansell, Blood, 2014, 124, 3197–3200. 
35 A. Younes, N. L. Bartlett, J. P. Leonard, D. A. Kennedy, C. M. Lynch, E. L. Sievers 
and A. Forero-Torres, N. Engl. J. Med., 2010, 363, 1812–1821. 
36 S. Verma, D. Miles, L. Gianni, I. E. Krop, M. Welslau, J. Baselga, M. Pegram, D.-Y. 
Oh, V. Diéras, E. Guardino, L. Fang, M. W. Lu, S. Olsen, K. Blackwell and EMILIA 
 186 
Study Group, N. Engl. J. Med., 2012, 367, 1783–1791. 
37 J. M. Lambert and R. V. J. Chari, J. Med. Chem., 2014, 57, 6949–6964. 
38 Y. N. Lamb, Drugs, 2017, 77, 1603–1610. 
39 B. Shor, H. P. Gerber and P. Sapra, Mol. Immunol., 2015, 67, 107–116. 
40 R. Lyon, Drug Discov. Today Technol., 2018, 30, 105–109. 
41 A. G. Poison, J. Calemine-Fenaux, P. Chan, W. Chang, E. Christensen, S. Clark, F. J. 
De Sauvage, D. Eaton, K. Elkins, J. Michael Elliott, G. Frantz, R. N. Fuji, A. Gray, K. 
Harden, G. S. Ingle, N. M. Kljavin, H. Koeppen, C. Nelson, S. Prabhu, H. Raab, S. 
Ross, J. P. Stephan, S. J. Scales, S. D. Spencer, R. Vandlen, B. Wranik, S. F. Yu, B. 
Zheng and A. Ebens, Cancer Res., 2009, 69, 2358–2364. 
42 V. Chudasama, A. Maruani and S. Caddick, Nat. Chem., 2016, 8, 114–119. 
43 P. Agarwal and C. R. Bertozzi, Bioconjug. Chem., 2015, 26, 176–192. 
44 I. Sela-Culang, V. Kunik and Y. Ofran, Front. Immunol., 2013, 4, 302. 
45 J. M. Woof and D. R. Burton, Nat. Rev. Immunol., 2004, 4, 89–99. 
46 Y. Cao, J. Y. Axup, J. S. Y. Ma, R. E. Wang, S. Choi, V. Tardif, R. K. V. Lim, H. M. 
Pugh, B. R. Lawson, G. Welzel, S. A. Kazane, Y. Sun, F. Tian, S. Srinagesh, T. 
Javahishvili, P. G. Schultz and C. H. Kim, Angew. Chemie - Int. Ed., 2015, 54, 7022–
7027. 
47 D. G. Maloney, Blood, 1997, 90, 2188–2195. 
48 R. G. Panchal, Biochem. Pharmacol., 1998, 55, 247–252. 
49 G. Köhler and C. Milstein, Nature, 1975, 256, 495–497. 
50 M. Kamionka, Curr. Pharm. Biotechnol., 2011, 12, 268–274. 
51 P. A. Trail, D. Willner, S. J. Lasch, A. J. Henderson, S. Hofstead, A. M. Casazza, R. 
A. Firestone, I. Hellström and K. E. Hellström, Science, 1993, 261, 212–215. 
52 A. W. Tolcher, S. Sugarman, K. A. Gelmon, R. Cohen, M. Saleh, C. Isaacs, L. Young, 
D. Healey, N. Onetto and W. Slichenmyer, J. Clin. Oncol., 1999, 17, 478–484. 
53 A. A. Epenetos, D. Snook, H. Durbin, J. Taylor-Papadimitriou and P. M. Johnson, 
Cancer Res., 1986, 46, 3183–3191. 
54 A. Beck, L. Goetsch, C. Dumontet and N. Corvaïa, Nat. Rev. Drug Discov., 2017, 16, 
315–337. 
55 A. Beck, T. Wurch, C. Bailly and N. Corvaïa, Nat. Rev. Immunol., 2010, 10, 345–352. 
 187 
56 M. D. Lee, T. S. Dunne, M. M. Siegel, G. O. Morton, D. B. Borders and C. C. Chang, 
J. Am. Chem. Soc., 1987, 109, 3464–3466. 
57 S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. 
Chace, R. L. DeBlanc, R. P. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. 
Wahl, D. L. Meyer and P. D. Senter, Nat. Biotechnol., 2003, 21, 778–784. 
58 U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright and M. Hussain, 
Clin. Cancer Res., 2000, 6, 4205–4208. 
59 S. M. Kupchan, Y. Komoda, W. A. Court, G. J. Thomas, R. M. Smith, A. Karim, C. J. 
Gilmore, R. C. Haitiwanger and R. F. Bryan, J. Am. Chem. Soc., 1972, 94, 1354–
1356. 
60 J. Mantaj, P. J. M. Jackson, K. M. Rahman and D. E. Thurston, Angew. Chemie - Int. 
Ed., 2017, 56, 462–488. 
61 A. C. Tiberghien, J. N. Levy, L. A. Masterson, N. V. Patel, L. R. Adams, S. Corbett, D. 
G. Williams, J. A. Hartley and P. W. Howard, ACS Med. Chem. Lett., 2016, 7, 983–
987. 
62 E. M. Stein, R. B. Walter, H. P. Erba, A. T. Fathi, A. S. Advani, J. E. Lancet, F. 
Ravandi, T. Kovacsovics, D. J. DeAngelo, D. Bixby, S. Faderl, A. P. Jillella, P. A. Ho, 
M. M. O’Meara, B. Zhao, C. Biddle-Snead and A. S. Stein, Blood, 2018, 131, 387–
396. 
63 R. C. Elgersma, R. G. E. Coumans, T. Huijbregts, W. M. P. B. Menge, J. A. F. 
Joosten, H. J. Spijker, F. M. H. De Groot, M. M. C. Van Der Lee, R. Ubink, D. J. Van 
Den Dobbelsteen, D. F. Egging, W. H. A. Dokter, G. F. M. Verheijden, J. M. 
Lemmens, C. M. Timmers and P. H. Beusker, Mol. Pharm., 2015, 12, 1813–1835. 
64 R. M. Sharkey, W. J. McBride, T. M. Cardillo, S. V. Govindan, Y. Wang, E. A. Rossi, 
C. H. Chang and D. M. Goldenberg, Clin. Cancer Res., 2015, 21, 5131–5138. 
65 L. N. Tumey, C. A. Leverett, B. Vetelino, F. Li, B. Rago, X. Han, F. Loganzo, S. 
Musto, G. Bai, S. C. K. Sukuru, E. I. Graziani, S. Puthenveetil, J. Casavant, A. 
Ratnayake, K. Marquette, S. Hudson, V. R. Doppalapudi, J. Stock, L. Tchistiakova, A. 
J. Bessire, T. Clark, J. Lucas, C. Hosselet, C. J. O’Donnell and C. Subramanyam, 
ACS Med. Chem. Lett., 2016, 7, 977–982. 
66 J. S. Parker, M. McCormick, D. W. Anderson, B. A. Maltman, L. Gingipalli and D. 
Toader, Org. Process Res. Dev., 2017, 21, 1602–1609. 
67 J. Y. Li, S. R. Perry, V. Muniz-Medina, X. Wang, L. K. Wetzel, M. C. Rebelatto, M. J. 
M. Hinrichs, B. Z. Bezabeh, R. L. Fleming, N. Dimasi, H. Feng, D. Toader, A. Q. 
 188 
Yuan, L. Xu, J. Lin, C. Gao, H. Wu, R. Dixit, J. K. Osbourn and S. R. Coats, Cancer 
Cell, 2016, 29, 117–129. 
68 L. Ducry and B. Stump, Bioconjug. Chem., 2010, 21, 5–13. 
69 K. Tsuchikama and Z. An, Protein Cell, 2018, 9, 33–46. 
70 A. D. Ricart, Clin. Cancer Res., 2011, 17, 6417–6427. 
71 B. J. Mills and C. A. Lang, Biochem. Pharmacol., 1996, 52, 401–406. 
72 G. Wu, Y.-Z. Fang, S. Yang, J. R. Lupton and N. D. Turner, J. Nutr., 2004, 134, 489–
492. 
73 W. Widdison, S. Wilhelm, K. Veale, J. Costoplus, G. Jones, C. Audette, B. Leece, L. 
Bartle, Y. Kovtun and R. Chari, Mol. Pharm., 2015, 12, 1762–1773. 
74 M. N. Saleh, S. Sugarman, J. Murray, J. B. Ostroff, D. Healey, D. Jones, C. R. Daniel, 
D. LeBherz, H. Brewer, N. Onetto and A. F. LoBuglio, J. Clin. Oncol., 2000, 18, 2282–
2292. 
75 H. Xie, J. Pharmacol. Exp. Ther., 2004, 308, 1073–1082. 
76 C. S. Gondi and J. S. Rao, Expert Opin. Ther. Targets, 2013, 17, 281–291. 
77 J. E. Koblinski, M. Ahram and B. F. Sloane, Clin. Chim. Acta, 2000, 291, 113–135. 
78 G. M. Dubowchik, R. A. Firestone, L. Padilla, D. Willner, S. J. Hofstead, K. Mosure, J. 
O. Knipe, S. J. Lasch and P. A. Trail, Bioconjug. Chem., 2002, 13, 855–869. 
79 B. Wei, J. Gunzner-Toste, H. Yao, T. Wang, J. Wang, Z. Xu, J. Chen, J. Wai, J. 
Nonomiya, S. P. Tsai, J. Chuh, K. R. Kozak, Y. Liu, S. F. Yu, J. Lau, G. Li, G. D. 
Phillips, D. Leipold, A. Kamath, D. Su, K. Xu, C. Eigenbrot, S. Steinbacher, R. Ohri, H. 
Raab, L. R. Staben, G. Zhao, J. A. Flygare, T. H. Pillow, V. Verma, L. A. Masterson, 
P. W. Howard and B. Safina, J. Med. Chem., 2018, 61, 989–1000. 
80 N. Jain, S. W. Smith, S. Ghone and B. Tomczuk, Pharm. Res., 2015, 32, 3526–3540. 
81 N. Albin, L. Massaad, C. Toussaint, M. C. Mathieu, J. Morizet, O. Parise, A. Gouyette 
and G. G. Chabot, Cancer Res., 1993, 53, 3541–3546. 
82 S. C. Jeffrey, J. B. Andreyka, S. X. Bernhardt, K. M. Kissler, T. Kline, J. S. Lenox, R. 
F. Moser, M. T. Nguyen, N. M. Okeley, I. J. Stone, X. Zhang and P. D. Senter, 
Bioconjug. Chem., 2006, 17, 831–840. 
83 S. C. Jeffrey, M. T. Nguyen, R. F. Moser, D. L. Meyer, J. B. Miyamoto and P. D. 
Senter, Bioorganic Med. Chem. Lett., 2007, 17, 2278–2280. 
84 P. J. Burke, P. D. Senter, D. W. Meyer, J. B. Miyamoto, M. Anderson, B. E. Toki, G. 
 189 
Manikumar, M. C. Wani, D. J. Kroll and S. C. Jeffrey, Bioconjug. Chem., 2009, 20, 
1242–1250. 
85 S. C. Jeffrey, J. De Brabander, J. Miyamoto and P. D. Senter, ACS Med. Chem. Lett., 
2010, 1, 277–280. 
86 R. V. Kolakowski, K. T. Haelsig, K. K. Emmerton, C. I. Leiske, J. B. Miyamoto, J. H. 
Cochran, R. P. Lyon, P. D. Senter and S. C. Jeffrey, Angew. Chemie - Int. Ed., 2016, 
55, 7948–7951. 
87 B. A. Schröder, C. Wrocklage, A. Hasilik and P. Saftig, Proteomics, 2010, 10, 4053–
4076. 
88 J. C. Kern, M. Cancilla, D. Dooney, K. Kwasnjuk, R. Zhang, M. Beaumont, I. Figueroa, 
S. C. Hsieh, L. Liang, D. Tomazela, J. Zhang, P. E. Brandish, A. Palmieri, P. Stivers, 
M. Cheng, G. Feng, P. Geda, S. Shah, A. Beck, D. Bresson, J. Firdos, D. Gately, N. 
Knudsen, A. Manibusan, P. G. Schultz, Y. Sun and R. M. Garbaccio, J. Am. Chem. 
Soc., 2016, 138, 1430–1445. 
89 P. E. Brandish, A. Palmieri, S. Antonenko, M. Beaumont, L. Benso, M. Cancilla, M. 
Cheng, L. Fayadat-Dilman, G. Feng, I. Figueroa, J. Firdos, R. Garbaccio, L. Garvin-
Queen, D. Gately, P. Geda, C. Haines, S. Hseih, D. Hodges, J. Kern, N. Knudsen, K. 
Kwasnjuk, L. Liang, H. Ma, A. Manibusan, P. L. Miller, L. Y. Moy, Y. Qu, S. Shah, J. 
S. Shin, P. Stivers, Y. Sun, D. Tomazela, H. C. Woo, D. Zaller, S. Zhang, Y. Zhang 
and M. Zielstorff, Bioconjug. Chem., 2018, 29, 2357–2369. 
90 J. C. Kern, D. Dooney, R. Zhang, L. Liang, P. E. Brandish, M. Cheng, G. Feng, A. 
Beck, D. Bresson, J. Firdos, D. Gately, N. Knudsen, A. Manibusan, Y. Sun and R. M. 
Garbaccio, Bioconjug. Chem., 2016, 27, 2081–2088. 
91 H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, 
R. J. Lutz, V. S. Goldmacher and W. A. Blättler, Cancer Res., 2006, 66, 4426–4433. 
92 A. H. Staudacher and M. P. Brown, Br. J. Cancer, 2017, 117, 1736–1742. 
93 S. Golfier, C. Kopitz, A. Kahnert, I. Heisler, C. A. Schatz, B. Stelte-Ludwig, A. Mayer-
Bartschmid, K. Unterschemmann, S. Bruder, L. Linden, A. Harrenga, P. Hauff, F.-D. 
Scholle, B. Muller-Tiemann, B. Kreft and K. Ziegelbauer, Mol. Cancer Ther., 2014, 13, 
1537–1548. 
94 Y. V. Kovtun, C. A. Audette, Y. Ye, H. Xie, M. F. Ruberti, S. J. Phinney, B. A. Leece, 
T. Chittenden, W. A. Blättler and V. S. Goldmacher, Cancer Res., 2006, 66, 3214–
3221. 
95 M. T. Taylor, J. E. Nelson, M. G. Suero and M. J. Gaunt, Nature, 2018, 562, 563–568. 
 190 
96 C. D. Spicer and B. G. Davis, Nat. Commun., 2014, 5, 4740. 
97 E. A. Hoyt, P. M. S. D. Cal, B. L. Oliveira and G. J. L. Bernardes, Nat. Rev. Chem., 
2019, 3, 147–171. 
98 T. Tamura and I. Hamachi, J. Am. Chem. Soc., 2019, 141, 2782–2799. 
99 E. M. Sletten and C. R. Bertozzi, Angew. Chemie - Int. Ed., 2009, 48, 6974–6998. 
100 N. Krall, F. P. Da Cruz, O. Boutureira and G. J. L. Bernardes, Nat. Chem., 2016, 8, 
103–113. 
101 A. Wakankar, Y. Chen, Y. Gokarn and F. S. Jacobson, MAbs, 2011, 3, 164–175. 
102 K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. 
M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, D. L. Meyer and J. A. 
Francisco, Clin. Cancer Res., 2004, 10, 7063–7070. 
103 T. H. Pillow, J. D. Sadowsky, D. Zhang, S. F. Yu, G. Del Rosario, K. Xu, J. He, S. 
Bhakta, R. Ohri, K. R. Kozak, E. Ha, J. R. Junutula and J. A. Flygare, Chem. Sci., 
2016, 8, 366–370. 
104 B. Q. Shen, K. Xu, L. Liu, H. Raab, S. Bhakta, M. Kenrick, K. L. Parsons-Reponte, J. 
Tien, S. F. Yu, E. Mai, D. Li, J. Tibbitts, J. Baudys, O. M. Saad, S. J. Scales, P. J. 
McDonald, P. E. Hass, C. Eigenbrot, T. Nguyen, W. A. Solis, R. N. Fuji, K. M. 
Flagella, D. Patel, S. D. Spencer, L. A. Khawli, A. Ebens, W. L. Wong, R. Vandlen, S. 
Kaur, M. X. Sliwkowski, R. H. Scheller, P. Polakis and J. R. Junutula, Nat. Biotechnol., 
2012, 30, 184–189. 
105 P. Strop, S.-H. Liu, M. Dorywalska, K. Delaria, R. G. Dushin, T.-T. Tran, W.-H. Ho, S. 
Farias, M. G. Casas, Y. Abdiche, D. Zhou, R. Chandrasekaran, C. Samain, C. Loo, A. 
Rossi, M. Rickert, S. Krimm, T. Wong, S. M. Chin, J. Yu, J. Dilley, J. Chaparro-
Riggers, G. F. Filzen, C. J. O’Donnell, F. Wang, J. S. Myers, J. Pons, D. L. Shelton 
and A. Rajpal, Chem. Biol., 2013, 20, 161–167. 
106 L. Wang, G. Amphlett, W. A. Blättler, J. M. Lambert and W. Zhang, Protein Sci., 2005, 
14, 2436–2446. 
107 D. S. Wilbur, M. K. Chyan, H. Nakamae, Y. Chen, D. K. Hamlin, E. B. Santos, B. T. 
Kornblit and B. M. Sandmaier, Bioconjug. Chem., 2012, 23, 409–420. 
108 I. Dovgan, S. Ursuegui, S. Erb, C. Michel, S. Kolodych, S. Cianférani and A. Wagner, 
Bioconjug. Chem., 2017, 28, 1452–1457. 
109 G. Chaubet, F. Thoreau and A. Wagner, Drug Discov. Today Technol., 2018, 30, 21–
26. 
 191 
110 M. J. Matos, B. L. Oliveira, N. Martínez-Sáez, A. Guerreiro, P. M. S. D. Cal, J. 
Bertoldo, M. Maneiro, E. Perkins, J. Howard, M. J. Deery, J. M. Chalker, F. Corzana, 
G. Jiménez-Osés and G. J. L. Bernardes, J. Am. Chem. Soc., 2018, 140, 4004–4017. 
111 M. Hayakawa, N. Toda, N. Carrillo, N. J. Thornburg, J. E. Crowe and C. F. Barbas, 
ChemBioChem, 2012, 13, 2191–2195. 
112 A. R. Nanna, X. Li, E. Walseng, L. Pedzisa, R. S. Goydel, D. Hymel, T. R. Burke, W. 
R. Roush and C. Rader, Nat. Commun., 2017, 8, 1112. 
113 J. M. Chalker, G. J. L. Bernardes, Y. A. Lin and B. G. Davis, Chem. - An Asian J., 
2009, 4, 630–640. 
114 P. Trail, Antibodies, 2013, 2, 113–129. 
115 P. A. Szijj, C. Bahou and V. Chudasama, Drug Discov. Today Technol., 2018, 30, 27–
34. 
116 A. D. Baldwin and K. L. Kiick, Bioconjug. Chem., 2011, 22, 1946–1953. 
117 S. C. Alley, D. R. Benjamin, S. C. Jeffrey, N. M. Okeley, D. L. Meyer, R. J. Sanderson 
and P. D. Senter, Bioconjug. Chem., 2008, 19, 759–765. 
118 J. F. Ponte, X. Sun, N. C. Yoder, N. Fishkin, R. Laleau, J. Coccia, L. Lanieri, M. 
Bogalhas, L. Wang, S. Wilhelm, W. Widdison, J. Pinkas, T. A. Keating, R. Chari, H. K. 
Erickson and J. M. Lambert, Bioconjug. Chem., 2016, 27, 1588–1598. 
119 J. D. Gregory, J. Am. Chem. Soc., 1955, 77, 3922–3923. 
120 W. Huang, X. Wu, X. Gao, Y. Yu, H. Lei, Z. Zhu, Y. Shi, Y. Chen, M. Qin, W. Wang 
and Y. Cao, Nat. Chem., 2019, 11, 310–319. 
121 R. P. Lyon, J. R. Setter, T. D. Bovee, S. O. Doronina, J. H. Hunter, M. E. Anderson, 
C. L. Balasubramanian, S. M. Duniho, C. I. Leiske, F. Li and P. D. Senter, Nat. 
Biotechnol., 2014, 32, 1059–1062. 
122 L. N. Tumey, M. Charati, T. He, E. Sousa, D. Ma, X. Han, T. Clark, J. Casavant, F. 
Loganzo, F. Barletta, J. Lucas and E. I. Graziani, Bioconjug. Chem., 2014, 25, 1871–
1880. 
123 I. Dovgan, S. Kolodych, O. Koniev and A. Wagner, Sci. Rep., 2016, 6, 30835. 
124 E. Tobaldi, I. Dovgan, M. Mosser, J. M. Becht and A. Wagner, Org. Biomol. Chem., 
2017, 15, 9305–9310. 
125 R. J. Christie, R. Fleming, B. Bezabeh, R. Woods, S. Mao, J. Harper, A. Joseph, Q. 
Wang, Z. Q. Xu, H. Wu, C. Gao and N. Dimasi, J. Control. Release, 2015, 220, 660–
670. 
 192 
126 D. Kalia, S. P. Pawar and J. S. Thopate, Angew. Chemie - Int. Ed., 2017, 56, 1885–
1889. 
127 E. V. Vinogradova, C. Zhang, A. M. Spokoyny, B. L. Pentelute and S. L. Buchwald, 
Nature, 2015, 526, 687–691. 
128 S. S. van Berkel and F. L. van Delft, Drug Discov. Today Technol., 2018, 30, 3–10. 
129 S. Jeger, K. Zimmermann, A. Blanc, J. Grünberg, M. Honer, P. Hunziker, H. Struthers 
and R. Schibli, Angew. Chemie - Int. Ed., 2010, 49, 9995–9997. 
130 P. Dennler, A. Chiotellis, E. Fischer, D. Brégeon, C. Belmant, L. Gauthier, F. 
Lhospice, F. Romagne and R. Schibli, Bioconjug. Chem., 2014, 25, 569–578. 
131 R. R. Beerli, T. Hell, A. S. Merkel and U. Grawunder, PLoS One, 2015, 10, e0131177. 
132 N. Stefan, R. Gébleux, L. Waldmeier, T. Hell, M. Escher, F. I. Wolter, U. Grawunder 
and R. R. Beerli, Mol. Cancer Ther., 2017, 16, 879–892. 
133 P. Agarwal, R. Kudirka, A. E. Albers, R. M. Barfield, G. W. De Hart, P. M. Drake, L. C. 
Jones and D. Rabuka, Bioconjug. Chem., 2013, 24, 846–851. 
134 P. M. Drake, A. E. Albers, J. Baker, S. Banas, R. M. Barfield, A. S. Bhat, G. W. De 
Hart, A. W. Garofalo, P. Holder, L. C. Jones, R. Kudirka, J. McFarland, W. Zmolek 
and D. Rabuka, Bioconjug. Chem., 2014, 25, 1331–1341. 
135 L. Liu, J. Pharm. Sci., 2015, 104, 1866–1884. 
136 T. B. Parsons, W. B. Struwe, J. Gault, K. Yamamoto, T. A. Taylor, R. Raj, K. Wals, S. 
Mohammed, C. V. Robinson, J. L. P. Benesch and B. G. Davis, Angew. Chemie - Int. 
Ed., 2016, 55, 2361–2367. 
137 B. Ramakrishnan and P. K. Qasba, J. Biol. Chem., 2002, 277, 20833–20839. 
138 Z. Zhu, B. Ramakrishnan, J. Li, Y. Wang, Y. Feng, P. Prabakaran, S. Colantonio, M. 
A. Dyba, P. K. Qasba and D. S. Dimitrov, MAbs, 2014, 6, 1190–1200. 
139 B. M. Zeglis, C. B. Davis, R. Aggeler, H. C. Kang, A. Chen, B. J. Agnew and J. S. 
Lewis, Bioconjug. Chem., 2013, 24, 1057–1067. 
140 C. J. Noren, S. J. Anthony-Cahill, M. C. Griffith and P. G. Schultz, Science, 1989, 244, 
182–188. 
141 J. W. Chin, Nature, 2017, 550, 53–60. 
142 J. Y. Axup, K. M. Bajjuri, M. Ritland, B. M. Hutchins, C. H. Kim, S. A. Kazane, R. 
Halder, J. S. Forsyth, A. F. Santidrian, K. Stafin, Y. Lu, H. Tran, A. J. Seller, S. L. 
Biroc, A. Szydlik, J. K. Pinkstaff, F. Tian, S. C. Sinha, B. Felding-Habermann, V. V 
 193 
Smider and P. G. Schultz, Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 16101–16106. 
143 E. S. Zimmerman, T. H. Heibeck, A. Gill, X. Li, C. J. Murray, M. R. Madlansacay, C. 
Tran, N. T. Uter, G. Yin, P. J. Rivers, A. Y. Yam, W. D. Wang, A. R. Steiner, S. U. 
Bajad, K. Penta, W. Yang, T. J. Hallam, C. D. Thanos and A. K. Sato, Bioconjug. 
Chem., 2014, 25, 351–361. 
144 H. Xiao, A. Chatterjee, S. H. Choi, K. M. Bajjuri, S. C. Sinha and P. G. Schultz, 
Angew. Chemie - Int. Ed., 2013, 52, 14080–14083. 
145 B. Oller-Salvia, G. Kym and J. W. Chin, Angew. Chemie - Int. Ed., 2018, 57, 2831–
2834. 
146 T. Hofer, L. R. Skeffington, C. M. Chapman and C. Rader, Biochemistry, 2009, 48, 
12047–12057. 
147 C. F. McDonagh, E. Turcott, L. Westendorf, J. B. Webster, S. C. Alley, K. Kim, J. 
Andreyka, I. Stone, K. J. Hamblett, J. A. Francisco and P. Carter, Protein Eng. Des. 
Sel., 2006, 19, 299–307. 
148 J. R. Junutula, S. Bhakta, H. Raab, K. E. Ervin, C. Eigenbrot, R. Vandlen, R. H. 
Scheller and H. B. Lowman, J. Immunol. Methods, 2008, 332, 41–52. 
149 J. R. Junutula, H. Raab, S. Clark, S. Bhakta, D. D. Leipold, S. Weir, Y. Chen, M. 
Simpson, S. P. Tsai, M. S. Dennis, Y. Lu, Y. G. Meng, C. Ng, J. Yang, C. C. Lee, E. 
Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, 
S. D. Spencer, W. Lee Wong, H. B. Lowman, R. Vandlen, M. X. Sliwkowski, R. H. 
Scheller, P. Polakis and W. Mallet, Nat. Biotechnol., 2008, 26, 925–932. 
150 J. R. Junutula, K. M. Flagella, R. A. Graham, K. L. Parsons, E. Ha, H. Raab, S. 
Bhakta, T. Nguyen, D. L. Dugger, G. Li, E. Mai, G. D. L. Phillips, H. Hiraragi, R. N. 
Fuji, J. Tibbitts, R. Vandlen, S. D. Spencer, R. H. Scheller, P. Polakis and M. X. 
Sliwkowski, Clin. Cancer Res., 2010, 16, 4769–4778. 
151 B. Bernardim, P. M. S. D. Cal, M. J. Matos, B. L. Oliveira, N. Martínez-Saéz, I. S. 
Albuquerque, E. Perkins, F. Corzana, A. C. B. Burtoloso, G. Jiménez-Osés and G. J. 
L. Bernardes, Nat. Commun., 2016, 7, 13128. 
152 M. J. Matos, C. D. Navo, T. Hakala, X. Ferhati, A. Guerreiro, D. Hartmann, B. 
Bernardim, K. L. Saar, I. Compañón, F. Corzana, T. P. J. Knowles, G. Jiménez-Osés 
and G. J. L. Bernardes, Angew. Chemie - Int. Ed., , DOI:10.1002/anie.201901405. 
153 J. P. M. Nunes, V. Vassileva, E. Robinson, M. Morais, M. E. B. Smith, R. B. Pedley, 
S. Caddick, J. R. Baker and V. Chudasama, RSC Adv., 2017, 7, 24828–24832. 
 194 
154 J. D. Sadowsky, T. H. Pillow, J. Chen, F. Fan, C. He, Y. Wang, G. Yan, H. Yao, Z. Xu, 
S. Martin, D. Zhang, P. Chu, J. Dela Cruz-Chuh, A. O’Donohue, G. Li, G. Del Rosario, 
J. He, L. Liu, C. Ng, D. Su, G. D. Lewis Phillips, K. R. Kozak, S. F. Yu, K. Xu, D. 
Leipold and J. Wai, Bioconjug. Chem., 2017, 28, 2086–2098. 
155 C. Zhang, M. Welborn, T. Zhu, N. J. Yang, M. S. Santos, T. Van Voorhis and B. L. 
Pentelute, Nat. Chem., 2016, 8, 120–128. 
156 C. Zhang, P. Dai, A. A. Vinogradov, Z. P. Gates and B. L. Pentelute, Angew. Chemie - 
Int. Ed., 2018, 57, 6459–6463. 
157 N. Forte, V. Chudasama and J. R. Baker, Drug Discov. Today Technol., 2018, 30, 11–
20. 
158 M. E. B. Smith, F. F. Schumacher, C. P. Ryan, L. M. Tedaldi, D. Papaioannou, G. 
Waksman, S. Caddick and J. R. Baker, J. Am. Chem. Soc., 2010, 132, 1960–1965. 
159 F. F. Schumacher, J. P. M. Nunes, A. Maruani, V. Chudasama, M. E. B. Smith, K. A. 
Chester, J. R. Baker and S. Caddick, Org. Biomol. Chem., 2014, 12, 7261–7269. 
160 J. P. M. Nunes, M. Morais, V. Vassileva, E. Robinson, V. S. Rajkumar, M. E. B. Smith, 
R. B. Pedley, S. Caddick, J. R. Baker and V. Chudasama, Chem. Commun., 2015, 
51, 10624–10627. 
161 M. Morais, J. P. M. Nunes, K. Karu, N. Forte, I. Benni, M. E. B. Smith, S. Caddick, V. 
Chudasama and J. R. Baker, Org. Biomol. Chem., 2017, 15, 2947–2952. 
162 C. R. Behrens, E. H. Ha, L. L. Chinn, S. Bowers, G. Probst, M. Fitch-Bruhns, J. 
Monteon, A. Valdiosera, A. Bermudez, S. Liao-Chan, T. Wong, J. Melnick, J. W. 
Theunissen, M. R. Flory, D. Houser, K. Venstrom, Z. Levashova, P. Sauer, T. S. 
Migone, E. H. Van Der Horst, R. L. Halcomb and D. Y. Jackson, Mol. Pharm., 2015, 
12, 3986–3998. 
163 V. Chudasama, M. E. B. Smith, F. F. Schumacher, D. Papaioannou, G. Waksman, J. 
R. Baker and S. Caddick, Chem. Commun., 2011, 47, 8781–8783. 
164 E. Robinson, J. P. M. Nunes, V. Vassileva, A. Maruani, J. C. F. Nogueira, M. E. B. 
Smith, R. B. Pedley, S. Caddick, J. R. Baker and V. Chudasama, RSC Adv., 2017, 7, 
9073–9077. 
165 A. Maruani, M. E. B. Smith, E. Miranda, K. A. Chester, V. Chudasama and S. 
Caddick, Nat. Commun., 2015, 6, 6645. 
166 C. Bahou, D. A. Richards, A. Maruani, E. A. Love, F. Javaid, S. Caddick, J. R. Baker 
and V. Chudasama, Org. Biomol. Chem., 2018, 16, 1359–1366. 
 195 
167 S. Shao, M. H. Tsai, J. Lu, T. Yu, J. Jin, D. Xiao, H. Jiang, M. Han, M. Wang and J. 
Wang, Bioorganic Med. Chem. Lett., 2018, 28, 1363–1370. 
168 M. T. W. Lee, A. Maruani, J. R. Baker, S. Caddick and V. Chudasama, Chem. Sci., 
2016, 7, 799–802. 
169 M. T. W. Lee, A. Maruani, D. A. Richards, J. R. Baker, S. Caddick and V. 
Chudasama, Chem. Sci., 2017, 8, 2056–2060. 
170 P. Bryant, M. Pabst, G. Badescu, M. Bird, W. McDowell, E. Jamieson, J. Swierkosz, 
K. Jurlewicz, R. Tommasi, K. Henseleit, X. Sheng, N. Camper, A. Manin, K. 
Kozakowska, K. Peciak, E. Laurine, R. Grygorash, A. Kyle, D. Morris, V. Parekh, A. 
Abhilash, J. W. Choi, J. Edwards, M. Frigerio, M. P. Baker and A. Godwin, Mol. 
Pharm., 2015, 12, 1872–1879. 
171 G. Badescu, P. Bryant, M. Bird, K. Henseleit, J. Swierkosz, V. Parekh, R. Tommasi, 
E. Pawlisz, K. Jurlewicz, M. Farys, N. Camper, X. Sheng, M. Fisher, R. Grygorash, A. 
Kyle, A. Abhilash, M. Frigerio, J. Edwards and A. Godwin, Bioconjug. Chem., 2014, 
25, 1124–1136. 
172 M. Pabst, W. McDowell, A. Manin, A. Kyle, N. Camper, E. De Juan, V. Parekh, F. 
Rudge, H. Makwana, T. Kantner, H. Parekh, A. Michelet, X. B. Sheng, G. Popa, C. 
Tucker, F. Khayrzad, D. Pollard, K. Kozakowska, R. Resende, A. Jenkins, F. Simoes, 
D. Morris, P. Williams, G. Badescu, M. P. Baker, M. Bird, M. Frigerio and A. Godwin, 
J. Control. Release, 2017, 253, 160–164. 
173 Z. Miao, Y. Hong, T. Zhu and A. W. Chucholowski, WO/2013/173391, 2013. 
174 O. Koniev, I. Dovgan, B. Renoux, A. Ehkirch, J. Eberova, S. Cianférani, S. Kolodych, 
S. Papot and A. Wagner, Med. Chem. Commun., 2018, 9, 827–830. 
175 Q.-Y. Hu and H. Imase, WO/2014/083505, 2014. 
176 M. Friedman, L. H. Krull and J. F. Cavins, J. Biol. Chem., 1970, 245, 3868–3871. 
177 R. Sebastiano, A. Citterio, M. Lapadula and P. G. Righetti, Rapid Commun. Mass 
Spectrom., 2003, 17, 2380–2386. 
178 J. R. Winther and C. Thorpe, Biochim. Biophys. Acta - Gen. Subj., 2014, 1840, 838–
846. 
179 J. Heukeshoven, Anal. Biochem., 1980, 109, 421–425. 
180 G. Gorin, P. A. Martic and G. Doughty, Arch. Biochem. Biophys., 1966, 115, 593–597. 
181 K. Lindorff-Larsen and J. R. Winther, Anal. Biochem., 2000, 286, 308–310. 
182 A. R. Katritzky, G. R. Khan and O. A. Schwarz, Tetrahedron Lett., 1984, 25, 1223–
 196 
1226. 
183 A. R. Katritzky, I. Takahashi and C. M. Marson, J. Org. Chem., 1986, 51, 4914–4920. 
184 A. G. Watts, T. Kantner and A. B. Mackensie, WO/2010/070300, 2010. 
185 A. D. Baxter, C. M. Birchall, D. J. Mansell, J. H. Mysliwy and J. Thirlway, 
WO/2016/067021, 2016. 
186 M. S. Frei, M. K. Bilyard, T. A. Alanine, W. R. J. D. Galloway, J. E. Stokes and D. R. 
Spring, Bioorganic Med. Chem., 2015, 23, 2666–2679. 
187 D. G. Twigg, N. Kondo, S. L. Mitchell, W. R. J. D. Galloway, H. F. Sore, A. Madin and 
D. R. Spring, Angew. Chemie - Int. Ed., 2016, 55, 12479–12483. 
188 Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless and M. G. Finn, J. Am. 
Chem. Soc., 2003, 125, 3192–3193. 
189 C. S. McKay and M. G. Finn, Chem. Biol., 2014, 21, 1075–1101. 
190 D. E. Scott, M. T. Ehebauer, T. Pukala, M. Marsh, T. L. Blundell, A. R. Venkitaraman, 
C. Abell and M. Hyvönen, ChemBioChem, 2013, 14, 332–342. 
191 M. Rossmann, S. J. Greive, T. Moschetti, M. Dinan and M. Hyvönen, Protein Eng. 
Des. Sel., 2017, 30, 419–430. 
192 T. Moschetti, T. Sharpe, G. Fischer, M. E. Marsh, H. K. Ng, M. Morgan, D. E. Scott, T. 
L. Blundell, A. R. Venkitaraman, J. Skidmore, C. Abell and M. Hyvönen, J. Mol. Biol., 
2016, 428, 4589–4607. 
193 J. Peränen, M. Rikkonen, M. Hyvönen and L. Kääriäinen, Anal. Biochem., 1996, 236, 
371–373. 
194 T. Liu, Y. Wang, X. Luo, J. Li, S. A. Reed, H. Xiao, T. S. Young and P. G. Schultz, 
Proc. Natl. Acad. Sci., 2016, 113, 5910–5915. 
195 A. L. Schechter, D. F. Stern, L. Vaidyanathan, S. J. Decker, J. A. Drebin, M. I. Greene 
and R. A. Weinberg, Nature, 1984, 312, 513–516. 
196 D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich and W. McGuire, Science, 1987, 
235, 177–182. 
197 I. L. Andrulis, S. B. Bull, M. E. Blackstein, D. Sutherland, C. Mak, S. Sidlofsky, K. P. 
H. Pritzker, R. W. Hartwick, W. Hanna, L. Lickley, R. Wilkinson, A. Qizilbash, U. 
Ambus, M. Lipa, H. Weizel, A. Katz, M. Baida, S. Mariz, G. Stoik, P. Dacamara, D. 
Strongitharm, W. Geddie and D. McCready, J. Clin. Oncol., 1998, 16, 1340–1349. 
198 B. A. Gusterson, R. D. Gelber, A. Goldhirsch, K. N. Price, J. Säve-Söderborgh, R. 
 197 
Anbazhagan, J. Styles, C. M. Rudenstam, R. Golouh and R. Reed, J. Clin. Oncol., 
2017, 10, 1049–1056. 
199 Y. Yarden and M. X. Sliwkowski, Nat. Rev. Mol. Cell Biol., 2001, 2, 127–137. 
200 D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. 
Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton, N. Engl. J. 
Med., 2001, 344, 783–792. 
201 K. S. Gunturu, Y. Woo, N. Beaubier, H. E. Remotti and M. W. Saif, Ther. Adv. Med. 
Oncol., 2013, 5, 143–151. 
202 C. A. Hudis, N. Engl. J. Med., 2007, 357, 39–51. 
203 G. Valabrega, F. Montemurro and M. Aglietta, Ann. Oncol., 2007, 18, 977–984. 
204 S. Sun, P. Akkapeddi, M. C. Marques, N. Martínez-Sáez, V. M. Torres, C. Cordeiro, 
O. Boutureira and G. J. L. Bernardes, Org. Biomol. Chem., 2019, 17, 2005–2012. 
205 K. Lang and J. W. Chin, ACS Chem. Biol., 2014, 9, 16–20. 
206 Y. A. Lin, J. M. Chalker, N. Floyd, G. J. L. Bernardes and B. G. Davis, J. Am. Chem. 
Soc., 2008, 130, 9642–9643. 
207 Y. A. Lin, J. M. Chalker and B. G. Davis, J. Am. Chem. Soc., 2010, 132, 16805–
16811. 
208 N. J. Agard, J. A. Prescher and C. R. Bertozzi, J. Am. Chem. Soc., 2004, 126, 15046–
15047. 
209 X. Ning, J. Guo, M. A. Wolfert and G. J. Boons, Angew. Chemie - Int. Ed., 2008, 47, 
2253–2255. 
210 P. Holliger, T. Prospero and G. Winter, Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 
6444–6448. 
211 P. Holliger and P. J. Hudson, Nat. Biotechnol., 2005, 23, 1126–1136. 
212 M. P. Deonarain, G. Yahioglu, I. Stamati and J. Marklew, Expert Opin. Drug Discov., 
2015, 10, 463–481. 
213 D. Litvak-Greenfeld and I. Benhar, Adv. Drug Deliv. Rev., 2012, 64, 1782–1799. 
214 C. Wu, H. Ying, C. Grinnell, S. Bryant, R. Miller, A. Clabbers, S. Bose, D. McCarthy, 
R. R. Zhu, L. Santora, R. Davis-Taber, Y. Kunes, E. Fung, A. Schwartz, P. Sakorafas, 
J. Gu, E. Tarcsa, A. Murtaza and T. Ghayur, Nat. Biotechnol., 2007, 25, 1290–1297. 
215 N. A. Goebl, C. M. Babbey, A. Datta-Mannan, D. R. Witcher, V. J. Wroblewski and K. 
W. Dunn, Mol. Biol. Cell, 2008, 19, 5490–5505. 
 198 
216 A. L. Nelson and J. M. Reichert, Nat. Biotechnol., 2009, 27, 331–337. 
217 F. Selis, G. Focà, A. Sandomenico, C. Marra, C. Di Mauro, G. S. Jotti, S. 
Scaramuzza, A. Politano, R. Sanna, M. Ruvo and G. Tonon, Int. J. Mol. Sci., 2016, 
17, 1–15. 
218 L. Castañeda, A. Maruani, F. F. Schumacher, E. Miranda, V. Chudasama, K. A. 
Chester, J. R. Baker, M. E. B. Smith and S. Caddick, Chem. Commun., 2013, 49, 
8187–8189. 
219 R. P. Lyon, T. D. Bovee, S. O. Doronina, P. J. Burke, J. H. Hunter, H. D. Neff-Laford, 
M. Jonas, M. E. Anderson, J. R. Setter and P. D. Senter, Nat. Biotechnol., 2015, 33, 
733–735. 
220 S. V. Govindan, T. M. Cardillo, R. M. Sharkey, F. Tat, D. V. Gold and D. M. 
Goldenberg, Mol. Cancer Ther., 2013, 12, 968–978. 
221 H. J. Ross, L. L. Hart, P. M. Swanson, M. U. Rarick, R. A. Figlin, A. D. Jacobs, D. E. 
McCune, A. H. Rosenberg, A. D. Baron, L. E. Grove, M. D. Thorn, D. M. Miller, J. G. 
Drachman and C. M. Rudin, Lung Cancer, 2006, 54, 69–77. 
222 J. H. Beijnen, G. Wiese and W. J. Underberg, Pharm. Weekbl. Sci., 1985, 7, 109–116. 
223 G. A. Pietersz, J. Kanellos, M. J. Smyth, J. Zalcberg and I. F. C. McKenzie, Immunol. 
Cell Biol., 1987, 65, 111–125. 
224 S. Knutson, E. Raja, R. Bomgarden, M. Nlend, A. Chen, R. Kalyanasundaram and S. 
Desai, PLoS One, 2016, 11, e0157762. 
225 H. Bouchard, M.-P. Brun and P. Hubert, WO/2018/206635, 2018. 
226 A. Dal Corso and D. Neri, J. Control. Release, 2017, 246, 39–45. 
227 F. Garro-Helion, A. Merzouk and F. Guibé, J. Org. Chem., 1993, 58, 6109–6113. 
228 F. Kratz, J. Control. Release, 2008, 132, 171–183. 
229 J. Drevs, I. Hofmann, D. Marmé, C. Unger and F. Kratz, Drug Deliv. J. Deliv. Target. 
Ther. Agents, 1999, 6, 89–95. 
230 M. T. Larsen, M. Kuhlmann, M. L. Hvam and K. A. Howard, Mol. Cell. Ther., 2016, 4, 
3. 
231 N. Martínez-Sáez, S. Sun, D. Oldrini, P. Sormanni, O. Boutureira, F. Carboni, I. 
Compañón, M. J. Deery, M. Vendruscolo, F. Corzana, R. Adamo and G. J. L. 
Bernardes, Angew. Chemie - Int. Ed., 2017, 56, 14963–14967. 
232 S. J. Walsh, S. Omarjee, W. R. J. D. Galloway, T. T.-L. Kwan, H. F. Sore, J. S. 
 199 
Parker, M. Hyvönen, J. S. Carroll and D. R. Spring, Chem. Sci., 2019, 10, 694–700. 
233 D. M. Patterson and J. A. Prescher, Curr. Opin. Chem. Biol., 2015, 28, 141–149. 
234 M. R. Levengood, X. Zhang, J. H. Hunter, K. K. Emmerton, J. B. Miyamoto, T. S. 
Lewis and P. D. Senter, Angew. Chemie - Int. Ed., 2017, 56, 733–737. 
235 H. Pye, M. A. Butt, H. W. Reinert, A. Maruani, J. P. M. Nunes, J. S. Marklew, M. 
Qurashi, L. Funnell, A. May, I. Stamati, R. Hamoudi, J. R. Baker, M. E. B. Smith, S. 
Caddick, M. P. Deonarain, G. Yahioglu, V. Chudasama and L. B. Lovat, Photochem. 
Photobiol. Sci., 2016, 15, 1227–1238. 
236 S. Puthenveetil, S. Musto, F. Loganzo, L. N. Tumey, C. J. O’Donnell and E. Graziani, 
Bioconjug. Chem., 2016, 27, 1030–1039. 
237 L. S. Kocsis, E. Benedetti and K. M. Brummond, Org. Lett., 2012, 14, 4430–4433. 
238 L. W. K. Moodie and D. S. Larsen, European J. Org. Chem., 2014, 1684–1694. 
239 J. R. Parikh and W. von E. Doering, J. Am. Chem. Soc., 1967, 89, 5505–5507. 
240 S. S. Kelkar and T. M. Reineke, Bioconjug. Chem., 2011, 22, 1879–1903. 
241 A. Kumar, T. Mastren, B. Wang, J. T. Hsieh, G. Hao and X. Sun, Bioconjug. Chem., 
2016, 27, 1681–1689. 
242 X. Wu, X. Sun, Z. Guo, J. Tang, Y. Shen, T. D. James, H. Tian and W. Zhu, J. Am. 
Chem. Soc., 2014, 136, 3579–3588. 
243 J. B. Wu, T. P. Lin, J. D. Gallagher, S. Kushal, L. W. K. Chung, H. E. Zhau, B. Z. 
Olenyuk and J. C. Shih, J. Am. Chem. Soc., 2015, 137, 2366–2374. 
244 S. A. Kularatne, K. Wang, H. K. R. Santhapuram and P. S. Low, Mol. Pharm., 2009, 6, 
780–789. 
245 S. Santra, C. Kaittanis, O. J. Santiesteban and J. M. Perez, J. Am. Chem. Soc., 2011, 
133, 16680–16688. 
246 A. Moss, J. Gudas, T. Albertson, N. Whiting and C.-L. Law, Cancer Res., 2015, 74, 
104. 
247 K. L. Moek, D. Giesen, I. C. Kok, D. J. A. de Groot, M. Jalving, R. S. N. Fehrmann, M. 
N. Lub-de Hooge, A. H. Brouwers and E. G. E. de Vries, J. Nucl. Med., 2017, 58, 
83S–90S. 
248 C. Bahou, E. A. Love, S. Leonard, R. J. Spears, A. Maruani, K. Armour, J. R. Baker 
and V. Chudasama, Bioconjug. Chem., 2019, 30, 1048–1054. 
249 K. Lang, L. Davis, S. Wallace, M. Mahesh, D. J. Cox, M. L. Blackman, J. M. Fox and 
 200 
J. W. Chin, J. Am. Chem. Soc., 2012, 134, 10317–10320. 
250 B. L. Oliveira, Z. Guo and G. J. L. Bernardes, Chem. Soc. Rev., 2017, 46, 4895–4950. 
251 I. Nikic̈, T. Plass, O. Schraidt, J. Szymański, J. A. G. Briggs, C. Schultz and E. A. 
Lemke, Angew. Chemie - Int. Ed., 2014, 53, 2245–2249. 
252 P. M. S. D. Cal, R. F. M. Frade, V. Chudasama, C. Cordeiro, S. Caddick and P. M. P. 
Gois, Chem. Commun., 2014, 50, 5261–5263. 
253 J. Iegre, J. S. Gaynord, N. S. Robertson, H. F. Sore, M. Hyvönen and D. R. Spring, 
Adv. Ther., 2018, 1, 1800052. 
254 T. Uhlig, T. Kyprianou, F. G. Martinelli, C. A. Oppici, D. Heiligers, D. Hills, X. R. Calvo 
and P. Verhaert, EuPA Open Proteomics, 2014, 4, 58–69. 
255 Y. H. Lau, P. De Andrade, S. T. Quah, M. Rossmann, L. Laraia, N. Sköld, T. J. Sum, 
P. J. E. Rowling, T. L. Joseph, C. Verma, M. Hyvönen, L. S. Itzhaki, A. R. 
Venkitaraman, C. J. Brown, D. P. Lane and D. R. Spring, Chem. Sci., 2014, 5, 1804–
1809. 
256 C. E. Schafmeister, J. Po and G. L. Verdine, J. Am. Chem. Soc., 2000, 122, 5891–
5892. 
257 A. J. Rojas, C. Zhang, E. V. Vinogradova, N. H. Buchwald, J. Reilly, B. L. Pentelute 
and S. L. Buchwald, Chem. Sci., 2017, 8, 4257–4263. 
258 C. M. Grison, G. M. Burslem, J. A. Miles, L. K. A. Pilsl, D. J. Yeo, Z. Imani, S. L. 
Warriner, M. E. Webb and A. J. Wilson, Chem. Sci., 2017, 8, 5166–5171. 
259 Z. Li, R. Huang, H. Xu, J. Chen, Y. Zhan, X. Zhou, H. Chen and B. Jiang, Org. Lett., 
2017, 19, 4972–4975. 
260 D. Willner, P. A. Trail, S. J. Hofstead, S. J. Lasch, G. R. Braslawsky, S. J. Lasch, R. 
S. Greenfield, G. R. Braslawsky, T. Kaneko, R. S. Greenfield and T. Kaneko, 
Bioconjug. Chem., 1993, 4, 521–527. 
  
 201 






































































































































































































































































































































































T = 14 days 
T = 7 days 
T = 0 days 
12 
GSH 
T = 14 days 
T = 7 days 









T = 14 days 
T = 7 days 
T = 0 days 
27 
GSH 
T = 14 days 
T = 7 days 






























Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 82
Injection Date  : 02/02/2018 12:04:02                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-02-02 11-59-01\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 02/02/2018 11:59:02 by SYSTEM
Additional Info : Peak(s) manually integrated















































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.148 BB    0.0631    5.57240    1.27261   3.4118
   2   5.384 BB    0.0850   15.59567    2.79843   9.5487
   3   6.968 BB    0.0606   78.08182   19.52781  47.8066
   4  10.343 BB    0.0627   14.72388    3.68008   9.0149
   5  11.097 BB    0.0715   42.51913    8.93925  26.0329
   6  17.623 BB    0.0651    6.83557    1.55923   4.1852
 
Totals :                   163.32846   37.77741
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-02-02 11-59-01\STEVEW0224.D
Sample Name: SW517P1





















Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 82
Injection Date  : 06/02/2018 11:23:41                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-02-06 11-18-43\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 06/02/2018 11:18:44 by SYSTEM
Additional Info : Peak(s) manually integrated
















































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.309 BV    0.0664 1336.20386  309.36707 100.0000
 
Totals :                  1336.20386  309.36707
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-02-06 11-18-43\STEVEW0229.D
Sample Name: SW520P1


































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 22
Injection Date  : 22/01/2018 17:22:21                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-22 17-16-59\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 22/01/2018 17:17:00 by SYSTEM
Additional Info : Peak(s) manually integrated



























                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.237 BB    0.0663 2037.53271  472.31924 100.0000
 
Totals :                  2037.53271  472.31924
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-22 17-16-59\STEVEW0215.D
Sample Name: SW513P1






















Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 22
Injection Date  : 22/01/2018 19:25:30                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-22 19-20-35\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 22/01/2018 19:20:35 by SYSTEM
Additional Info : Peak(s) manually integrated





































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.016 VB    0.0774 1351.28528  274.49490 100.0000
 
Totals :                  1351.28528  274.49490
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-22 19-20-35\STEVEW0217.D
Sample Name: SW514C1



































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 21
Injection Date  : 09/05/2018 16:56:45                  Inj :   1
                                                Inj Volume : 5.000 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-05-09 16-51-44\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/05/2018 16:51:45 by SYSTEM
Additional Info : Peak(s) manually integrated















































































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.795 VV    0.0672 2804.73560  639.49677 100.0000
 
Totals :                  2804.73560  639.49677
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-05-09 16-51-44\STEVEW0276.D
Sample Name: SW555P1



























Acq. Operator   : SYSTEM                    Seq. Line :  1
Acq. Instrument : HPLC                            Location : Vial 21
Injection Date  : 10/07/2018 17:28:44                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-07-10 17-23-39\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 10/07/2018 17:23:40 by SYSTEM
Additional Info : Peak(s) manually integrated


















































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-07-10 17-23-39\STEVEW0299.D
Sample Name: SW579P1

































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 21
Injection Date  : 10/05/2018 14:48:16                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-05-10 14-42-55\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 10/05/2018 14:42:56 by SYSTEM
Additional Info : Peak(s) manually integrated





















































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  13.281 VV    0.0752 4649.88965  947.75555 100.0000
 
Totals :                  4649.88965  947.75555
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-05-10 14-42-55\STEVEW0277.D
Sample Name: SW557P1






























Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 21
Injection Date  : 23/06/2018 11:50:03                  Inj :   1
                                               Inj Volume : 5.000 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 30.000 µl
Method : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-06-23 11-44-54\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 23/06/2018 11:44:55 by SYSTEM
Additional Info : Peak(s) manually integrated

































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-06-23 11-44-54\STEVEW0294.D
Sample Name: SW571_1_1





































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 11
Injection Date  : 03/03/2018 13:56:59                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-03 13-51-57\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 03/03/2018 13:51:58 by SYSTEM
Additional Info : Peak(s) manually integrated







































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  13.203 VV    0.0789 1.46698e4  2907.25293 100.0000
 
Totals :                  1.46698e4  2907.25293
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-03 13-51-57\STEVEW0238.D
Sample Name: SW523P1



























Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : H LC                          Location : Vial 43
Injection Date  : 05/03/2018 17:55:47                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03- 5 17-50-48\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 05/03/2018 17:50:49 by SYSTEM
Additional Info : Peak(s) manually integrated



































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.252 VV    0.0675 4802.50781 1086.90259 100.0000
 
Totals :                  4802.50781 1086.90259
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-05 17-50-48\STEVEW0241.D
Sample Name: SW525P1






























Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 07/03/2018 17:12:39                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-07 17-07-16\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 07/03/2018 17:07:17 by SYSTEM
Additional Info : Peak(s) manually integrated






























































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.599 VB    0.0702  838.83868  180.44707 100.0000
 
Totals :                   838.83868  180.44707
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-03-07 17-07-16\STEVEW0243.D
Sample Name: SW526P1


































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 22
Injection Date  : 23/01/2018 17:56:10                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-23 17-51-11\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 23/01/2018 17:51:12 by SYSTEM
Additional Info : Peak(s) manually integrated





























                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.921 BB    0.0644  668.43500  154.84354 100.0000
 
Totals :                   668.43500  154.84354
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-23 17-51-11\STEVEW0219.D
Sample Name: SW515P1




























Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 22
Injection Date  : 24/01/2018 12:42:40                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-24 12-37-32\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 24/01/2018 12:37:32 by SYSTEM
Additional Info : Peak(s) manually integrated



































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.966 VV    0.0636 1747.85059  428.17630 100.0000
 
Totals :                  1747.85059  428.17630
 
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-01-24 12-37-32\STEVEW0222.D
Sample Name: SW516P1







































Acq. Operator   : jossy                          Seq. Line :   1
Acq. Instrument : Instrument 1                    Location : Vial 61
Injection Date  : 2/19/2019 2:43:21 PM                 Inj :   1
                                                Inj Volume : 5.000 µl
Acq. Method     : C:\CHEM32\1\DATA\STEVE W\STEVE W 2019-02-19 14-38-17\ACN_5_95_15_MINS.M
Last changed    : 5/16/2018 10:48:10 AM by jossy
Analysis Method : C:\CHEM32\1\METHODS\WASHINGS.M
Last changed    : 3/19/2019 8:20:39 AM by jossy
Additional Info : Peak(s) manually integrated





























                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=220,4 Ref=off
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.056 BB    0.0731 2611.76660  533.42035 100.0000
 
Totals :                  2611.76660  533.42035
 
 
Data File C:\CHEM32\1\DATA\STEVE W\STEVE W 2019-02-19 14-38-17\0028STEVE W.D
Sample Name: SW703P1































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 31
Injection Date  : 15/01/2019 14:42:45                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2019-01-15 14-37-37\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 15/01/2019 14:37:39 by SYSTEM
Additional Info : Peak(s) manually integrated














































































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2019-01-15 14-37-37\STEVEW0333.D
Sample Name: SW673P1




































Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 31
Injection Date  : 01/03/2019 16:08:38                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2019-03-01 16-03-40\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 01/03/2019 16:03:41 by SYSTEM
Additional Info : Peak(s) manually integrated










































































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2019-03-01 16-03-40\STEVEW0358.D
Sample Name: SW706P1
HPLC 30/03/2019 14:28:43 SYSTEM Page 1 of 3
 243 




Figure A: HPLC trace of a) DVP 15, b) the reaction of DVP 15 with N-Boc-Cys-OMe and N-Boc-Lys-


















(pH 8, 50 mM)




MW = 617.78 MW = 382.48
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 09/10/2018 16:00:57                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 15-55-55\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 15:55:56 by SYSTEM
Additional Info : Peak(s) manually integrated
































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 15-55-55\STEVEW0309.D
Sample Name: SW616_2h
HPLC 10/10/2018 13:11:57 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 43
Injection Date  : 09/10/2018 17:14:06                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 17-09-06\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 17:09:07 by SYSTEM
Additional Info : Peak(s) manually integrated
























































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 17-09-06\STEVEW0311.D
Sample Name: SW616_4h
HPLC 10/10/2018 13:10:31 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 09/10/2018 13:31:56                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 13-26-54\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 13:26:55 by SYSTEM
Additional Info : Peak(s) manually integrated


































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 13-26-54\STEVEW0308.D
Sample Name: SW615P1











Figure B: HPLC trace of a) DVP 18, b) the reaction of DVP 18 with N-Boc-Cys-OMe and N-Boc-Lys-























(pH 8, 50 mM)









Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 10/10/2018 16:40:43                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-10 16-35-39\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 10/10/2018 16:35:40 by SYSTEM
Additional Info : Peak(s) manually integrated























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-10 16-35-39\STEVEW0313.D
Sample Name: SW618_2h
HPLC 10/10/2018 17:15:01 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 10/10/2018 18:19:37                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-10 18-14-36\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 10/10/2018 18:14:37 by SYSTEM
Additional Info : Peak(s) manually integrated

















































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution            :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-10 18-14-36\STEVEW0314.D
Sample Name: SW618_4h
HPLC 10/10/2018 18:43:49 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 43
Injection Date  : 09/10/2018 11:54:22                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 11-49-17\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 11:49:18 by SYSTEM
Additional Info : Peak(s) manually integrated























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 11-49-17\STEVEW0306.D
Sample Name: SW613P1











Figure C: HPLC trace of a) DVP 15, b) the reaction of DVP 15 with N-Boc-Cys-OMe and N-Boc-Lys-
OMe after two hours and c) after four hours, d) HPLC of carboxylic acid 27 and e) MS of the reaction 


















(pH 8, 50 mM)





MW = 689.84 MW = 454.54
=====================================================================
Acq. Operator   : SYSTEM                        Seq. Line :   1
Acq. Instrument : PLC                           Location : Vial 44
Injection Date  : 09/10/2018 12:18:41                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 12-13-40\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 12:13:41 by SYSTEM
Additional Info : Peak(s) manually integrated























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 12-13-40\STEVEW0307.D
Sample Name: SW537P1
HPLC 10/10/2018 13:13:13 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 42
Injection Date  : 09/10/2018 16:49:47                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 16-44-46\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 16:44:47 by SYSTEM
Additional Info : Peak(s) manually integrated












































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 16-44-46\STEVEW0310.D
Sample Name: SW617_2h
HPLC 10/10/2018 13:11:13 SYSTEM Page 1 of 2
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 09/10/2018 18:01:54                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 17-56-53\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 17:56:53 by SYSTEM
Additional Info : Peak(s) manually integrated
























































































































































































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution            :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 17-56-53\STEVEW0312.D
Sample Name: SW617_4h
HPLC 10/10/2018 13:08:58 SYSTEM Page 1 of 4
=============== =====================================================
Acq. Operator   : SYSTEM                         Seq. Line :   1
Acq. Instrument : HPLC                            Location : Vial 41
Injection Date  : 09/10/2018 10:41:16                  Inj :   1
                                                Inj Volume : 5.000 µl
Method          : C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 10-36-15\ACN_5_95_15MINS_RT.M (
                  Sequence Method)
Last changed    : 09/10/2018 10:36:16 by SYSTEM
Additional Info : Peak(s) manually integrated































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution            :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\STEVEW\STEVEW 2018-10-09 10-36-15\STEVEW0304.D
Sample Name: SW604P1















The arrow in TIC trace indicates area that was analysed. Peaks outside of this range 
did not contain proteinogenic signals and were excluded. Analysis was conducted in 































































































































































































































































































































































Appendix D – PfRadA-dCys 
pBAT4 Vector 
 






* N-terminus methionine cleaved 
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Appendix E – Publication 
 
A general approach for the site-selective
modification of native proteins, enabling the
generation of stable and functional antibody–drug
conjugates†‡
Stephen J. Walsh, a Soleilmane Omarjee,b Warren R. J. D. Galloway,a
Terence T.-L. Kwan,a Hannah F. Sore, a Jeremy S. Parker, c Marko Hyvönen, d
Jason S. Carroll *b and David R. Spring *a
Antibody–drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of
antibodies to selectively deliver highly potent cytotoxins to target cells. Although recent years have
witnessed significant interest in ADCs, problems remain with the standard linkage chemistries used for
cytotoxin-antibody bioconjugation. These typically (1) generate unstable constructs, which may lead to
premature cytotoxin release, (2) often give a wide variance in drug–antibody ratios (DAR) and (3) have
poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile.
Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent
re-bridging of reduced disulfide bonds on native antibodies. Model studies using the non-engineered
trastuzumab antibody validate the utility of this linker platform for the generic generation of highly
plasma-stable and functional antibody constructs that incorporate variable biologically relevant payloads
(including cytotoxins) in an efficient and site-selective manner with precise control over DAR. DVP
linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems,
demonstrating their potential utility for general protein modification, protein stabilisation or the
development of other protein-conjugate therapeutics.
Introduction
The emergence of biotherapeutics in recent decades has opened
up vast new areas of research for the treatment of a range of
grievous diseases,1,2 with antibody–drug conjugates (ADCs)
demonstrating considerable promise as anticancer agents.3,4
ADCs utilize the impeccable cell-targeting ability of an antibody
in combination with the highly potent nature of a cytotoxic
payload to achieve cell-selective cytotoxicity5 while overcoming
the dose-limiting toxicity of classical non-targeted small mole-
cule chemotherapy.6,7 There are currently four ADCs on the
market8–11 and over 60 other ADCs in clinical trials.12 However,
current approaches for ADC production still have numerous
shortcomings. Stability, drug–antibody ratio (DAR) and drug
distribution have all been shown to be crucial to the efficacy,
safety and overall pharmacological prole of ADCs and
are strongly inuenced by the chemistry used to attach the
linker to the antibody. Commonly employed nucleophilic bio-
conjugation at cysteine or lysine residues are pseudorandom: in
theory, any of the targeted amino acids within the antibody can
be modied. Consequently, there is a lack of selectivity, leading
to the formation of ADCs which are heterogeneous in terms of
the number of cytotoxin molecules incorporated (the DAR) and
their locations on the antibody. Such constructs are associated
with unreliable pharmacokinetic proles and therefore,
a reduced pharmacological effect.13–17 Maleimide conjugation to
reduced antibody cysteine thiols has been extensively used in
ADC development (Fig. 1a). However, the formed succinimide
thioether is inherently unstable in the body (due to a retro-
Michael reaction) which leads to premature dissociation of
the payload from the antibody.18,19 The plasma stability of
maleimide-based linkers has been increased by hydrolysis of
the succinimide thioether ring through linker modications or
antibody engineering.20,21 However, an inherently stable linker
is preferential. The development of new ADC formats to enable
site-selective antibody modication, including the
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E-mail: spring@ch.cam.ac.uk
bCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2
0RE, UK. E-mail: jason.carroll@cruk.cam.ac.uk
cEarly Chemical Development, Pharmaceutical Development, IMED Biotech Unit,
AstraZeneca, Maccleseld, UK
dDepartment of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, UK
† Dedicated to Professor Jack Baldwin on the occasion of his 80th birthday.
‡ Electronic supplementary information (ESI) available. See DOI:
10.1039/c8sc04645j
Cite this: Chem. Sci., 2019, 10, 694
All publication charges for this article
have been paid for by the Royal Society
of Chemistry
Received 18th October 2018
Accepted 6th November 2018
DOI: 10.1039/c8sc04645j
rsc.li/chemical-science




incorporation of engineered cysteine residues13 and unnatural
amino acids22,23 into the antibody sequence and the use of
various enzymatic processes,24–26 have produced ADCs with
precise DAR and dened attachment points. While effective,
these methods are complicated and generally inefficient.27
Recently, disulde-bridging linkers have emerged for ADC
production: a bis-reactive linker moiety undergoes reaction with
both thiol residues derived from a reduced cysteine disulde
bond, leading to covalent re-bridging of the protein. Such
linkers are capable of generating ADCs with more precise DAR
and drug distribution as well as reforming covalent bonds
between the antibody chains. Signicant progress has been
made in the eld with this class of linker by Baker, Caddick and
Chudasama and their co-workers, amongst others.27–36 Despite
these impressive advances, new methods are still required for
the production of stable and homogeneous ADCs from non-
engineered antibodies. We sought to develop a new disulde
bridging linker platform, which generated highly stable ADCs
with precise DAR and drug distribution. Vinylpyridines have
previously been used to modify proteins via cysteine conjuga-
tion.37 Glythera has recently developed a monovinylpyridine-
based linker platform for ADC construction with such conju-
gates demonstrating excellent stability (Fig. 1a). We envisaged
that divinyl-functionalised hetero-aryl linkers could be used to
achieve cysteine re-bridging, generating inherently stable
constructs whilst also achieving precise control of DAR and site-
of-attachment with native antibodies.
Herein, we report upon our investigations in this area and
development of a novel divinylpyrimidine (DVP) linker platform
for cysteine-bridging bioconjugation with a range of proteins
(Fig. 1b). Model studies using the non-engineered trastuzumab
antibody validate the utility of this linker platform for the
generation of highly plasma-stable antibody constructs that
incorporate different biologically relevant payloads in a robust
and efficient manner. The utility of the DVP linker platform was
also exemplied on other protein systems, exemplifying the
Fig. 1 (a) Previous work using monovinylpyridine or maleimide linkers
for the generation of ADCs from native antibodies and (b) the
divinylpyrimidine (DVP) linkers developed in this work generate
homogeneous and stable ADCs via cysteine re-bridging (cross-
linking).
Fig. 2 Development and analysis of the DVP linkers. (a) conjugation of
vinylpyrimidine 1 with N-Boc-Cys-OMe, (b) selectivity experiment by
reaction ofN-Boc-Cys-OMe andN-Boc-Lys-OMewith an excess of 1,
(c) stability comparison of vinylpyrimidine-conjugate 3 versus mal-
eimide conjugate 6 in the presence of reducedGSH and (d) DVP linkers
7, 8 and 9.
Fig. 3 Reaction conditions and subsequent LC-MS analysis for (a)
modification of recombinant PfRadA with DVP linkers 7, 8 and 9
resulted in covalently re-bridged conjugates 10, 11 and 12, and (b)
bridging of trastuzumab Fab with 7, 8 and 9 resulted in the desired
interchain bridged conjugates 13, 14 and 15.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 694–700 | 695
Edge Article Chemical Science
capability of such linkers for a range of protein or peptide
modication applications.
Results and discussion
We began our study by identifying the potential of a vinyl-
heteroaryl scaffold for cysteine re-bridging. It was postulated
that vinylpyridine bioconjugation would be too slow to enable
efficient cross-linking but that replacement of the pyridine with
a pyrimidine would enhance the reactivity to desirable levels by
increasing the electron accepting capacity of the heteroaryl ring,
without compromising the stability seen with vinylpyridine
conjugates.38 To test this hypothesis, vinylpyrimidine 1
(prepared by a Suzuki–Miyaura cross-coupling, see ESI‡) was
reacted with Boc-Cys-OMe in a mixture of aqueous buffer and
acetonitrile. Pleasingly, full conversion from 1 to conjugate 3
was achieved in 15 minutes, monitored by thin layer chroma-
tography (TLC), under these bioconjugation compatible condi-
tions (Fig. 2a). A competition experiment involving the reaction
of 1 with Boc-Cys-OMe and Boc-Lys-OMe at alkaline pH showed
full conversion to the cysteine conjugate 3. No evidence of the
lysine conjugate 5 was observed, even with an excess of vinyl-
pyrimidine 1 present in the reaction (Fig. 2b and ESI Fig. S1‡).
Similarly, 1 showed poor reactivity with tris(2-carboxyethyl)
phosphine hydrochloride (TCEP), a commonly used reducing
agent in cysteine bioconjugation (ESI Fig. S5‡), demonstrating
the capability of this scaffold for chemoselective cysteine
conjugation. The stability of conjugate 3 under physiological
conditions was investigated by incubation with an excess of
reduced L-glutathione (GSH) in pH 7.4 buffer at 37 C. The
stability was tracked via 1H NMR and pleasingly, almost no
degradation (<5%) was observed aer two weeks. In
comparison, the corresponding maleimide conjugate 6 showed
>50% conversion to the glutathione-maleimide conjugate aer
two weeks under the same conditions (Fig. 2c and S6‡). This
suggested that vinylpyrimidine bioconjugation could indeed be
used to generate conjugates that are stable under physiological
conditions. Efforts then turned to the synthesis of divinylpyr-
imidine (DVP) linkers which contained reactive synthetic
handles suitable for attachment of other modalities, such as
drugs or uorophores. To this end, DVP linkers 7, 8 and 9 were
synthesised in one, two and three steps, respectively (Fig. 2d,
see ESI‡ for synthetic details). The chemoselectivity of linkers 7,
8 and 9 was then conrmed in an analogous way to mono-
vinylpyrimidine 1 (ESI Fig. S1–S4‡). Subsequently, the stability
of Boc-Cys-OMe modied 7, 8 and 9 in the presence of GSH was
also demonstrated via 1H NMR (ESI Fig. S6‡).
We next sought to ascertain the reactivity of the DVP linkers
in protein systems. RadA from Pyrococcus furiosus is a DNA
recombinase enzyme that does not contain any cysteine resi-
dues. Through site-directed mutagenesis, a monomeric version
was produced that contained two cysteine residues in close
proximity in the tertiary structure (PfRadA-dCys, ESI Fig. S25‡).
Pleasingly, reduction of the mutant PfRadA with TCEP followed
by the addition of linkers 7, 8 or 9 (15 equiv.) for 1 hour at 37 C
yielded excellent conversion to the desired covalently re-bridged
conjugates 10, 11 and 12, as detected by LC-MS (Fig. 3a and ESI
Fig. S7–S9‡). To evaluate the intended strategy further, the
bridging reaction was appraised in a system where interchain
bridging between two polypeptide chains would be required.
Antibody Fabs (fragment, antigen binding) are heterodimeric
proteins with the chains linked by a single disulde. Evaluation
of the DVP linker platform by reduction of trastuzumab Fab
with TCEP, followed by reaction with 7, 8 or 9 led to complete
Fig. 4 Reaction of trastuzumab with the DVP linkers and subsequent analysis. (a) Cysteine bridging of trastuzumab with 7, 8 or 9 resulted in re-
bridged mAbs 16, 17 and 18, (b) analysis of conjugate 16, 17 and 18 by SDS-PAGE; lane 1 is non-reducing, lanes 2–5 are reducing; lanes: (M)
molecular weight marker, (1) trastuzumab, (2) reduced trastuzumab, (3) 16, (4) 17, (5) 18, and (c) SEC analysis of 18.
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conversion to the desired interchain-bridged conjugates 13–15
in 30 minutes using a slight excess of the linker (10 equiv.)
(Fig. 3b and ESI Fig. S10–S13‡). Kinetic analysis of the bridging
rate of 8 was conducted with 10 and 20 equivalents linker aer
TCEP reduction. Strikingly, >90% re-bridging of the Fab chains
was observed for both stoichiometries aer only 15 minutes
(ESI Fig. S14‡). To conrm the selectivity of the DVP linker
platform for cysteine residues, 8 was incubated with unreduced
trastuzumab Fab and no reaction was observed aer two hours
at 37 C (ESI Fig. S23‡). These results exemplify the potential for
the DVP linker platform to serve as a general protein modi-
cation tool for monomeric and multimeric proteins.
Encouraged by earlier results, efforts shied toward modi-
cation of an IgG antibody. DVP linkers potentially enable
modication of all four interchain disuldes in an IgG1,
generating an ADC with denitive modication sites while
giving a consistent DAR of four.39 Trastuzumab mAb was
reduced with TCEP, revealing eight free thiols as evidenced by
LC-MS and Ellman's assay (ESI Fig. S15‡). Subsequently, the
reduced antibody was treated with a slight excess of 7, 8 or 9 (10
equiv. per disulde) for two hours at 37 C (Fig. 4a). Removal of
small molecule reagents by dialysis was followed by LC-MS,
SDS-PAGE and RP-HPLC analysis. The fully re-bridged mAbs
16, 17 and 18 were evident by LC-MS, suggesting good conver-
sion to the desired bioconjugates (ESI Fig. S15, S17 and S18‡).
Analysis by SDS-PAGE and RP-HPLC conrmed the presence of
the correctly bridged antibodies (Fig. 4b and ESI Fig. S17‡)
along with the ‘half-antibody’ formed by intrachain bridging of
the hinge region heavy chain cysteines, an issue seen with other
re-bridging linkers.35,40 A large number of conditions (reaction
concentration, time, linker stoichiometry) were explored to
avoid this ‘half-antibody’ formation, with little change observed
(ESI Table S1 and Fig. S16‡). Through this process, it was found
that the reaction worked efficiently (90–95% conversion to the
bridged bioconjugates) at low concentrations (<10 mM) and with
a slight excess of DVP (2.5 equiv. per disulde). We postulate
that the half-antibody conjugate remains useful as the modi-
cation site and DAR are still controlled and the stability of the
Fig. 5 Functional modification and stability analysis of DVP-modified trastuzumab. (a) On-antibody CuAAC reaction between modified tras-
tuzumab, 18 forming a doxorubicin conjugate, 21 and an AlexaFluor™ 488 conjugate, 22, (b) stability analysis by SDS-PAGE of conjugate 22 in
human plasma supplemented with GSH; P ¼ human plasma, MW ¼ molecular weight marker, days of incubation indicated above the repre-
sentative lane. Left gel is after coomassie staining, right gel is in-gel fluorescence measured before staining, and (c) DVP-mediated formation of
an MMAE ADC, 25.
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conjugate conferred through the DVP linker remains. Crucially,
the light and heavy chains are always re-bridged efficiently,
ensuring that the Fab region (the region that confers receptor
specicity to the antibody) is covalently linked. In order to
determine the effect of bridging on mAb aggregation, antibody
conjugate 18 was analysed by size-exclusion chromatography
(SEC). This showed identical aggregation levels observed for 18
and the unmodied mAb (Fig. 4c).
It was anticipated that the synthetic handles present in DVP
linkers would enable modular and divergent functionalisa-
tion, both before and aer DVP antibody conjugation.
Terminal alkyne-functionalised DVP 8 was identied as
a suitable candidate for post-conjugation modication, as
copper-catalysed azide-alkyne cycloaddition (CuAAC) chem-
istry offers a well-established method for diverse functionali-
sation under physiologically relevant conditions.41 An
azide-functionalised doxorubicin (19) was synthesised and
reacted with 18 in the presence of CuSO4$5H2O, tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) and sodium
ascorbate (Fig. 5a). Gratifyingly, excellent conversion to tri-
azole product 21 was observed by LC-MS. DAR analysis by UV-
vis spectroscopy also conrmed high conversion with
a measured DAR of 4.0 (ESI Fig. S19‡). With the aim of creating
a potentially valuable cellular imaging agent, conjugate 18 was
reacted with AlexaFluor™ 488 azide 20 under CuAAC condi-
tions (Fig. 5a). Similarly, excellent conversion was observed
with a measured uorophore-antibody ratio (FAR) of 3.9 (ESI
Fig. S20‡).
Synthesis of 22 enabled assessment of the plasma stability of
DVP bioconjugates. The uorescent antibody conjugate was
incubated in human plasma supplemented with GSH at 37 C
for two weeks. Pleasingly, in-gel uorescence and coomassie
staining revealed almost no transfer of the AlexaFluor™ 488
label onto plasma proteins, or release of individual heavy or
light chains from the antibody (Fig. 5b and ESI Fig. 22‡). This
analysis conrms the stability assessment made on the small
molecule model system that DVP linkers enable the generation
of highly stable bioconjugates.
Functionalisation before antibody conjugation was then
examined using the highly potent dolastatin 10 analogue,
monomethylauristatin E (MMAE) as a representative payload. A
DVP–PEG4–MMAE linker-warhead, 24 was prepared from 8 and
azide-functionalised MMAE (23) (see ESI‡). Reaction of reduced
trastuzumab with 24 (10 equiv. per disulde) proceeded with
excellent conversion to 25 via LC-MS (Fig. 5c and ESI Fig. S21‡).
The biological effects of DVP-bridging were then investi-
gated. Firstly, trastuzumab conjugates, 16–18 all demonstrated
comparable affinities to the native antibody for the HER2
receptor via enzyme-linked immunosorbent assay (ELISA)
(Fig. 6a). Fluorescence-activated cell sorting (FACS) coupled
with live individual cell imaging was next used to ensure that
the DVP conjugation did not alter cellular recognition and
selectivity. Fluorescent trastuzumab conjugate, 22 was incu-
bated in both HER2-positive (SKBR3 and BT474) and HER2-
negative (MCF7 and T47D) breast cancer cell lines. The cells
were incubated at 37 C for 1 hour to allow antigen binding and
complex internalisation, followed by washing with PBS to
remove any unbound antibody. Subsequent FACS analysis
revealed full labelling of both HER2-positive cell lines while
only minor labelling was observed with HER2-negative cell lines
(Fig. 6b). Internalisation of the conjugate was observed in
both HER2-positive cell types, with no internalisation visible in
either HER2-negative cell line (Fig. 6c), conrming that DVP
bridging does not affect receptor specicity, affinity or complex
internalisation.
Finally, evaluation of the in vitro cytotoxicity of a thera-
peutically relevant ADC was undertaken. DVP-MMAE ADC 25,
containing a non-cleavable linker was used to treat both
HER2-positive (SKBR3 and BT474) and HER2-negative (MCF7
and T47D) cell lines. Cytotoxicity was only observed in the
HER2-positive cell lines (Fig. 6f and ESI Fig. S24‡), demon-
strating that DVP linkers do not affect the cell-killing ability of
MMAE, enabling the use of these linkers for the delivery of
auristatin payloads with non-cleavable linkers. In contrast to
the specic cytotoxicity observed with our ADC, treatment of
the same cell lines with free MMAE resulted in high levels of
cytotoxicity in both HER2-positive and HER2-negative cell
lines (Fig. 6d). Furthermore, incubation of unmodied tras-
tuzumab with these cell lines did not cause signicant cyto-
toxicity (Fig. 6e).
Fig. 6 Biological evaluation of the DVP linker platform. (a) Binding
affinity comparison of trastuzumab, 16, 17 and 18 via ELISA. Error bars
represent the standard deviation of biological quadruplicates, (b)
percentage labelling of HER2-positive and HER2-negative cells with
22, (c) internalisation of 22 in HER2-positive cells without any observed
internalisation in HER2-negative cells, and cytotoxicity in HER2-posi-
tive and HER2-negative cells with (d) MMAE, (e) trastuzumab and (f)
DVP-MMAE ADC 25. Viability data shows the mean of three inde-
pendent experiments and error bars represent s.e.m.
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Conclusion
In conclusion, we have developed a novel DVP linker platform
for bioconjugation through the covalent re-bridging of cysteine
residues generated by the reduction of native disulde bonds.
Model studies using the trastuzumab antibody validate the
utility of this linker platform for the efficient generation of
highly plasma-stable antibody constructs from non-engineered
antibodies. We have shown that this technology can be used to
introduce different biologically relevant payloads, in an efficient
and site-selective manner with control over DAR, either before
or aer bioconjugation, without recourse to any other addi-
tional processes. Furthermore, the conjugation platform
utilizes a reaction that is orthogonal to other biocompatible
reactions (such as the CuAAC), enabling their use in tandem
with one another. The modied antibodies maintained their
cellular specicity and receptor affinity, and a DVP-ADC
demonstrated exquisite potency and selectivity for its target
cells, while having little effect on the mechanism of action of its
auristatin payload. In addition, the DVP linkers showed excel-
lent cysteine re-bridging of monomeric and dimeric proteins,
enabling their use for general protein modication,42 protein
stabilisation43,44 or the development of other biotherapeutics
such as stapled peptides.45,46
Conflicts of interest
There are no conicts to declare.
Acknowledgements
We thank AstraZeneca for providing trastuzumab and MMAE
for this research, Dr Philip Howard, Dr Luke Masterson and Dr
Balakumar Vijayakrishnan at Spriogen for access to SEC and
RP-HPLC, and Richard Grenfell and the Flow Cytometry Core at
the CRUK Cambridge Institute for their help with FACS anal-
ysis. S. J. W. acknowledges a scholarship from AstraZeneca and
the Cambridge Trusts. D. R. S. acknowledges support from
the Engineering and Physical Sciences Research Council
(EP/P020291/1) and Royal Society (Wolfson Research Merit
Award). The Spring lab acknowledges general lab support from
the EPSRC, BBSRC, MRC and Royal Society.
Notes and references
1 A. Beck, T. Wurch, C. Bailly and N. Corvaia, Nat. Rev.
Immunol., 2010, 10, 345–352.
2 T. Ueda, Biochim. Biophys. Acta, Proteins Proteomics, 2014,
1844, 2053–2057.
3 B. A. Teicher and J. H. Doroshow, N. Engl. J. Med., 2012, 367,
1847–1848.
4 A. Beck and J. M. Reichert, mAbs, 2014, 6, 15–17.
5 L. Ducry and B. Stump, Bioconjugate Chem., 2010, 21, 5–13.
6 H. L. Perez, P. M. Cardarelli, S. Deshpande, S. Gangwar,
G. M. Schroeder, G. D. Vite and R. M. Borzilleri, Drug
Discovery Today, 2014, 19, 869–881.
7 N. Diamantis and U. Banerji, Br. J. Cancer, 2016, 114, 362–
367.
8 P. D. Senter and E. L. Sievers, Nat. Biotechnol., 2012, 30, 631–
637.
9 J. M. Lambert and R. V. J. Chari, J. Med. Chem., 2014, 57,
6949–6964.
10 C. D. Godwin, R. P. Gale and R. B. Walter, Leukemia, 2017, 31,
1855–1868.
11 B. Shor, H.-P. Gerber and P. Sapra, Mol. Immunol., 2015, 67,
107–116.
12 A. Beck, L. Goetsch, C. Dumontet and N. Corväıa, Nat. Rev.
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